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 Avian leukosis virus (ALV) is a simple retrovirus that infects chickens and causes cancer.  
Chickens exposed to ALV typically develop B-cell lymphomas within a few months after hatching.  ALV-
induced tumors have been shown to develop by insertional mutagenesis mediated by proviral 
integration.  ALV proviral integration into the chicken genome disrupts the normal expression of 
neighboring host genes, commonly by promoter insertion and/or enhancer activation.  Previous studies 
have identified several common proviral integration sites near genes that are now known to drive 
tumorigenesis.  Notable genes include MYC, MYB, mir-155, and, more importantly, TERT. 
 Unique clonal integrations in the TERT promoter suggest that they are early events in ALV-
induced B-cell lymphomas.  In this thesis, I report the results of overexpressing TERT in early chicken 
embryos coinfected with ALV in new in vivo experiments.  Although no definite conclusion could be 
made about TERT overexpression and tumor progression, two tumors in one chicken were identified to 
retain the recombinant virus used to overexpress TERT.  High-throughput sequencing analysis of 
integration sites in one tumor implicated genes previously described.  In contrast, the other tumor 
implicated an AT-rich interacting transcriptional coactivator, ARIDB5, as the top potential cooperating 
gene in TERT overexpressing cells. 
 In addition, we observed an unexpected prevalence of hemangiomas in our chickens infected 
with ALV-A, which is more commonly associated with ALV-J.  Integration site analysis of multiple 
hemangiomas implicate an exclusive subset of genes that include FRK, PLAG1, and GLIS3.  
 In human cancers, the association between TERT promoter methylation and TERT expression is 
an area of active investigation.  The relationship between the two factors has proven to be complex and 
controversial.  Proviral integration adds another layer of complexity.  Investigation of clonal TERT 
promoter integrations by bisulfite sequencing showed that ALV integration is associated with a decrease 
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in methylation of the flanking genomic DNA, suggesting that ALV may contribute to TERT expression by 
inhibiting methylation at the TERT promoter. 
 Lastly, we surveyed an extensive subset of human hematological malignancies for the 
prevalence of previously reported TERT promoter mutations by conventional Sanger sequencing.  TERT 
promoter mutations have been recently identified as a highly conserved and ubiquitous somatic change 
in various cancers where TERT expression has been directly induced.  We observed a lack of TERT 
promoter mutations in the human samples tested, suggesting that TERT promoter mutations are not a 
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 Retrovirology began with two seminal discoveries looking at neoplastic diseases in the chicken.  
In 1908, Vilhelm Ellermann and Oluf Bang demonstrated that chicken leukosis was caused by a virus 
(Vilhelm and Bang 1908).  In 1911, Peyton Rous reported the cell free transmission of a sarcoma in 
chickens (Rous 1911).  These agents turned out to be related and became known as avian leukosis virus 
(ALV) and Rous sarcoma virus (RSV), respectively.  Together, these viruses are collectively referred to as 
avian sarcoma/leukosis viruses (ASLV), and their discovery provided the first evidence of virus-induced 
tumors in animals.  Inevitably, the discovery of virus-induced tumors was extended to mammalian 
species.  In 1957, Ludwik Gross reported one of the first isolations of a murine leukemia virus (MLV) 
(Gross, 1957).  More than fifty years after the initial discoveries, using RSV, Howard Temin described 
evidence of DNA proviruses and, more importantly, viral reverse transcriptase, which are now 
considered a defining property of retroviruses (Mizutani, Boettiger, and Temin 1970).  These 
observations were independently described at the same time by David Baltimore using other RNA 
containing viruses (Baltimore 1970).  With this knowledge, the first human oncogenic retrovirus, human 
T-cell leukemia virus 1 (HTLV-1) was discovered as the causative agent of aggressive T-cell leukemia in 
humans (Poiesz et al. 1980).  Around this time, the human immunodeficiency virus (HIV) was discovered 
as the retrovirus responsible for acquired immunodeficiency syndrome (Barré-Sinoussi et al. 1983).  
From their initial discoveries, ALSV, along with other retroviruses, continue to serve as excellent sources 
of information for the understanding of retroviral biology and cancer (Weiss and Vogt 2011). 
ASLV Genome 
 ASLVs are members of the Alpharetrovirus genus of the family Retroviridae (International 
Committee on Taxonomy of Viruses. and King 2011).  They are categorized as simple retroviruses, which 
are characterized by at most one additional coding region to the three essential genes: gag, pol, and 
env.  These genes are found to be common among all retroviruses (Figure 1.1).  In contrast, the complex 
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retroviruses include additional genes that encode for functional accessory proteins.  The ASLV gag gene 
encodes the structural proteins capsid (CA), matrix (MA), nucleocapsid (NC), and viral protease (PR).  The 
ASLV pol gene encodes the reverse transcriptase (RT) and integrase (IN) enzymes, and the env gene 
encodes the transmembrane (TM) and surface (SU) envelope glycoproteins.  The 7.5 kb genome is 
flanked by two identical long terminal repeats (LTR) sequences that are approximately 350 bp (Figure 
1.1).  The LTR is divided into three notable segments (Figure 1.1).  The unique 3’ (U3) region contains the 
polyadenylation sequence, the transcriptional promoter, and enhancer sequences (Figure 1.1).  The 
beginning of the repeat (R) region marks the start of transcription in the 5’ LTR and the end of R is the 
site of polyadenylation in the 3’ LTR (Figure 1.1). 
 
Figure 1.1. Schematic of the avian leukosis virus (ALV) proviral genome.  (Top) Integrated ALV genomes are 
composed of three genes: gag, pol, and env, which are flanked by two identical sequences called the long 
te i al epeats LTRs .  Botto  The ’ LTR of ALV is o posed of a U , R, a d U  egio .  
 
ASLVs are further classified into 11 distinct subgroups (A-K) based on the properties of the viral 
envelope glycoproteins (Fadly and Nair 2008; Coffin 1992).  Subgroups A, B, C, D, and J are exclusively 
exogenous ALSVs while subgroup E ALSVs are endogenous.  The chicken genome encodes many 
endogenous retroviruses (ERVs).  The majority of the these ERVs do not share any significant homology 
with known exogenous ALSVs (Bolisetty et al. 2012).  Most are related to beta- and gammaretroviruses, 
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suggesting that these exogenous viruses were once a dominant type of exogenous avian retrovirus 
(Bolisetty et al. 2012). 
Viral Entry 
 Key concepts for viral entry were established using ASLV as a model.  Like all known 
retroviruses, ASLV virions, are coated with Env proteins.  Env proteins are transmembrane proteins that 
bind to specific cellular receptors on the target cell surface and facilitate viral entry into the host cell.  As 
previously mentioned, ASLVs are classified into distinct subgroups partly based on the cellular receptor 
specificity of their Env proteins.  Genetic analyses revealed genes involved with susceptibility to 
infection.  The tva and tvc genes confer susceptibility to ASLV infection by subgroup A and C, 
respectively, while the tvb locus confers susceptibility to subgroups B, D, and E (Crittenden et al. 1967; 
Duff and Vogt 1969; Hanafusa 1965; Payne and Biggs 1966; Payne and Biggs 1964; Payne and Pani 1971; 
Rubin 1965; Vogt and Ishizaki 1965).  In the case of tvb, two functional alleles were discovered.  The 
tvbS1 allele conferred susceptibility to infection by all three viral subgroups, and tvbS3 conferred 
susceptibility for subgroups B and D only (Adkins, Brojatsch, and Young 2000; Barnard and Young 2003; 
Brojatsch et al. 1996; Crittenden and Motta 1975; Crittenden, Wendel, and Motta 1973).  The tva gene 
encodes TVA, a low-density lipoprotein (LDL) receptor-related protein (Bates, Young, and Varmus 1993; 
Young, Bates, and Varmus 1993).  The tvb alleles encodes TVB, members of the tumor necrosis factor 
receptor (TNFR) family (Adkins, Brojatsch, and Young 2000; Barnard and Young 2003; Brojatsch et al. 
1996).  The tvc gene encodes for TVC, a member of the immunoglobulin superfamily (Elleder et al. 
2005).  More recently, the chicken Na+/H+ exchanger type 1 (chNHE1) was identified as a cellular 
receptor protein for subgroup J (Chai and Bates 2006).  ASLV was shown to have a broad range of cell 
targets, being able to infect and replicate in many types of chicken tissues and organs (Dougherty and Di 
Stefano 1967; S. M. Williams et al. 2004).   
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 Once bound to its receptor on the target cell, viral entry is achieved through a two-step fusion 
activation mechanism (Mothes et al. 2000).  The first step involves receptor-mediated conformational 
changes in Env at neutral pH, exposing the fusion peptide of Env, which allows the insertion of this 
peptide into the cell surface membrane.  Next, low pH activation facilitates completion of the fusion 
reaction in an acidic endosomal compartment after virus uptake and endosomal trafficking (Barnard and 
Young 2003).  Once in the cytoplasm, reverse transcription of the viral RNA genome occurs through a 
complex multi-step process in which cellular nucleotides and packaged tryptophan tRNAs are utilized by 
the viral reverse transcriptase to convert viral RNA into a double-stranded DNA provirus.  A more 
detailed description of these steps is available in Retroviruses (Coffin, Hughes, and Varmus 1997).  
Nuclear Entry and Proviral Integration 
 From studies of HIV, the DNA copy of the viral genome associates with viral integrase (IN) and 
other viral and cellular proteins to form the preintegration complex (PIC) prior to nuclear entry (Piller, 
Caly, and Jans 2003).  The ability of the PIC to gain access to nuclear DNA varies among retroviruses.  
Some retroviruses, like the gammaretroviruses, are able to integrate only during mitosis, following 
nuclear envelope disassembly.  In contrast, lentiviruses, like HIV, circumvent the need for actively 
dividing host cells by utilizing a form of active transport across the nuclear envelope (Lewis and 
Emerman 1994).  Initially, alpharetroviruses were believed to share the same restriction of the nuclear 
envelope (Temin 1967).  However, more recent work from multiple groups demonstrated the successful 
infection of non-cycling cells by ALSV (Hatziioannou and Goff 2001; Richard A. Katz, Greger, and Skalka 
2005; Richard A Katz et al. 2002; Greger et al. 2004).  These observations were further supported by the 
characterization of a nuclear localization signal (NLS) that is sufficient for active transport of the ASV 
integrase through the nuclear pore (Andrake et al. 2008).  Once in the nucleus, the PIC mediates 
integration of the provirus into the host genomic DNA.  Integration is achieved through a two-step 
e ha is .  Fi st, the ’ th idi e di u leotide of the proviral genome is cleaved by IN; subsequently, 
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the PIC binds the host cell DNA and allows IN to catalyze a strand transfer reaction with the opposite 
strands of the host DNA (Bushman and Craigie 1990; Bushman, Fujiwara, and Craigie 1990; Engelman, 
Mizuuchi, and Craigie 1991).  Following proviral integration, the host cell repair machinery fills any gaps 
at the ends of the integration site, which results in a six-nucleotide repeat sequence at both ends of the 
provirus (Hughes et al. 1981).   
Integration site selection varies significantly among retroviruses.  Site preferences are 
influenced by targeting factors that interact with the PIC and the viral genome during integration.  
Retroviruses like HIV-1 preferentially integrate into actively transcribed and spliced genes (Schröder et 
al. 2002; Singh et al. 2015).  The lens epithelial derived growth factor (LEDGF), a general transcriptional 
co-activator, was reported to play a role in facilitating HIV-1 integration into gene regions (Maertens et 
al. 2003).  In comparison, MLV preferentially integrates close to transcriptional start sites (TSS) and CpG 
islands (Mitchell et al. 2004; X. Wu et al. 2003).  This preference is mediated by the interaction with host 
bromodomain and extraterminal domain (BET) proteins and the MLV integrase (Sharma et al. 2013). 
In contrast to HIV and MLV, ALV was initially reported to integrate relatively randomly with 
slight preferences for transcribed genes (Barr et al. 2005; Mitchell et al. 2004; Narezkina et al. 2004; 
Withers-Ward et al. 1994).  Further investigation from our lab provided a more comprehensive and 
improved analysis of ALV integration preferences (Malhotra, Winans, et al. 2017).  Analysis of ALV 
integration sites in cultured cells infected with ALV revealed that ALV integration was relatively random, 
which is consistent with previous reports; however, slight preferences for genes, transcriptional start 
sites, and CpG islands were also observed (Malhotra, Winans, et al. 2017).  In addition, a preference for 
integrations in and near expressed and spliced genes was observed (Malhotra, Winans, et al. 2017).  This 
preference is likely in part influenced by the facilitates chromatin transcription (FACT) complex, which is 





 The process of transcription is directed by the viral LTRs.  ASLVs do not encode any 
transcriptional activators; consequently, they rely entirely on host transcription factors for transcription.  
The host transcription factors bind the U3 region of the LTR which drives RNA Polymerase II 
transcription of the provirus.  All viral transcripts undergo m7G appi g at the ’ e d a d ’ e d lea age 
and polyadenylation by cellular machinery prior to export from the nucleus. 
 All replication-competent ASLVs produce a single primary RNA transcript.  This full-length, 
unspliced viral RNA serves as a mRNA for translation of gag and pol genes, as well as the genomic 
material to be packaged into new virions.  A fraction of these primary transcripts is also spliced to 
generate env mRNA.  In contrast, replication-deficient ASLVs such as myelocytomatosis virus (MC29) 
generally produces a single unspliced gag-onc fusion transcript due to the lack of an env gene.  For 
future infection and replication, replication-deficient viruses like MC29 require the presence of a helper 
virus that provides the means for viral entry into a host cell.  Additionally, avian retroviruses like RSV are 
able to produce a second spliced transcript as a result of acquiring new cellular genes.  In the case of 
RSV, a second spliced transcript that encodes the v-src oncogene can be generated. 
 The ~7-9kb ASLV full-length viral RNA transcript is a foreign element in the host cell that harbors 
various characteristics that would be considered a target of host cellular restriction factors.  To ensure 
successful replication, ASLV has evolved various properties that aid in necessary transcription, export, 
and translation of its genome.  For example, while most RNA transcripts would undergo splicing, ASLV 
has se e al ele e ts that p ote t these t a s ipts f o  spli i g.  These ele e ts i lude su opti al ’ 
splice sites (McNally and Beemon 1992) and cis-acting RNA elements.  
 The efficiency of splicing is significantly dependent on the architecture of the transcripts.  The 
consensus se ue e fo  ’ spli e sites is AG/GURAGU, he e the e o /i t o  ju tio  is denoted by the 
slash.  This sequence is recognized by the small nuclear ribonucleoprotein (snRNP), U1.  The consensus 
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se ue e fo  the ’ spli e site is YAG/G, and the branch point sequence (YNYURAC) is optimally located 
~  t upst ea  of the ’ spli e site (Burge, Tuschl, and Sharp 1999).  The intervening sequence 
between the splice sites contain a polypyrimidine tract that binds U2 auxiliary factor (U2AF) and 
facilitates the recruitment of U2 snRNP to the branch point.  Following U2 binding, the two exons are 
brought together, and splicing is achieved through the coordinated action of U2, U5, and U6 snRNPs.  
The two exons are joined, and any intervening intron, in the form of a lariat, is debranched and 
degraded (Burge, Tuschl, and Sharp 1999).  In contrast, the ASLV env splice acceptor region is 
su opti all  lo ated  ts upst ea  of the ’ spli e site, which ultimately reduces splicing efficiency (R 
A Katz and Skalka 1990). 
An example of a cis-acting element is the negative regulator of splicing (NRS).  A 230 nts RNA 
element located in the gag coding sequence (Arrigo and Beemon 1988), the NRS is located ~300 nts 
do st ea  of the ’ spli e site and has been shown to be functional as long as it is located in close 
p o i it  to the ’ spli e site (McNally, Gontarek, and Beemon 1991).  The NRS has been proposed to 
act in a competitive manner as a pseudo ’ spli e site that e uits o po e ts of the spli eoso e  
i te a ti g ith the ’ spli e site.  This i te a tio  se ueste s the ’ spli e site away from the bonafide 
’ spli e site, edu i g the effi ie  of p ope  spli i g of the i al t a s ipts in addition to the 
su opti al ’ spli e site (McNally and Beemon 1992; Cook and McNally 1999; Giles and Beemon 2005). 
 In contrast to other complex retroviruses that encode additional accessory proteins that 
mediate nuclear export, ASLV contains a 100-nt direct repeat (DR) RNA element that facilitates nuclear 
export.  The number of DRs may vary between retroviruses where ALSV may utilize a single DR located 
i  the ’ u t a slated egio  UTR . RSV has two DRs flanking the src oncogene.  One DR element was 
shown to be sufficient to form a highly stable stem loop structure that mediates nuclear export.  This 
method of nuclear export was shown to be dependent on the nuclear export factor, Tap (LeBlanc et al. 
2007; Paca et al. 2000). 
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 The RNA stability element (RSE) is another example that aids the proper life cycle of ASLVs.  In 
contrast to cellular mRNA, the ASLV RNA viral transcript is polygenic.  More specifically, the viral RNA 
has a stop codon at the end of the gag gene.  To the cellular host factors, this would be considered a 
premature stop codon, and the region downstream of the gag stop ould appea  to e a lo g ’UTR, 
which often targets cellular transcripts for degradation by the nonsense mediated decay (NMD) 
machinery.  In order to circumvent degradation, ASLV has evolved this 400 nt element, RSE (Weil, 
Hadjithomas, and Beemon 2009).  When positioned near a premature stop codon like the gag stop 
codon in ASLV, the RSE protects the full length viral RNA from NMD-mediated decay (Ge et al. 2016). 
Translation 
 The full-length viral transcript serves as a template for the synthesis of two different 
polyproteins, Gag-Pro and Gag-Pro-Pol.  In order to replicate efficiently, virions require a significantly 
greater expression of the Gag structural proteins than Pol proteins.  All retroviruses evolved a strategy 
to achieve this requirement, despite being encoded on the same transcript.  ASLV accomplishes this with 
a short A-U i h slippe  se ue e  upst ea  of the gag termination codon next to a downstream RNA 
pseudoknot (Jacks et al. 1988).  This sequence promotes ribosome pausing which leads to occasionally 
slipping a single nucleotide backwards before continuing forward approximately five percent of the 
time.  This one nucleotide frameshift places the gag stop codon out of frame and allows the ribosome to 
read through to the pol termination codon, generating the Gag-Pro-Pol polyprotein.  ASLV Gag is known 
to be additionally modified with low levels of N-terminal phosphorylation and acetylation (Swanstrom 
and Wills 1997; Palmiter et al. 1978). 
 The ASLV spliced proviral transcript serves as a template for the synthesis of Env polyproteins 
which are produced by splicing of the env splice donors located eighteen nucleotides downstream of the 
gag start codon.  Consequently, ASLV Env polyproteins contains the first six amino acids of the Gag 
protein at the N-terminus (Ficht, Chang, and Stoltzfus 1984; Swanstrom and Wills 1997).  The Env 
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polyproteins is post-translationally modified by terminal glycosylation and, subsequently, proteolytically 
cleaved into three peptides.  These peptides oligomerize to form a trimer (Einfeld and Hunter 1988).  
Subsequently, the Env trimer is exported to the cell surface and may then interact with host cell 
receptors that are processed concurrently.  This interaction forms the basis of resistance against 
additional infection by the virions using the same host cell receptor.  This phenomenon is called super 
infection resistance. 
Virion Assembly and Budding 
 Gag protein mediates most of the assembly and budding process.  After synthesis, Gag is 
imported into the nucleus and interacts with a packaging sequence Ψ  o  the i al RNA ge o e 
through its NC domain (Gudleski et al. 2010; Scheifele, Ryan, and Parent 2005).  Gag dimerizes and then 
nuclear export occurs, mediated by the nuclear export signal within the p10 domain of Gag.  The export 
of the entire ribonucleoprotein (RNP) complex is mediated by the CRM1 Pathway (Gudleski et al. 2010; 
Scheifele, Ryan, and Parent 2005).  Trafficking from the nucleus is a phosphoinositide-dependent 
process (Nadaraia-Hoke et al. 2013).  Gag mediates stable association with the plasma membrane 
through its membrane-binding domain (MBD) (Verderame, Nelle, and Wills 1996).  At the plasma 
membrane, processed Env proteins, viral polyproteins, two linked genomic RNAs, and viral tRNAs are 
assembled into viral particles, which is facilitated by Gag protein and different cellular proteins 
(Swanstrom and Wills 1997; Pincetic and Leis 2009).  After budding, the viral PR mediates cleavage of 
the polyproteins, leading to the maturation of the virions for future infection. 
 ALV Insertional Mutagenesis as a Model for Tumorigenesis 
 Lacking any viral oncogene, ALV is considered a non-acute transforming virus.  Non-acute 
transformation is characterized by a long latency period (4-8 months) between the time of infection to 
death from tumors (Fan and Johnson 2011).  The major source of transformation occurs through ALV 
integration events.  Proviral integration into the host genome can dysregulate the expression of 
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neighboring host genes mediated through the strong enhancer and promoter elements in the viral LTRs 
(Figure 1.2). 
 
Figure 1.2. Schematic of proviral insertional mutagenesis.  (Left) Proviral integration activating neighboring 
cellular proto-oncogene by promoter insertion or enhancer activation.  (Right) Clonal expansion of 
transformed precursor cell. 
 
Integration near or within specific host genes like pro-survival and proliferation genes can 
upregulate their expression, leading to tumor formation.  The viral genome could also induce the 
expression of truncated gene products or impact post-transcriptional processes (Jiang et al. 1997).  ALV 
enhancer elements can have long range effects on the expression of host genes (Y. Li et al. 2014).  These 
characteristics of proviral integration are referred to as viral insertional mutagenesis (Uren et al. 2005). 
 Since the initial discovery and association of avian retroviruses with tumorigenesis, there are 
various properties that poise ALV as an attractive insertional mutagenesis model for the study of 
tumorigenesis.  Like other integrating retroviruses, proviral integration is an efficient and naturally 
occurring event that researchers can exploit for cancer gene discovery.  If ALV integration occurs near or 
within an oncogenic element, the host cell can undergo oncogenic transformation and proliferation, 
leading to tumor formation that is populated by a clonal expansion of the initial infected cell (Figure 
1.2).  Identification of these sites can be easily achieved by sequencing the junction between the proviral 
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and host genome.  Initial studies mapping integration sites made use of low-throughput techniques to 
identity hotspots of proviral integrations to identify genes that may drive oncogenesis.  In chapter 2, our 
work shows an example of a more efficient method to study hotspots of ALV integration in tumors by 
the application of high throughput sequencing techniques previously described (Justice, Morgan, and 
Beemon 2015; J. Justice et al. 2015; Malhotra, Winans, et al. 2017). 
 Clonal expansion in cancer is the concept that a tumor is derived from a small number of 
precursor cells that originally transformed and proliferated into expanded clones.  In the context of 
retroviral infections, one can easily demonstrate clonality through quantitation of proviral integrations 
by various techniques.  Initially using Southern blots, ALV tumors were shown to be clonal (Neiman et al. 
2003; Yang et al. 2007).  An empirical method of measuring the degree of clonality and extent of clonal 
expansion in different stages of tumorigenesis through the application of sequencing technology has 
been previously defined using HTLV-1 and HTLV-2 induced tumors (Gillet et al. 2011; Berry et al. 2012).  
This method was later applied in the analysis of ALV induced B-cell lymphoma tumors in our lab 
(Malhotra, Winans, et al. 2017).  The study revealed a change in integration pattern when comparing 
ALV infection in cultured cells and tumors.  In cell culture, observed integrations are relatively random 
with slight preferences for genes, TSS, and CpG islands.  There is also a preference for integrations in or 
near expressed and spliced genes.  In comparison, tumors show more selection for ALV integrations near 
TSS.  There is also a significant selection of ALV integrations away from CpG islands in clonally expanded 
cells in tumors. 
As previously mentioned, ALV integration occurs in a quasi-random fashion and exhibits minimal 
discrimination for specific integration sites, in contrast, to other retroviruses like MLV and HIV.  
Consequently, using ALSV as an insertional mutagen allows forward genetic studies of tumorigenesis in a 
more unbiased manner.  The minimal integration site bias allows for the discovery of functional non-
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coding elements like long non-coding RNA (lncRNA) (Nehyba et al. 2016) and micro-RNA (miR) (Clurman 
and Hayward 1989). 
 While ALSV can infect different bird species like ducks and turkeys (Payne et al. 1992), chickens 
are the natural hosts of ALSV infections.  ALSV infections predominantly spread horizontally through 
physical contact, but may be transmitted vertically from the chicken to egg (Justice and Beemon 2013).  
Although chickens are more phylogenetically different from humans compared to mice as model 
organisms, many studies have demonstrated that discoveries in chickens are translatable to humans and 
may even serve as more appropriate tumorigenesis models than mice.   
ALSV integration events may induce a wide range of tumors, the most common being lymphoid 
leukosis.  Lymphoid leukosis is a type of B-cell lymphoma that originates in the bursa of Fabricius, an 
avian specific organ that serves as a site for B-cell development.  ALSV infection initially causes 
transformation of B-cells in the bursa that eventually metastasize to distant organs like the liver, spleen, 
and kidney (Fadly and Nair 2008).  Other types of ALSV induced tumors include hemangiomas, myeloid 
leukosis and erythroblastomas (Beemon and Rosenberg 2012; Justice and Beemon 2013; Justice, 
Morgan, and Beemon 2015).  The spectrum of ALSV induced tumors is ultimately dependent on many 
factors including the type of viral strain, the age of the bird at the time of infection, as well as the 
genetic background of the birds.   
 ALV insertional mutagenesis studies have previously identified several cancer-associated genes 
like MYC, MYB, BIC (the gene locus for miR 155), and TERT (Baba and Humphries 1986; Clurman and 
Hayward 1989; Hayward, Neel, and Astrin 1981; Justice, Morgan, and Beemon 2015; Yang et al. 2007).  
In 1981, mapping of ALV integrations in long latency B-cell lymphomas identified MYC as an integration 
hotspot with the majority of the tumors (approximately 80%) having integrations in intron 1 of MYC 
(Neel et al. 1981; Hayward, Neel, and Astrin 1981).  The integration led to the overexpression of MYC 
through the upregulation of a viral fusion transcript driven by the inserted strong promoter element in 
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the ’ LTR of the i us.  Tu o s e e ide tified i  hickens infected at 2-7 days after hatching and 
development of B-cell lymphomas were observed 4-6 months after infection.  This seminal discovery 
demonstrates that oncogenic transformation could be caused by the activation of a cellular gene 
(Wasylishen and Penn 2010).  Later, c-bic was shown to be a common integration site that often 
coincided with tumors that had MYC integrations (Clurman and Hayward 1989).  Much later, c-bic was 
identified to be an oncogenic microRNA, now recognized as mir-155 (Tam, Ben-Yehuda, and Hayward 
1997). 
 Further investigation into the time of infection revealed that ALV could also cause short-latency 
lymphomas by insertional mutagenesis.  Approximately 14% of ten day-old chick embryos infected with 
ALV develop short-latency B-cell lymphomas within weeks (Pizer, Baba, and Humphries 1992).  
Furthermore, a recombinant strain of ALV, EU-8, was discovered later to have higher tumor incidence 
(40%-80%) under similar conditions (Kanter, Smith, and Hayward 1988; Simon et al. 1987).  Integration 
site analysis of these tumors revealed a common integration site at the MYB locus, suggesting that MYB 
expression contributes to the short-latency lymphomas (Kanter, Smith, and Hayward 1988).  EU-8 is a 
recombinant between two related viruses the ring-necked pheasant virus (RPV) and UR2 associated 
virus (UR2AV) (Simon et al. 1987).  RPV is a subgroup F ALV, originally isolated from pheasant cells, and 
UR2AV is subgroup A.  As characteristic of ALV, RPV lacks any viral oncogenes and contains endogenous 
retroviral sequences related to pheasant endogenous retroviruses.  When RPV infects 10 day-old chick 
embryos, a high frequency of angiosarcomas is observed (Carter, Proctor, and Smith 1983).   
In an effort to identify the genetic determinant for angiosarcomas, recombinants between RPV 
and UR2AV were created.  Serendipitously, one of the recombinants, EU-8, was discovered to induce 
short-latency B-cell lymphomas.   EU-8 is comprised mostly of RPV except for the env of UR2AV.  In 
contrast, another recombinant, LR-9, which has gag, pol, and env of UR2AV, is unable to induce short-
latency B-cell lymphomas.  By sequence comparison, the genetic determinant was narrowed down to a 
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42-nucleotide deletion in the gag gene of RPV.  Deletion of this 42-nucleotide element in LR-9, named 
ΔLR-9, enabled the virus to induce short-latency lymphomas at comparable levels to EU-8 (Smith et al. 
1997).  Later, the deletion was determined to be localized to the region of gag that corresponded to the 
matrix protein as well as in the NRS element (Polony et al. 2003).  Testing by mutagenesis generated a 
virus, LR-9 G919A, which contain a single silent point mutation in the NRS, that was able recapitulate the 
effe ts of ΔLR-9 with an even higher incidence (Polony et al. 2003).  This result suggested that disruption 
of the NRS sequence allows increased viral readthrough, and increases the efficiency of splicing to 
downstream genes like MYB, which ultimately contributes to rapid tumor formation (Smith et al. 1997; 
O’“ulli a  et al. ; Polo  et al. ; Wilusz a d Bee o  . 
Prior to my thesis work, the tumors generated from these experiments with LR- , ΔLR-9, and LR-
9 G919A represent the majority of the original pool of samples used for recent integration site analysis 
from our lab (Yang et al. 2007; Justice, Morgan, and Beemon 2015; Malhotra, Winans, et al. 2017).  In 
these studies, one of the most notable discoveries is the identification of clonal ALV integrations into the 
telomerase reverse transcriptase (TERT) promoter.  This discovery implicates the maintenance or early 
upregulation of TERT expression as a selection factor for ALV-induced B-cell lymphomas.  This discovery 
serves as the core source of inspiration for the majority of my thesis work covered in the following 
chapters. 
Telomerase and Tumorigenesis 
 In humans, TERT encodes the reverse transcriptase component of telomerase and together with 
its RNA partner TR, which provides a template for TERT, constitute the telomerase reverse transcriptase 
enzyme.  The canonical function of telomerase is to extend and maintain telomeres, preventing 
replicative senescence.  Replicative senescence is the state in which cells stop dividing when their 
telomeres are critically short (Harley, Futcher, and Greider 1990).  Senescence occurs in most cells 
because of telomere shortening with successive cell divisions (Blackburn 2000).  With a few exceptions, 
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such as germ cells and stem cells, TERT is not actively transcribed and, consequently, telomerase activity 
in these cells is low (Wright et al. 1996).  However, in cancer cells, TERT is often transcriptionally 
reactivated by various mechanisms, accounting for 90% of all human cancers (Shay and Bacchetti 1997).  
The reactivation of TERT enables replicative immortality, a hallmark of cancer characterized by the 
ability to grow endlessly (Hanahan and Weinberg 2011). 
 Mice have been extensively used as a model for human telomerase function.  One direct way of 
accessing the function of telomerase is to knockout its expression in vivo.  Knockout mice for the 
telomerase RNA component, mTERC, were initially generated by Blasco and colleagues in 1997 (Blasco 
et al. 1997).   These knockout mice were viable, fertile, and phenotypically normal until the fifth 
generation.  Cells grown past the fourth generation exhibit evidence of telomere shortening, lack of 
detectable telomere repeats at chromosome ends, aneuploidy, and chromosomal abnormalities that 
include end-to-end fusions, which is similar to observations in the propagations of normal somatic 
human cells (Blasco et al. 1997; Counter et al. 1992).  In contrast, late generation mTERC, or mTR, 
knockout mice cells show the ability to overcome senescence/crisis like most mouse cell lines, which is 
not commonly observed in normal human somatic cells (Blasco et al. 1997; Counter et al. 1992).  
Furthermore, oncogenically transformed telomerase null mouse cells can form tumors, suggesting that 
telomerase is not required for tumor formation in mice (Blasco et al. 1997).  mTERT knockout mice were 
first described by Yuan and colleagues in 1999, sharing similar observations to the mTERC knockout mice 
(Yuan et al. 1999). 
 While telomerase may not be required for tumorigenesis in mice, studies with targeted 
overexpression of mTERT suggest a role in promoting tumorigenesis (Gonzalez-Suarez et al. 2001; 
Canela et al. 2004; Cayuela, Flores, and Blasco 2005).  In one study, a conditional mouse line, K5-Tert, is 
generated with targeted expression of mTERT to basal keratinocytes.  While mice are viable and show 
histologically normal epithelia with high levels of telomerase activity and normal telomeres, they are 
17 
 
more susceptible to chemically induced carcinogenesis than their wild-type littermates (Gonzalez-Suarez 
et al. 2001).  This susceptibility is determined to be dependent on the expression of mTR, implicating 
telomerase as the contributing factor (Cayuela, Flores, and Blasco 2005).  Similarly, targeted 
overexpression of mTERT to T cells in two independent mouse lines shows higher incidences of 
spontaneous T-cell lymphoma than their corresponding age-matched wild-type controls (Canela et al. 
2004). 
 Although studies in mice indicate an association between telomerase and tumorigenesis, these 
studies reveal that the association is likely telomere-independent.  Overexpression of mTERT did not 
impact telomere length in mice (Canela et al. 2004; Cayuela, Flores, and Blasco 2005; Gonzalez-Suarez et 
al. 2001).  Investigation into telomere-independent functions of telomerase is an area of active 
investigation (for a detailed review, see Low and Tergaonkar 2013)).  Presently, noncanonical functions 
appear to be associated with telomerase and transcription of genes involved in various aspects of 
tumorigenesis.  In mice, TERT expression is associated with the activation of Wnt-related pathways (Choi 
et al. 2008).  This is in part achieved through direct interaction between TERT and a SWI/SNF-related 
chromatin remodeling protein, BRG1, which in turn activates Wnt-dependent genes (Park et al. 2009).  
In humans, TERT can also regulate NF-κB-dependent transcription, which can be mediated through the 
direct interaction between TERT and p65 subunit of NF-κB.  This interaction recruits TERT to NF-κB 
regulated promoters and activates genes that promote cancer progression (Ghosh et al. 2012). 
 Using mice as a model of human telomerase function and telomere biology does present some 
limitations.  Although telomerase appears to promote tumorigenesis in mice, mice possess significant 
differences in telomere biology when compared to humans.  Constitutive telomerase expression is 
found throughout the lifespan of a mouse in both somatic and renewable tissues; furthermore, mice 
show a significantly higher susceptibility to spontaneous oncogenesis (Blasco et al., 1997; Forsyth et al., 
2002; Sherr and DePinho, 2000; Wright and Shay, 2000).  In addition, laboratory mice and other rodents 
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generally do not exhibit age-related or division-dependent telomere shortening (Forsyth, Wright, and 
Shay 2002; M A Blasco et al. 1997; Samper, Flores, and Blasco 2001; Wright and Shay 2000) and 
maintain long telomeres even at senescence (Parrinello et al. 2003). 
 In contrast, the chicken may present a optimal model for the study of telomeres and 
telomerase.  Like humans, telomerase activity is observed early in development, maintained in 
renewable tissues and stem cells, and diminishes in most somatic tissues following embryogenesis in 
chickens (Forsyth, Wright, and Shay 2002; S.E. Swanberg and Delany 2003; Taylor and Delany 2000).  
Telomerase expression and activity is upregulated in most transformed cells as well (Swanberg and 
Delany 2003).  In proliferating cells, division-dependent telomere shortening is observed in chicken 
somatic tissues in vivo, which also correlates with age (Taylor and Delany 2000; M. Delany et al. 2003). 
 Much less research has been published utilizing chicken as a model for the study of telomeres 
and telomerase.  However, what is available suggest that telomerase functions in a similar manner to 
humans.  Upregulated levels of chTERT and chTR, the chicken telomerase RNA component, is observed 
in a chicken lymphoma cell line, DT40, which also correlates with telomerase activity when compared to 
non-transformed chicken embryonic fibroblasts (CEF) (Swanberg et al. 2004).  Furthermore, telomerase 
activation is associated with increase c-myc expression which has been shown to be involved with the 
reactivation of telomerase in many human cancers (K.-J. Wu et al. 1999).   
I  Ma ek’s disease he pes i us (MDV) induced T-cell lymphoma, the expression of a viral TR 
(vTR), which shares 88% sequence identity to chicken TR, driven by MDV is associated with increased 
incidence of T-cell lymphoma in chickens (Trapp et al. 2006).  Constitutive expression of vTR in the 
chicken fibroblast cell line DF-1 is associated with phenotype consistent with oncogenic transformation 
(Trapp et al. 2006).  More recently, overexpression of chTERT alone or in combination with chTR is 
sufficient to immortalize chicken preadipocytes in vitro (Wang et al. 2017).  Two independent cell lines 
generated from this process display greater than 100 population doublings, high telomerase activity, 
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and lack any signs of replicative senescence (Wang et al. 2017).  Interestingly, neither of the cell lines 
show any morphological features of malignant transformation, such as the development of cell cloning 
foci or loss of contact inhibition in culture (Wang et al. 2017).  These observations suggest that TERT 
alone is not sufficient to drive malignant transformation in cultured chicken cells. 
In chapter 2, I take advantage of our established model using ALV and chickens to test the 
effects of overexpression of chicken TERT in tumorigenesis.  Overexpression expression of TERT can be 
achieved through the use of recombinant avian virus.  As many lines of evidence suggest that early TERT 
activation is likely not sufficient to drive tumorigenesis per se, we can combine TERT overexpression 
with ALV infection to screen for potential cooperating genes through proviral integration site analysis. 
Proviral and TERT Promoter DNA Methylation 
 Epigenetic events play a significant role in the development and progression of disease states.  
DNA methylation is one of these mechanisms.  DNA methylation occurs by the covalent addition of a 
methyl group to the cytosine ring, resulting in 5-methylcytosine (5mC) (Bird 2002).  This process is 
catalyzed by enzymes called DNA methyltransferases (DNMTs).    This modification is most commonly 
associated with transcriptional silencing and found in nonexpressed or noncoding regions of the 
genome.  In mammalian DNA, 5mC is found in approximately 4% of the genomic DNA and is located 
almost exclusively at cytosine-guanosine dinucleotides (CpGs).  CpG sites occur relatively randomly 
throughout the genome with the exception of small stretches of DNA with high concentrations (>50% 
CpGs) of CpGs sites, called CpG islands (Bird 2002).   These CpG islands are commonly found near 
promoter regions of genes, where transcription starts (Herman and Baylin 2003).  While most CpG sites 
are often methylated, CpG islands are more dynamic, and changing methylation states depends on the 
cellular environment (Bird 2002). 
 Accessible methylation data for chicken are relatively limited compared to their mammalian 
counterparts.  In 2011, Li and colleagues performed one of the first genome-wide methylome studies of 
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liver and muscle tissues from red jungle fowl and avian broilers.  Their results suggested that chickens 
show analogous patterns of DNA methylation compared to mammals (Li et al. 2011; Eckhardt et al. 
2006).  More specifically, repetitive sequences are hypermethylated, most CpG islands remain 
hypomethylated, and gene body regions show relatively higher levels of DNA methylation than the 
flanking regions (Li et al. 2011).  Furthermore, gene expression level is negatively correlated with DNA 
methylation in the proximal promoter regions (Li et al. 2011).  This would suggest that DNA methylation 
functions in the traditional sense of suppressing transcription in chickens like in mammals.   
In cancer, there is significant change in DNA methylation patterns that supports tumorigenesis.  
In normal cells, most CpG sites in intergenic regions are methylated, whereas CpG-island sites of active 
gene promoters are unmethylated.  In contrast, cancer cells are often characterized with loss of 
methylation in normally silent regions of the genome, which leads to inappropriate expression of proto-
oncogenes.  In addition, selective hypermethylation of promoter regions is associated with aberrant 
silencing of many known tumor suppressor genes (Jones and Baylin 2002; Herman and Baylin 2003).  
Epigenetic silencing by DNA methylation has been shown to occur just as frequently as somatic 
mutations in the aberrant silencing of tumor-suppressor function (Jones and Baylin 2002; Herman and 
Baylin 2003).   
 The human TERT gene is characterized by a large (2 kb) CpG island, which starts 846 bp 
upstream from its transcriptional start site (TSS) and extends into the first intron, 1178 bp downstream 
of the TSS.  Similarly, the chicken also has a large (1.1 kb) CpG island, extending from -337 to +746 bps 
relative to its TSS.  The relationship between TERT promoter methylation and expression has proven to 
be more complex in human cancers.  On the one hand, initial reports suggest that TERT promoter DNA 
methylation is associated with gene silencing (Liu et al. 2004; Lopatina et al. 2003; Shin et al. 2003).  A 
decrease of TERT promoter activity is observed when human teratocarcinoma (HT) and human acute 
myeloid leukemia (HL60) cells undergo induced differentiation by retinoic acid treatment (Liu et al. 
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2004; Lopatina et al. 2003).  This reduction in TERT promoter activity during differentiation correlates 
with a gradual accumulation of DNA methylation in the TERT promoter (Liu et al. 2004; Lopatina et al. 
2003).  Treatment with a common demethylating agent, 5-azacytidine, reduces TERT promoter 
methylation and is associated with a reactivation of TERT expression (Lopatina et al. 2003).  Similar 
results are observed using normal cells.  Actively replicating normal human oral keratinocytes (NHOK) 
express TERT and have telomerase activity, which gradually decreases and is inactivated during 
senescence (Kang, Guo, and Park 1998).  The inactivation of TERT is associated with the gradual 
hypermethylation of the TERT promoter during senescence in NHOK (Kang, Guo, and Park 1998).  
Treatment of senescent NHOK with 5-azacytidine restores expression of TERT (Shin et al. 2003).   
In contrast, other reports suggest a direct, positive correlation between TERT promoter 
methylation and expression (Devereux et al. 1999; Dessain et al. 2000; Nomoto et al. 2002; Guilleret and 
Benhattar 2004; Guilleret et al. 2002).  The independent methylation status of different normal and 
tumor tissues and cell lines reveals that telomerase-negative samples are characterized by 
hypomethylation at the TERT promoter, and telomerase-positive samples by hypermethylation.  
Treatment with 5-azacytidine can induce expression in some cell lines (Devereux et al. 1999; Dessain et 
al. 2000).  In addition, hypermethylation of the TERT promoter appears to be one of the most prominent 
biomarkers of cancer and may also correlate with cancer progression and relapse (Barthel et al. 2017; 
Castelo-Branco et al. 2013, 2016). 
Further investigation suggests that these two seemingly contradictory observations may likely 
involve separate functional domains of the promoter.  Baylin and colleagues later reported that breast, 
lung, and colon cancer cells retain alleles with little or no detectable methylation near the TSS (-150 to 
+150 around the TSS) while being hypermethylated in regions further upstream of the TSS (>600 bp) 
(Zinn et al. 2007).  Hypomethylated regions are associated with active chromatin marks, while 
hypermethylated regions are associated with inactive chromatin marks, suggesting that DNA 
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methylation at the TERT promotor displays the usual dynamics of gene expression (Zinn et al. 2007).  
The mechanism behind TERT expression upregulation and hypermethylation of the TERT promoter is still 
under investigation. 
 In addition to the maintenance of cellular gene expression, DNA methylation is a known 
mechanism in suppressing any potentially harmful viral sequences, both endogenous and exogenous.  
One of the earliest evidence of proviral DNA methylation was observed using an interspecies model.  In 
these studies, DNA methylation of RSV LTRs is investigated using a rat restriction cell line (XC).  This cell 
line was established from rare rat sarcomas induced by inoculating rats with Rous sarcoma tissue from 
chickens (Svoboda 1960).  At the time, RSV was known to be non-permissive in rats, or unable to 
replicate after infecting the host cells (Svoboda 1960).  However, low frequency rat sarcomas may form 
in a large cohort of infected rats.  Upon further investigation of the XC cells, the block on RSV replication 
is associated with methylation of stably integrated RSV proviral DNA which is later shown to suppress 
proviral transcription (Guntaka et al. 1980; J Hejnar et al. 1999; Svoboda et al. 2000).  Transcriptional 
silencing can be achieved through different mechanisms that include proviral de novo DNA methylation.  
Daxx, a cytoplasmic Fas death domain-associated protein, was later discovered to be involved in the 
maintenance of DNA methylation of avian proviruses in mammalian cells (Shalginskikh et al. 2013).  DNA 
methylation of LTRs is demonstrated to be associated with the silencing of related mammalian 
retroviruses including MLV (Stewart et al. 1982), RSV (J Hejnar et al. 1999), HIV-1 (Bednarik, Cook, and 
Pitha 1990), HTLV-1 (Koiwa et al. 2002), as well as endogenous retroviruses (Lavie et al. 2005). 
 The impact of integrating viruses on the methylation state at the site of integration is an area of 
active investigation.  Elucidating contributing factors may offer insights into practical applications like 
optimizing viral vectors for gene therapy, as well as understanding proviral selection in virus-induced 
tumorigenesis.  Presently, the resulting DNA methylation at the site of integration is dependent on a 
growing list of factors.  In the case of the XC cell line, rat cells appear to suppress RSV transcription 
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through DNA methylation of the proviral LTRs; in contrast, RSV provirus is not significantly targeted by 
DNA methylation in chickens (Guntaka et al. 1980; J Hejnar et al. 1999; Svoboda et al. 2000).  These 
observations support the importance of the properties of the host cell on the transcriptional activity of 
proviruses.  In comparison, MLV integration into mouse cells is associated with de novo methylation of 
MLV LTRs (Jähner and Jaenisch 1985), suggesting that the properties of the integrating virus can impact 
its susceptibility to DNA methylation. 
 Further investigations reveal that proviral integrations can alter the methylation state of the 
host genome at the site of integration.  RSV integration has been associated with transient 
hypomethylation of flanking genomic DNA in hamster cells (Hejnar et al. 2003).  In contrast, MLV 
integration is associated with de novo methylation in mice (Jähner and Jaenisch 1985).  The DNA 
methylation state of the host genome at the site of integration may also determine the resulting 
methylation state of the provirus.  Proviruses integrated close to transcriptional start sites of active 
genes may have long-term transcriptional activity and be resistant to transcriptional silencing by DNA 
methylation; in contrast, proviruses in intergenic regions, which are characterized by high methylation, 
tend to become transcriptionally silenced (Senigl, Auxt, and Hejnar 2012).  In human tumors, early 
reports investigating integrated Hepatitis B virus (HBV) and human papilloma virus (HPV) 16 suggest a 
direct correlation between the methylation state at the site of integration prior to proviral integration 
and the methylation states of the provirus after integration (Hatano et al. 2017; Watanabe et al. 2015).  
Consequently, human proviruses located near highly methylated regions, which are likely 
transcriptionally inactive, become methylated and, subsequently, transcriptionally inactive, while 
proviruses located near hypomethylated regions remain active. 
 Previously, our lab has reported that the TERT promoter is a hot spot for ALV integration – also 
called a common integration site – in ALV-induced B-cell lymphomas.  Additionally, these TERT promoter 
integrations are one of the most clonally expanded – or most abundant unique – integrations in tumors 
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tested (Justice, Morgan, and Beemon 2015; Malhotra, Winans, et al. 2017).  Clonally expanded TERT 
integrations would suggest that selection for these integrations likely occurred early during 
tumorigenesis, implicating the importance of early TERT activation in chicken B-cell lymphoma.  TERT 
activation may be achieved through promoter insertion or enhancer activation from the ALV provirus. 
 Interestingly, the majority of the TERT promoter integrations are found to be in the opposite 
orientation of the TERT gene, which suggest that the TERT promoter may be bidirectional or two 
promoters (Nehyba et al. 2016).  This observation later led to the identification of a novel antisense long 
non-coding RNA (lncRNA), which we referred to as TERT antisense promoter associated RNA (TAPAS) 
(Nehyba et al. 2016).  The viral promoter drives the expression of fusion transcripts containing viral 
sequences spliced to exons 4 through 7 of TAPAS, which suggest that its overexpression may be 
contributing to tumorigenesis (Nehyba et al. 2016).  TAPAS expression appears to correlate directly with 
TERT expression in various normal chicken tissues, which suggest that TAPAS may be an active factor in 
normal chicken tissues in addition to tumorigenesis (Nehyba et al. 2016).  The functional and 
downstream consequences of TAPAS overexpression is still under investigation. 
 In the case of TERT, placing the ALV LTR in the opposite orientation next to the endogenous 
TERT promoter has been shown to be sufficient to drive expression of downstream coding genes using 
an in vitro reporter assay in chicken cells (Yang et al. 2007).  Alternatively, DNA methylation is likely to 
play a role in the activation of TERT in ALV-induced lymphomas.  As previously mentioned, TERT 
promoter methylation is a ubiquitous mechanism of regulation of TERT expression during development 
(Liu et al. 2004; Lopatina et al. 2003; Shin et al. 2003) and, especially, cancer in humans and other 
animals (Jones and Baylin 2002; Herman and Baylin 2003).  These observations likely extend to the 
chicken genome as it has been shown to share analogous patterns of DNA methylation to those of 
mammals (Li et al. 2011; Eckhardt et al. 2006).  In chapter 3, we investigate the influence of DNA 
methylation at the TERT promoter following ALV integration of chicken tumors. 
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 Understanding the interplay between the epigenome of the host DNA and provirus in chickens 
may reveal significant insights into TERT regulation that can further apply to human TERT regulation.  In 
human cancers, there are similar observations that involve somatic changes at the TERT promoter and in 
expression.  Interestingly, a group has recently reported that the human TERT promoter region is a 
common integration site in hepatitis B virus-associated hepatocellular carcinomas (Buendia and Neuveut 
2015).  Presently, the methylation status at these integration sites have not been tested.  More recently, 
investigations into known common point mutations in the human TERT promoter in different cancers 
reveal that even a single point mutation is capable of activating TERT expression in an allele-specific 
manner – discussed in more detail in the following section (Stern et al. 2017).  These tumors with TERT 
promoter mutations are associated with an allele-specific perturbation of normal maintenance 
methylation of the TERT promoter (Stern et al. 2017).  More specifically, alleles with TERT promoter 
mutations show decreased methylation at the TERT promoter, which likely contributes to the activation 
of TERT expression (Stern et al. 2017). 
TERT Promoter Mutations in Cancer 
 In 2013, a high penetrant disease-segregating causal germline mutation in the TERT promoter of 
a melanoma family was discovered (Horn et al. 2013).  This mutation lead to the discovery of specific 
and recurrent somatic mutations in tumors from unrelated patients in the TERT promoter (Horn et al. 
2013; Huang et al. 2013).  This discovery provided an example of a bona fide direct mechanism for 
cancer-specific activation of TERT expression.  In the original study, genetic linkage analysis reveals the 
disease segregating mutation as a cytosine to thymine transition 57 bps upstream of the ATG start site 
(Horn et al. 2013).   The mutation carriers within the family developed rapid onset and aggressive 
melanoma, as well as, multiple malignancies (Horn et al. 2013).  Consequently, this prompted rapid 
screening of tumors of unrelated patients with metastatic melanomas.  Sequencing of the TERT 
promoter in melanoma cell lines detected two recurrent and mutually exclusive somatic mutations, a 
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cytosine to thymine transition at 124 and 146 bases upstream from the ATG start site in the TERT 
promoter (Horn et al. 2013; Huang et al. 2013). 
 Each point mutation generates new Ets binding motifs (Horn et al. 2013).  Of the four well-
characterized Ets transcription factors, the GA-binding protein (GABP) has been demonstrated to bind 
specifically to the new Ets binding site generated by either mutation (Bell et al. 2015).  Following GABP 
binding, enrichment of active chromatin mark H3K4me2/3 as well as pol II binding occurs, leading to 
monoallelic expression of TERT (Stern et al. 2017, 2015; Huang et al. 2013).  As previously mentioned, 
allele-specific hypomethylation is observed with mutated alleles.  Although TERT is invariably 
upregulated in most tumors, tumors with the promoter mutations have been reproducibly shown to 
have significantly increased expression compared with the same type of tumors without mutations 
(Heidenreich, Nagore, et al. 2014; Heidenreich et al. 2015). 
 Following the initial discovery, screenings of other cancers reveal that the TERT promoter 
mutations are not specific to melanomas and occur in varying frequencies.  An early exhaustive study 
looking at 60 different cancers types report that the frequencies of the mutations can generally be 
grouped into low (<15%) or high (>15%) frequency mutation types, suggesting that frequency may 
correlate with self-renewal capacity of the tissues (Heidenreich, Nagore, et al. 2014; Killela et al. 2013).  
Tumors originating from canonical telomerase-negative compartments are likely initially challenged with 
a telomere-dependent proliferative barrier which is alleviated with the acquisition of TERT promoter 
mutations.  Mutations lead to an immediately advantageous proliferative effect, which could explain the 
high frequencies of TERT promotor mutations originating from tissues with relatively low rates of self-
renewal that includes melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, 
medulloblastomas and subtypes (Heidenreich, Nagore, et al. 2014; Killela et al. 2013).   
In contrast, the effects of TERT promoter mutations in telomerase-positive compartments would 
likely be neutral, reducing selection for such alterations, in cancers that include the hematopoietic 
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system, gastrointestinal stromal tumors, lung, ovarian and uterine cervix cancer, and prostate 
carcinomas (Killela et al. 2013; Campanella et al. 2015; Wu et al. 2014; Stoehr et al. 2015; Panero et al. 
2016; Huang et al. 2013).  Nevertheless, more screening identified exceptions to this generalization that 
include prostate cancer and mantle cell carcinomas (Stoehr et al. 2015; Panero et al. 2016).  
Furthermore, frequencies of TERT promoter mutations also vary depending on histological sub-classes.  
For example, desmoplastic melanomas, or melanocytic lesions in chronically exposed skin, carry TERT 
promoter mutations at a frequency exceeding 80% (Shain et al. 2015).  In contrast, acral and mucosal 
melanoma are nearly free of TERT promoter mutations (Liau et al. 2014).  For adult gliomas, high 
frequencies are observed in primary glioblastoma (70-80%), followed by oligodendrogliomas (60-70%), 
oligoastrocytomas (35-55%), and astrocytomas (30-40%) (Killela et al. 2013).  
 From the literature, initial screens of hematological malignancies were limited to a few types 
that included leukemia and diffused large B-cell lymphomas or restricted to small sample sizes (Mosrati 
et al. 2015; Yan et al. 2013; Vinagre et al. 2013; Killela et al. 2013).  These studies suggested that 
hematological malignancies may not be subjects for somatic promoter mutations in the TERT gene.  
While the observation regarding the relationship between self-renewal potential and frequency of TERT 
promoter mutations may fit the current data, exceptions were identified which included the presence of 
TERT promoter mutations in 33% of mantle cell lymphomas tested (Panero et al. 2016). 
Although cells of hematological origin are characterized with persistent telomerase activity, 
evidence of early activation, as well as, late activation of TERT expression and telomerase activity is 
observed in hematological malignancies.  In adult T-cell leukemia/lymphoma (ATLL), telomerase activity 
appears as a key event in the development and progression of the disease, and ATLL cells are 
characterized with long telomeres that suggest an early activation of TERT that may contribute to a 
delay in replicative senescence and prolonged time to acquire genetic alterations for the induction of a 
fully transformed phenotype (Dolcetti and De Rossi 2012; Kubuki et al. 2005).   In contrast, in acute 
28 
 
myeloid leukemia (AML), chronic myeloid leukemia (CML), and B-cell disease, telomerase activity is not 
required for the initiation of disease but is required for its maintenance at later stages (Röth et al. 2003; 
Vicente-Dueñas et al. 2012; Bruedigam and Lane 2016; Deville, Hillion, and Ségal-Bendirdjian 2009).  
TERT promoter mutations may simply offer another method to achieve TERT activation and, 
subsequently, increase telomerase activity. 
Taking into account the aforementioned factors, the prevalence of promoter mutations in 
hematological malignancies remains unclear.  To improve upon current data, we screened a more robust 
collection of different hematological malignancies for TERT promoter mutations which is covered in 
chapter 4.  If there are hematological malignancies with TERT promoter mutations, we can draw and test 
potential associations between our studies using ALV insertional mutagenesis in the chicken TERT 











































Avian leukosis virus (ALV) induces B-cell lymphoma and other neoplasms in chickens by integrating 
within or near cancer genes and perturbing their expression.  The TERT promoter region have been 
previously identified as a common integration site in these lymphomas, suggesting a causal role in 
tumorigenesis.  In addition, TERT promoter integrations are clonal, implicating selection for these 
integrations early in tumorigenesis.  Tumors with TERT promoter integrations are associated with 
increased TERT expression.  In this study, we test the effects of early TERT expression in chicken 
embryos on ALV-induced tumorigenesis.  Overall, we were unable to conclude if TERT overexpression 
had any impact on tumor progression.  Nevertheless, two tumors with TERT overexpressing provirus 
were detected.  ALV integration site analysis implicates ARIB4B as a potential TERT cooperating gene.  In 
addition, we observed an unexpected high frequency of ALV-A induced hemangiomas.  Integration 
analysis of these hemangiomas reveal potential novel players in hemangioma development.   
Introduction 
 Avian leukosis virus (ALV) is a simple retrovirus that primarily causes B-cell lymphomas in 
infected chickens (Beemon and Rosenberg 2012; Hayward, Neel, and Astrin 1981; Justice and Beemon 
2013).  ALV-induced lymphomas develop in a multi-stage process, originating initially as neoplastic 
follicles in the bursa, which can develop into primary bursal tumors.  Primary tumors can then 
metastasize and form secondary tumors in other tissues, which commonly include the liver, kidney, and 
spleen (Neiman et al. 2003).  This study uses a specific ALV strain that can induce rapid-onset 
lymphomas, which develop in less than 3 months after infection of 10-day chicken embryos (Polony et 
al. 2003; Smith et al. 1997).  
 Cellular transformation is caused by multiple genetic changes that result in the dysregulation of 
genes that promote tumorigenesis.  ALV-induced lymphomas commonly occur through insertional 
mutagenesis by means of proviral integration.  Generally, proviral integration induces the aberrant 
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expression of oncogenic factors via promoter insertion or enhancer activation that is mediated by its 
long terminal repeats (LTRs) (Beemon and Rosenberg 2012; Hayward, Neel, and Astrin 1981; Justice and 
Beemon 2013). 
From the investigation of ALV integration sites in chicken tumors, sites that are often targets of 
integrations – or common integration sites – can be observed.  These common integration sites 
implicate neighboring genes as potential oncogenic factors in tumorigenesis (Hayward, Neel, and Astrin 
1981; Baba and Humphries 1986; Clurman and Hayward 1989; Yang et al. 2007; Justice, Morgan, and 
Beemon 2015; Nehyba et al. 2016; Jiang et al. 1997).  Additionally, measuring the relative abundance of 
proviruses – or clonality – can provide insight into tumor development (Neiman et al. 2003; Yang et al. 
2007; Malhotra, Winans, et al. 2017).  Highly clonal integrations may implicate early activation of the 
associated neighboring genes during tumorigenesis.  Previously, the TERT promoter region was 
identified as a common integration site (Yang et al. 2007).  In addition, unique integrations in the TERT 
promoter were found to be one of the most clonally expanded integration sites.  This implicates TERT 
promoter integration and, subsequently, TERT activation as an early event in tumorigenesis (Justice, 
Morgan, and Beemon 2015; Malhotra, Winans, et al. 2017).  Twenty-six unique integration sites were 
identified in the region in multiple independent tumors (Justice, Morgan, and Beemon 2015; Malhotra, 
Winans, et al. 2017). 
Telomerase is a ribonucleoprotein complex that adds repeat sequences to chromosome ends, 
called telomeres.  It is comprised of a catalytic protein component, TERT, as well as a noncoding 
telomerase RNA template component, TERC.  Upregulation of telomerase activity has been associated 
with more than 90% of all human cancers, including lymphomas (Shay and Bacchetti 1997).  Elevated 
telomerase activity diminishes replication-associated telomere shortening by maintaining telomere 
lengths, allowing continual proliferation and survival of cancer cells (Blasco 2005).  
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Elevated TERT expression is observed in chicken tumors with clonal TERT promoter integrations, 
implicating the activation of TERT expression by ALV proviral integration as an early selection factor for 
tumorigenesis.  The effects of constitutive overexpression of TERT in whole organisms has been studied 
using transgenic mice.  While overexpression of TERT has been shown to be associated with increased 
tumorigenesis in mice, the majority of studies point to mechanisms that are independent of telomere 
length (Gonzalez-Suarez et al. 2001; Canela et al. 2004; Cayuela, Flores, and Blasco 2005; Flores, 
Cayuela, and Blasco 2005).  Currently, proposed telomerase-independent functions include increased 
wound healing (Cayuela, Flores, and Blasco 2005), mobilization of cells (Canela et al. 2004; Flores, 
Cayuela, and Blasco 2005), and cell survival (Lee et al. 2008). 
Telomere independence of mice may be partly due to the contrasting properties of murine 
telomere biology, compared to humans.  Constitutive telomerase expression is found throughout the 
lifespan of a mouse in both somatic and renewable tissues.  Subsequently, most cells in mice are 
characterized with long telomeres throughout their lifespan.  Furthermore, mice show a significantly 
higher susceptibility to spontaneous oncogenesis (Blasco et al. 1997; Forsyth, Wright, and Shay 2002; 
Sherr and DePinho 2000; Wright and Shay 2000).  In contrast, the chicken may present a optimal model 
for the study of telomeres and telomerase.  Like humans, telomerase activity is observed early in 
development, maintained in renewable tissues and stem cells, and diminishes in most somatic tissues 
following embryogenesis in chickens (Forsyth, Wright, and Shay 2002; S.E. Swanberg and Delany 2003; 
Taylor and Delany 2000).  Consequently, division-dependent telomere shortening is observed in chicken 
somatic tissues in vivo, which also correlates with age (Taylor and Delany 2000; M. Delany et al. 2003). 
Various converging lines of evidence suggest that TERT is likely not sufficient to drive 
tumorigenesis alone.  Chicken tumors with clonal TERT promoter integrations show coinciding selection 
for integrations near other genes like MYB in multiple tumors, suggesting that tumors are the result of 
multiple cooperating genes (Malhotra, Winans, et al. 2017).  Furthermore, while overexpression of TERT 
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is sufficient to immortalize chicken cells like adipocytes, cells overexpressing TERT do not show 
properties of malignant transformation such as loss of contact inhibition, foci formation, or anchorage-
independent growth (Wang et al. 2017).   In humans, melanoma patients with familial TERT promoter 
point mutations, which have been shown to promote TERT expression, are healthy until adulthood 
which is when they encounter higher incidences of melanoma compared to patients without mutations.  
This observation is consistent with the idea that TERT contributes to tumorigenesis, but additional 
factors are required during the patie ts’ lifeti e fo  alig a t t a sfo atio  (Horn et al. 2013).   
In this study, we attempted to investigate the effects of early TERT overexpression in ALV-
infected chicken embryos on tumorigenesis.  TERT overexpression is achieved through the use of 
replication-deficient recombinant ALV-derived virions.  Chickens are coinfected with recombinant virions 
and ALV.  Coinfection with ALV is expected to contribute additional genetic hits to TERT overexpression 
cells and, subsequently, enables cells to undergo malignant transformation.  Integration analysis of 
tumors with recombinant proviruses and ALV may provide potential insight into additional TERT-
cooperating genes. 
Materials and Methods 
Cloning of chTERT Overexpressing Recombinant Virus 
 Chicken embryo fibroblast (CEF) RNA was extracted using Amsbio RNA-Bee.  First strand cDNA 
synthesis was performed using Thermo Fisher SuperScript® III First-Strand Synthesis System.  Full length 
chicken TERT cDNA was cloned flanked with ClaI sites by PCR using primer 1 and 2 and New England 
Biolabs (NEB) Phusion® High-Fidelity DNA polymerase (Figure 2.1 and Table 2.1).  Cloned TERT was then 
cut with NEB ClaI and ligated with NEB T4 ligase into a vector called DAS, generating DAS TERT (Figure 
2.1).  DAS is a vector derived from ALV that lacks the env genes, allowing the encoded recombinant virus 
to accommodate large cDNA like TERT.  Lacking the env gene, DAS clones are replication deficient and 
require a helper virus for packaging.  Ligation products were used to transform XL-1 Blue competent 
34 
 
cells.  Single clones from ampicillin selection were screened by colony PCR using primer 1 and 2 with 
Phusion polymerase.  The 4041 bp full length chicken TERT cDNA was confirmed by conventional Sanger 
sequencing (Eurofins Genomics, Louisville, Kentucky), using staggered PCR primers: primer 3-7 (Figure 





Primer “e ue e ’- ’  Purpose 
1 GCAT-ClaI-ATGGAGCGCGGGGCTCAG Cloning chicken TERT into DAS 
2 GCAT-ClaI-TTAGTCCAGTATAGTTTTGAAA Cloning chicken TERT into DAS 
3 CGGGCAACCAATTTATGAAC Sequencing of TERT clone in DAS 
4 CCTGTGGCAGACAAAAGCTC Sequencing of TERT clone in DAS 
5 TGGGAAAGAGTCCACTGAGG Sequencing of TERT clone in DAS 
6 ACTAAGCCGTGTTGTTGAAGG Sequencing of TERT clone in DAS 
7 CTCTGTGGGATCCAGAAGGA Sequencing of TERT clone in DAS 
8 CGTGATGGAGAACAGGTTGA qPCR of total TERT cDNA (exon 2) 
9 GTGCTACATGCCAGGAGGTT qPCR of total TERT cDNA (exon 2) 
10 CCCTTAAAGTCTATAAGATGCATCTGTTTGGG Detection of DAS TERT viral cDNA and DAS TERT provirus in tumors 
11 ATGTTGCTAACTCATCGTTACCATGTTG Detection of DAS TERT viral cDNA and DAS TERT provirus in tumors 
12 AGGAGAAACCGCTAGCAACA Quantification of DAS TERT viral titer 
13 GCTCCATATCGATGCCACAG Quantification of DAS TERT viral titer 
14 TCAAGCATGGAAGCCGTC Detection of spliced proviral TERT cDNA 
15 CTGAGCCCCGCGCTCCAT Detection of spliced proviral TERT cDNA 
16 ATTCACTCGGCTATCGCGAG Detection of LR-9 viral cDNA in viral supernatant 
17 CAAGCCTTGCCCCGTTACAG Detection of LR-9 viral cDNA in viral supernatant 
18 AACCGGACATCACCCAAA Quantification of LR-9 viral titer 
19 CCTCACACAAGACCAGGACA Quantification of LR-9 viral titer 
20 GAGCTGAGCTGACTCTGCTG Detection of DAS cDNA in viral supernatant 
21 CCCTCCCTATGCAAAAGCGAAAC Detection of DAS cDNA in viral supernatant 
22 TGAGCTGACTCTGCTGGTG Quantification of DAS viral titer 
23 GGACTCCTAACCGCGTACAA Quantification of DAS viral titer 
Table 2.1.  Summary of primer sequences and purposes 
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Transfection, Infection, and Virion Production 
 CEFs were cultured in medium 199 (Thermo Fischer Scientific, Waltham, MA, USA) 
supplemented with 2% tryptose phosphate, 1% fetal calf serum, 1% chick serum, and 1% 
antibiotic/antimycotic (199 2-1-1) at 39°C and 5% CO2.  A specific mutant of ALV, called LR-9 G919A, was 
used as a helper virus for the packaging of DAS TERT and DAS virions.  Henceforth, referred to as either 
LR-9 or ALV, LR-9 G919A contains a silent mutation in a regulatory element that results in rapid onset of 
B-cell lymphomas in chickens (Polony et al. 2003).  LR-9 DNA was SacI digested and ligated to form 
recombinant competent products prior to electroporation. A 2:5 weight ratio of LR-9 to DAS TERT or 
DAS was used for electroporation.  CEFs were transfected in Opti-MEMTM (Thermo Fischer Scientific, 
Waltham, MA, USA) with 1 x 220 mV 40 ms pulse.  Cells were allowed to recover for 2 mins in 199 2-1-1 
at room temperature.  Transfected CEFs were transferred to a 60 mm plate and propagated until near 
confluency.  All cells were then transferred to 100 mm plates and once again into 150 mm plates.  
Supernatant was collected daily for three consecutive days once cells were confluent in 150 mm plates, 
which took an average of nine days.  Cells and supernatants were collected for further experiments. 
 Small aliquots of supernatant were collected throughout the propagation and to test for reverse 
transcriptase (RT) activity described in the following section.  For infection, CEFs were trypsinized, 
resuspended in in a small volume (800 µl per 60 mm plate), and plated with 100 µl of viral supernatant 
that was positive for RT activity.  Cell were incubated for 1 hour with occasional shaking and then allow 
to propagate until confluency.  Supernatants were then collected to test for RT activity, and cells were 
collected for further experiments. 
Reverse Transcriptase (RT) Assay 
   22 µl of viral supernatant was added to a 28.5 µl RT reaction mix – RT Assay buffer (20 mM 
MgCl2, 0.2% Triton X-100, 2 mM EDTA, and 100 mM Tris pH 8.0), 2.5 µl of poly(rC)-p(dG) 12-18 RT 
su st ate,  M dGTP, α-32P, and 0.1 M DTT.  Reaction was incubated at 37°C for 1 hour.  Reaction was 
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then subjected to speed vac to reduce the volume to approximately 10 µl.  The entire reaction was then 
spotted on to DE81 DEAE cellulose paper and allowed to dry for 10 mins at room temperature.  Spotted 
paper was washed 3 times for 5 mins each with 2x SSC buffer (300 mM NaCl, 30 mM sodium citrate) and 
followed by one wash for 5 mins in 100% EtOH.  Paper was air dried for 5 mins and exposed to a 
phosphor screen.  Phosphor screen was then imaged using a Typhoon Imager (General Electronic 
Healthcare, Piscataway, NJ, USA). 
Telomerase Repeated Amplification Protocol (TRAP) Assay 
 Whole cell extracts were prepared with CHAPS buffer (10 mM Tris-HCl pH7.5, 1 mM MgCl2, 1 
mM EGTA, 0.5% CHAPS, 10% glycerol).  Protein concentrations were determined by the Bradford 
method with Bio-Rad Protein Assay Reagent (Hercules, CA, USA).  Protein extracts (20 µg of total 
protein) were first incubated with 0.1 µg of unlabeled TS primer and all four dNTPs (50 µM each) in 1x 
TRAP buffer (25 mM Tris-HCl pH 8.4, 63 mM KCl, 1.5 mM MgCl2, 0.05% Tween 20, 1 mM EGTA), 0.5 
mg/ml purified BSA (NEB), 1 mM spermidine, and 5 mM beta-mercaptoethanol in a total reaction 
volume of 50 µl for 45 mins at 37°C.  Total volume of the extract was adjusted with CHAPS buffer.  The 
reaction was stopped by incubation at 94°C for 2 min. CHAPS buffer was included as a negative control, 
and commercially available telomerase positive cell extract was used as a positive control.  Heat 
inactivated extract was used as an additional control. 
 Aliquots of synthesis (1.25 µl) were then PCR amplified in 1x Herculase buffer with all four 
dNTPs (50 µM each). 0.5 mg/ml purified BSA, 0.05 µg Cy5-labeled-TS primer, 0.05 µg ACX primer, TSNT 
primer mix (0.1 µg of NT primer and 0.01 mol TSNT per 1 µl), and 0.25 µl of Herculase Hotstart (Thermo 
Fischer Scientific, Waltham, MA, USA) in 25 µl of total reaction volume.  All oligonucleotides – TS, ACX, 
NT, TSNT were made as described by Kirn and Wu (1997).  TS primer used in PCR amplification was 




 PCR amplification started with 94°C for 2 min followed with 27-36 cycles (30 secs at 95°C, 30 
secs at 55°C, and 1 min at 72°C).  STOP/loading buffer (BF blue, glycerol, EDTA) was added to the TRAP 
PCR products and separated on 7.5% acrylamide gels (ratio of acrylamide to bis-acrylamide 19:1) in 0.5x 
TBE.  Gel images were captured using Typhoon Imager in fluorescence mode (General Electronic 
Healthcare, Piscataway, NJ, USA). 
Quantitative PCR and End Point PCR of TERT and Viral RNA 
 All samples used were extracted using Amsbio RNA-Bee.  First strand cDNA synthesis was 
performed using Thermo Fisher SuperScript® III First-Strand Synthesis System.  All quantification of 
cDNA used standard qPCR conditions with SYBR® Green Master mix (Bio-Rad, Hercules, CA, USA) in a 
CFX96 real-time PCR detection system (Bio-Rad, Hercules, CA, USA).  All primer locations with respect to 
their target sequences are illustrated in Figure 2.1, and sequences and purposes are listed in Table 2.1.  
Quantification of total TERT cDNA in transfected and infected CEFs and tumor samples used primer 8 
and 9, located in exon 2 of chicken TERT.  For the detection of viral cDNA in supernatants from 
transfected and infected CEFs and tumors, p i e s ta geti g the egio  et ee  the ’ LTR a d the 
nearest genes were used.  Primer 10 and 11 were used for DAS TERT, primer 16 and 17 for LR-9, and 
primer 20 and 21 for DAS.  Tumors were screened for DAS TERT provirus by PCR using primer 10 and 11. 
 Quantification of viral titers in supernatants used primers targeting the junction between pol 
and the sequence downstream of each viral cDNA (Figure 2.1).  Primer 12 and 13 were used for DAS 
TERT, primer 18 and 19 used for LR-9, and primer 22 and 23 for DAS.  Viral titers were calculated by back 
calculating from qPCR measurements against a standard curve generated from known concentrations of 
corresponding vectors.  Spliced proviral TERT transcripts were quantified by qPCR using primer 14 and 





Tumor Induction and Tissue Isolation 
 12-day old chicken embryos were inoculated intravenously with viral supernatants prepared 
from transfected CEFs.  Three different conditions were used: ALV only (LR-9), vector control and ALV 
(DAS + LR-9), and DAS TERT and ALV (TERT + LR-9) (Table 2.2-2.4).  An additional mock group that was 
sham-inoculated with medium was used as a negative control.  Viral titers for inoculation were 
normalized to equivalent concentrations of ALV (1.49 x 105 virions/ml).  In addition to ALV, the DAS 
group was inoculated with 3.31 x 105 DAS virions/ml and the TERT group was inoculated with 1.56 x 105 
TERT virions/ml, as estimated by qRT-PCR.  In total, 9 birds infected with ALV only, 26 birds with DAS and 
ALV, and 27 birds with DAS TERT and ALV were followed and scored (Table 2.2-2.4). 
 Birds were kept in isolators for 14 weeks.  Isolator units were cleaned weekly, and containment 
was maintained throughout the 14 weeks.  Birds were removed as they died or became moribund.  A 
bird was considered moribund if it was unable to move.  Tumors tissues were excised at the time of 
death or sacrifice, snap frozen in liquid nitrogen, and stored at -80°C.  Tumor tissues included primary 
bursal (B) tissue, secondary tumors in the liver (L), kidney (K), spleen (S), muscle (M), and leg (LE). All 
birds were sacrificed at the final take-down on the 15th week.  All birds were necropsied, and cause of 
death was determined according to ALV lesions as listed in Diseases of Poultry.  Summary tables of the 



















 882 01-28-2015 03-08-2015 5.6 - + + Y 
 883 01-28-2015 05-14-2015 15.1 - + - N 
 884 01-28-2015 03-29-2015 8.6 + - - N 
 885 01-28-2015 05-07-2015 14.1 - + - N 
 886 01-28-2015 05-14-2015 15.1 + - + Y 
 887 01-28-2015 02-23-2015 3.7 - - - N 
 888 01-28-2015 05-14-2015 15.1 - + - N 
 889 01-28-2015 05-14-2015 15.1 + - - N 
 890 01-28-2015 04-18-2015 14.4 - - + N 
Total Birds 9    3 4 3 2 
























 81 01-29-2015 04-18-2015 11.3 + + - Y 
 82 01-29-2015 02-26-2015 4.0 + - - Y 
 83 01-29-2015 03-04-2015 4.9 - + - N 
 201 02-18-2015 05-04-2015 10.7 + - - N 
 202 02-18-2015 04-23-2015 9.1 - + - N 
 203 02-18-2015 03-29-2015 5.6 - - + N 
 204 02-18-2015 05-05-2015 10.9 + + - Y 
 205 02-18-2015 06-04-2015 15.1 - + - N 
 206 02-18-2015 04-15-2015 8.0 + - - N 
 207 02-18-2015 06-04-2015 15.1 - - - N 
 208 02-18-2015 04-16-2015 8.1 + - - N 
 209 02-18-2015 05-29-2015 14.3 + + - Y 
 210 02-18-2015 06-04-2015 15.1 - - - N 
 211 02-18-2015 04-05-2015 6.6 - + - N 
 212 02-18-2015 04-26-2015 9.6 + - - N 
 213 02-18-2015 05-01-2015 10.3 - + + Y 
 214 02-18-2015 04-09-2015 7.1 - + - N 
 215 02-18-2015 06-04-2015 15.1 + - + Y 
 216 02-18-2015 03-17-2015 3.9 - - - N 
 217 02-18-2015 04-17-2015 8.3 - + - N 
 218 02-18-2015 04-15-2015 8.0 - + - N 
 219 02-18-2015 03-26-2015 5.1 - + - N 
 220 02-18-2015 04-12-2015 7.6 + + - Y 
 221 02-18-2015 06-04-2015 15.1 - + - N 
 222 02-18-2015 06-04-2015 15.1 - - - N 
 223 02-18-2015 06-04-2015 15.1 - - + N 
Total Birds 26    10 14 4 7 
Table 2.3: Birds infected with DAS and LR-9 IDs, time of death, and neoplasms observed 
 

















 781 01-30-2015 05-04-2015 13.6 + - - N 
 782 01-30-2015 02-28-2015 4.1 - + - N 
 783 01-30-2015 05-14-2015 15.0 + + + Y 
 784 01-30-2015 02-22-2015 3.3 - - - N 
 785 01-30-2015 03-03-2015 4.6 - + - N 
 787 01-30-2015 05-14-2015 15.0 - - - N 
 788 01-30-2015 02-21-2015 3.1 - - - N 
 789 01-30-2015 05-14-2015 15.0 + - + Y 
 790 01-30-2015 05-14-2015 15.0 - + - N 
 791 01-30-2015 04-01-2015 8.9 + - - N 
 792 01-30-2015 05-14-2015 15.0 - + - N 
 793 01-30-2015 04-07-2015 9.6 - - + N 
 794 01-30-2015 03-13-2015 6.1 + + - Y 
 795 01-30-2015 05-14-2015 15.0 + - - Y 
 796 01-30-2015 02-23-2015 3.6 + - - Y 
 797 01-30-2015 05-14-2015 15.0 + - + Y 
 798 01-30-2015 03-27-2015 8.1 - + - N 
 799 01-30-2015 03-26-2015 8.0 + + - Y 
 892 01-30-2015 04-01-2015 8.7 - - - N 
 91 02-18-2015 04-16-2015 6.9 - + - N 
 92 02-18-2015 04-07-2015 6.9 - - + N 
 93 02-18-2015 05-18-2015 12.9 + + - Y 
 94 02-18-2015 04-01-2015 6.1 - - + N 
 95 02-18-2015 04-16-2015 8.3 + + - Y 
 96 02-18-2015 06-04-2015 15.3 - - + N 
 97 02-18-2015 06-04-2015 15.3 + + + Y 
 98 02-18-2015 05-25-2015 13.9 - + - N 
Total Birds 27    12 13 8 10 
Table 2.4: Birds infected with TERT + LR-9 IDs, time of death, and neoplasms observed 
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Integration Site Mapping and Quantification 
 DNA from tumors was isolated.  The sequencing libraries were prepared as described previously 
(Justice et al., 2015).  Ten µg of purified genomic DNA was sonicated with a Bioruptor UCD-200 
(Diagenode Inc., Denville, NJ, USA).  End repair, A-tailing, and adapter ligations were performed as 
described previously (Gillet et al. 2011) (P-GATCGGAAGAGCAAAAAAAAAAAAAAAA, and adapter long 
arm, CAAGCAGAAGACGGCATACGAGATXXXXXXGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC*T, where 
X’s  de ote the a ode se ue e, P  de otes phospho latio , a d *  de otes a phospho othioate 
bond).  Nested PCR was performed to enrich the library for proviral junctions. In the first round of PCR, 
23 cycles were used with an ALV-spe ifi  p i e  CGCGAGGAGCGTAAGAAATTTCAGG  et ee  the ’ 
LTR and env and a primer (CAAGCAGAAGACGGCATACGAGAT) within the adapter that was attached by 
ligation. In the second round of PCR, a primer (AATGATACGGCGACCACCGAGATCTACACXXXXXXXXGACG-
ACTACGAGCACATGCATGAAG  ea  the ’ e d of the LTR as used. This p i e  has a  additio al 
barcode for increased multiplexing and ended 12 nucleotides short of the junction between viral and 
genomic DNA. This primer was paired with an adapter-specific primer on the opposite side of the 
f ag e t, hi h o e lapped the adapto ’s a  ode se ue e CAAGCAGAAGACGGCATACGAGATXXXXX-
X). Libraries were quantified by quantitative PCR (qPCR) and then under-went single-end 100-bp 
multiplexed sequencing on the Illumina Hi-Seq 2000. A custom sequencing primer 
ACGACTACGAGCACATGCATGAAGCAGAAGG  as used, hi h h idized ea  the e d of the i al ’ 
LTR, 5 nucleotides short of the proviral/genomic DNA junction. The resulting reads could be validated as 
genuine integrations by verifying that they began with the last 5 nucleotides of the proviral DNA, CTTCA. 
The last two nucleotides of the unintegrated proviral DNA, TT, were cleaved by ALV integrase upon 






 Reads were curated with a custom python script to remove sequences that did not start with 
the last fi e u leotides of i al DNA, CTTCA  (J. F. Justice, Morgan, and Beemon 2015; Malhotra, 
Winans, et al. 2017).  The files were uploaded to Galaxy (Giardine et al. 2005; Blankenberg et al. 2010; 
Goecks et al. 2010).  In Galaxy, quality scores were converted to Sanger format with FastQ Groomer 
v1.0.4 (Blankenberg et al. 2010).  CTTCA and adapter sequences were removed using Galaxy Clip tool 
v1.0.1.  This tool also removed reads containing ambiguous nucleotides and reads less than 20 
nucleotides after adapter removal.  Reads were mapped with Bowtie (Goecks et al. 2010) against the 
Gallus gallus 4.0 genome (Nov. 2011).  Sequences were aligned using a seed length of 28 nucleotides, 
with a maximum of 2 mismatches permitted in the seed.  All alignments for a read were suppressed if 
more than one alignment existed to avoid multiple mapping and ensure reads correspond to only 
unique integration sites.  50,000 random reads were selected from each sample to be used for further 
analysis.  If less than 50,000 reads were obtained, all available reads were used.  A custom Perl pipeline 
developed in the lab was used to analyze the aligned reads from bowtie (Justice, Morgan, and Beemon 
2015).  The custom pipeline identified unique integration sites, hotspots of integration, and common 
integration sites among multiple samples.  Integrations from two unrelated barcodes on the same 
sequencing lanes were omitted. 
Statistical Analysis 
 For statistical analysis of data Microsoft Excel 2016 was used.  Cumulative mortality rates were 
estimated using linear regression.  Statistical significance between mortality rates were calculated by t-
test comparing the slope coefficients of any two linear regressions (Soper 2018).  Statistical significance 
between two population proportions, or percentages, were tested using Fishe ’s e a t test fo  a    




Cloning of Chicken TERT into a Recombinant ALV-derived Vector 
 Full length TERT cDNA was cloned into DAS, a vector encoding a replication-deficient 
recombinant virus derived from RSV.  The resulting clone is named DAS TERT (Figure 1.1).  The 4041 bp 
long TERT insert was confirmed by Sanger sequencing using staggered primers (Figure 2.1).  Sequence 
was identical to reference full length TERT transcript reported on Ensembl (ENSGALT000000021539.2).  
Transfection of CEF with DAS TERT or DAS TERT and ALV increased total TERT expression by 36-fold or 
568-fold, respectively (Figure 2.2A).  CEF transfected with DAS TERT and ALV had increased telomerase 
activity (Figure 2.2B).  In contrast, transfection by DAS and ALV did not significantly increase telomerase 
activity (Figure 2.2B). 
 
Virion Production and Infection with TERT Virus 
 Supernatant from CEFs cotransfected with DAS TERT and ALV tested positive for RT activity, 
indicating successful virion production post-transfection (Figure 2.3A).  Virions produced from 
coinfection were able to produce supernatant positive for RT activity, indicating successful virion 
production post-infection (Figure 2.3A).  Supernatant from CEFs cotransfected with DAS TERT and ALV 
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have detectable viral TERT and ALV cDNA (Figure 2.3B).  Quantification of TERT, DAS, and ALV viral titers 
was possible using qRT-PCR, targeting unique sequencing to each viral RNA (Figure 2.3C).  
Higher proportions of TERT virions were produced at earlier time points – eight days post 
transfection being the earliest with appreciable titers (Figure 2.3C).  An increase in the relative titer of 
ALV compared to TERT virions was observed over time in viral samples with TERT and ALV (Figure 2.3C).  
In contrast, viral samples containing DAS and ALV did not show any significant difference in virion 
production (Figure 2.3C).  Comparing the titers of TERT and DAS, packaging may be more efficient with 
smaller viral genomes.  Viral titers prepared from chicken experiments eight days after transfection 
were selected in order to maximize yield of TERT virions.    
CEFs infected with viral supernatant from DAS TERT and ALV transfected cells show increased 
telomerase activity (Figure 2.3D).  In contrast, CEFs infected with DAS and ALV did not show significant 






Significant Changes in Mortality/Morbidity Rates Between Chicken Groups 
 High morbidity in birds was observed as early as 4 weeks after hatching (Figure 1.3).  The first 
birds were sacrificed at the end of 4 weeks in both the DAS group and the TERT group.  Cumulative 
mortality appeared to increase in a linear manner with respect to time for all infected groups (Figure 
2.3).  Mortality rates were statistically significant between each group where DAS show the highest rate, 
followed by TERT, and LR-9.  At the end of 14 weeks, LR-9 had 44% (4/9) chickens sacrificed or died, the 
DAS group had 69% (18/26), and the TERT group had 56% (15/27).  No significant difference in morbidity 
was observed between the chicken groups at the end of 14 weeks, which is the week before the final 




No Significant Difference in Types of Lesions or Tumor Burden Between Chicken Groups 
 Types of lesions were scored and categorized into lymphoid, hemangiomas, or other – lesions 
that did not classically fit into lymphoid or hemangiomas – and tumor burden was reflected in the 
occurrence of multiple lesions in a single bird.  In all 3 chicken groups, hemangiomas accounted for the 
majority of tumors ranging from 44% to 54%, followed by lymphoid lesions ranging from 33% to 44%, 
and, lastly, lesions that were ambiguous ranging from 15% to 30% (Table 2.5).  Percentage of multiple 
lesions ranged from 22% to 37% (Table 2.5).  No statistical significance was found between the chicken 
groups across all four variables. 
 
Group Lymphoid Hemangioma Other Multiple lesions Any lesions 
LR-9 3/9 (33%) 4/9 (44%) 2/9 (22%) 2/9 (22%) 8/9 (89%) 
DAS + LR-9 10/26 (38%) 14/26 (54%) 4/26 (15%) 7/26 (27%) 22/26 (85%) 
TERT + LR-9 12/27 (44%) 13/27 (48%) 8/27 (30%) 10/27 (37%) 23/27 (85%) 
Table 2.5: Number and percentage of birds with specific types of lesions and tumor burden  
 
Chicken Tumors with TERT Recombinant Provirus 
 Using primers specific for the TERT recombinant provirus, a PCR screen of tumors from chickens 
coinfected with the TERT recombinant virus and ALV revealed two tumors out of 32 tumors (1 out of 27 
birds) that had an integrated TERT recombinant provirus (Figure 2.5A and 2.5B).  The two liver tumors, 
791L1 and 791L2, show the predicted amplification product of the unique TERT-ALV sequence in the 




Two different spliced proviral TERT transcripts were detected from PCR amplification of cDNA 
from both tumors (Figure 2.6A and 2.6B).  qRT-PCR for total TERT expression (Figure 2.6C) of both 
tumors shows greater than 40-fold expression compared to normal bursal control (Figure 2.5C).  Both 
tumors show greater than 20-fold expression compared to D2L, a previously identified tumor that was 
shown to have increased endogenous TERT expression (Figure 2.5C) (Yang et al. 2007; J. F. Justice, 
Morgan, and Beemon 2015; Malhotra, Winans, et al. 2017).  Sequencing analysis of ALV proviral 
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integrations of 791L1 and 791L2 suggest that the tumors were likely derived from two independent 
clonal expansions (Figure 2.gD).  ARID5B was the most abundant unique integration in 791L1.  A unique 





Multiple Tumors with Common Expanded Integration Sites 
High-throughput sequencing analysis of integration sites of ALV-induced tumors show different 
group of genes associated with lesion type.  Consistent with previous reports, multiple tumors harbored 
expanded integrations sites near MYB, mir-155, MYC, and TERT (Figure 2.7).  Tumors 81L, 206L, 215B, 
and 791L2 had unique clonal integration sites near MYB.  Tumors 81L, 206L, 783L5, and 791L2 had 
integrations near mir-155.  Tumors 886L1, 215B, 783L5 had integration near MYC.  Tumors 206L and 
208L2 had integrations near TERT.  For each gene, there was at least one tumor that had coinciding 
integrations near another of the four genes, and a tumor that was exclusive to one of these 4 genes.  
With the exception of 81 liver hemangioma and a mixed liver tumor in 783, tumors with expanded 







In addition to previously reported genes, multiple tumors harbored expanded integrations sites 
near FRK, PLAG1, and GLIS3 (Figure 2.8).  Tumors 83LE and 792M had integrations near FRK.  Tumor 
223K and 795K3 had integrations near PLAG1.  Tumor 94K and 792M have integrations near GLIS3.  
Tumors with FRK and PLAG1 integrations did not coincide with any previously reported sites.  In 
addition, a GLIS3 integration coincided with a FRK integration in tumor 792M, and a GLIS3 integration 
coincided with a mir-155 integration in tumor 94K.  In contrast to MYB, mir-155, MYC, and TERT, tumors 
with expanded unique integrations near FRK, PLAG1, and GLIS3 were enriched in hemangiomas and 









 In this study, we tested the effects of TERT overexpression on ALV-induced tumorigenesis by 
coinfecting chicken embryos with a TERT recombinant virus and ALV.  Overall, we cannot conclude if 
TERT overexpression contributes to tumor progression in ALV-induced tumorigenesis.  This conclusion 
was largely attributed to converging evidence that cells were not saturated with TERT virus during the 
course of the chicken experiment. 
There was a notable difference in mortality rates, where the DAS group showed a significantly 
higher rate, followed by TERT, and then ALV.  This difference in mortality rates is associated with the 
difference in initial total titers used for infection.  Both DAS and TERT virus may contribute to 
tumorigenesis by proviral integration.  If the chicken embryo was saturated, we would likely observe 
either a difference attributed to TERT overexpression or no difference in mortality rate.  In our case, the 
association between mortality rate and total initial infection titers suggests that the embryos were not 
saturated with DAS and TERT virus. 
To achieve TERT overexpression, a replication-deficient ALV-derived vector was used to 
accommodate the size of full length chicken TERT cDNA (4 kb).  Consequently, unlike ALV, the TERT virus 
is not able to replicate on its own.  Thus, ALV is needed as a helper virus for the packaging of new 
recombinant virions in cells initially coinfected with both viruses.  From the process of generating virus 
for the initial infection, ALV appears to prefer to package itself and DAS more efficiently than TERT 
recombinant virus over time.  This may be attributed to the greater genomic size of the TERT virus.  
Consequently, DAS and ALV probably replicated better than the TERT virus, which may also contribute to 
the increased mortality rate observed with DAS.  In the future, a scrambled sequence or an equally sized 
gene that is known to be unrelated to tumorigenesis could be used to mitigate this difference. 
No significant differences were found in overall mortality at the end of 14 weeks or in tumor 
incidence at the end of the experiments at 15 weeks. As the cells were likely unsaturated by TERT and 
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DAS virus, the actual events necessary for transformation likely became more dependent on the 
replication competent ALV, over time.  Being replication competent, ALV would be expected to saturate 
the available target cells eventually during chicken development.   
Furthermore, we did not rule out the potential lethality related to the overexpression of TERT in 
B cells.  Loss of B cells would reduce the pool of potential ALV target cells, which may lead to a reduction 
of malignant transformation in B cells.  This reduction in B cell transformation may then lead to a 
reduction in mortality rate and lymphoid lesions in our chicken experiments.  With the reduction of the 
characteristic rapid-onset B-cell lymphomas, ALV infection of endothelial cells may occur and lead to the 
prevalence of hemangiomas that we observed.  However, we did not observe a noticeable difference in 
chick viability post-infection and CEFs post-transfection. 
Consistent with these ideas, we observe a low frequency of tumors coinfected with the TERT 
virus and ALV (2 out of 11 lymphoid tumors in a total of 32 tumors tested).  In addition, no DAS provirus 
was detected in the DAS group.  Both tumors were found in the liver of chicken 791.  While tumor 791L2 
has clonal integration near MYB and mir-155, which is consistent with previous chicken tumor data, 
791L1 had a clonal integration in gene ARID5B, suggesting that this gene may potentially cooperate with 
TERT.  AT-rich interactive domain-containing protein 5B, ARID5B, is a transcription coactivator that acts 
as a binding domain for the histone demethylase PHD finger protein 2 (PHF2) and histone deacetylases 
(Hata et al. 2013; Leong et al. 2017).  Interestingly, tumor 791L2 also had a clonal integration near PHF2, 
which further supports the involvement of ARID5B and PHF2 in ALV-induced lymphomagenesis. 
Genome-wide association (GWAS) studies have revealed several single nucleotide 
polymorphisms in ARID5B that are significantly associated with risk for hematological malignancies in 
humans (Papaemmanuil et al. 2009; Treviño et al. 2009).  Interestingly, ARID5B has been shown to 
positively regulate the expression of MYC in t-cell acute lymphoblastic leukemia (Leong et al. 2017).  
MYC has been previously shown to be a major player in ALV-induced B-cell lymphomas (Hayward, Neel, 
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and Astrin 1981).  The clonal integration near ARID5B is located in the promoter region of ARID5B in the 
opposite orientation, which suggests enhancer activation of this gene in the chicken tumors. 
Alternatively, our data does not rule out the possibility that malignant transformation may be 
the result of proviral integrations from the TERT recombinant provirus activating nearby genes.  In order 
to test this, we can identify the location of the provirus by using inverse PCR and Sanger sequencing.  As 
previously noted, the DAS genome is ALV-derived; however, the LTR is varied enough to provide unique 
priming sites for amplification of the TERT specific provirus in tumor samples with LR-9 proviruses.  The 
data from tumors 791L1 and 791L2 suggest that the approach was sound in the identification of 
potential TERT cooperating genes, despite the many technical caveats mentioned.   
In order to address the primary issue of infection saturation, we could seek a method to 
generate TERT virions without the need of a helper virus or any other agent that may contribute to 
tumorigenesis and infect chickens with just the TERT recombinant virus.  We could then use a titer that 
may guarantee saturation of the cells in the chicken embryo to ensure that most of the cells are 
infected. 
An attractive approach to achieving TERT overexpression in the developing chicken embryo is to 
utilize CRISPR/Cas9.  Recently, this method of genome editing is shown to be feasible in the developing 
chicken embryo (Williams et al. 2018).  Rapid somatic gene knockout, as well as activation of 
endogenous target promoter, was shown to be possible in chicken embryos (Williams et al. 2018).  We 
could utilize a similar approach to activate TERT expression and observe any changes in cancer 
phenotype.  This approach also has the added benefit of mitigating confounding effects of proviral 
integration in approaches using recombinant retroviruses. 
In contrast to previous reports, hemangiomas were the predominant type of lesions observed in 
this study.  One possible explanation may be attributed to the potential variance in the genetic 
background of the chickens.  Genetic variance even in highly inbred chicken lines have been shown to 
56 
 
impact various aspects of chicken biology.  Interestingly, an area of active investigation involving genetic 
variance among inbred chickens concerns the susceptibility of chickens to Ma ek’s disease, a disease 
caused by an alphaherpesvirus (Luo et al. 2013).  Copy number variation is shown to be associated with 
Ma ek’s disease esista e that a  e t ansmitted vertically (Luo et al. 2013).  Considering this idea, 
one can reason that the sudden occurrence of hemangiomas induced by chickens infected with a 
previously characterized ALV may be partly attributed to genetic variance of the chickens. 
Nevertheless, this occurrence presented an opportunity to characterize the tumors for any 
patterns that may delineate among the different types of lesions observed in our chicken experiment.  
Integration site analysis suggests that there is selection for different genes between lymphoid tumors 
and hemangiomas.  Consistent with previous reports, integration sites near MYB, mir-155, MYC, and 
TERT were found to be associated with lymphoid tumors of liver tissue.  In comparison, multiple 
hemangiomas had integrations sites near FRK, PLAG1, and GLIS3. 
Retroviral induced hemangiomas in chickens is not entirely new.  Currently, ALV-J is a major 
economic problem in Asia.  ALV-J is known to cause hemangiomas and myeloid tumors in chickens.  
Recently, our lab had identified the MET gene as a common integration target in ALV-J-induced chicken 
hemangiomas (Justice et al. 2015).  In this study, ALV-A appears to also have the capacity to induce 
hemangiomas in chickens, and our integration data implicates FRK, PLAG1, and GLIS3 as potential genes 
involved in the development of hemangiomas. 
There is not a known association among the three genes identified in our ALV-A study and the 
MET gene implicated by our ALV-J study in hemangiomas.  All three genes have been previously 
associated with some type of cancer.  FRK and PLAG1 appears to be the most extensively studied, and 
much less is known about GLIS3.  The non-receptor tyrosine kinase Fyn-related kinase (FRK) is a member 
of the family of kinases that are distinctly related to the Src family kinases (Goel and Lukong 2016).  
Interestingly, Src is one of the first viral oncogenic gene products characterized through the investigation 
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of RSV (Beemon and Hunter 1978).  Not surprising, FRK has been shown to play a role in various human 
cancers albeit there is some controversy.  Originally discovered to potentially have tumor suppressive 
function, FRK has been recently shown to have oncogenic roles as well (Goel and Lukong 2016).  The 
functional paradox appears to be dependent on the tissue-specific context (Goel and Lukong 2016).   
Interestingly, translocation activation of FRK has been observed in a specific hematological 
malignancy.  More specifically, patients with acute myelogenous leukemia are shown to carry a 
translocation that results in the fusion of exon 4 of an ETS transcription factor, ETV6, to exon 3 of FRK 
(Hosoya et al. 2005).  The resulting fusion transcript is expressed as a chimeric protein consisting of the 
entire oligomerization domain of ETV6 and the kinase domain of FRK, which is shown to have kinase 
activity and be sufficient in driving transformation in Ba/F3 cells and NIH3T3 cells (Hosoya et al. 2005). 
Our data shows that the two expanded unique integrations in tumor 83LE and 792M are located in exon 
1 of FRK and are in the sense orientation, suggesting that FRK is likely activated by ALV.  This would likely 
implicate FRK as a potential oncogenic factor in driving ALV-induced tumorigenesis. 
Pleomorphic adenoma gene 1 (PLAG1) was first discovered in pleomorphic adenomas of the 
salivary gland (Kas et al. 1997).  Unlike FRK, the majority of the research suggests that PLAG1 is an 
oncogenic factor, which was later shown to be associated with other human cancers such as 
lipoblastoma, hepatoblastoma, and, interestingly, hematological malignancies like acute myeloid 
leukemia (Astrom et al. 2000; Zatkova et al. 2004; Landrette et al. 2005).  Interestingly, one of the main 
mechanisms of PLAG1-induced cancers is a reciprocal chromosomal translocation event.  Translocation 
events involve the swapping of the PLAG1 promoter with that of an ubiquitously expressed gene (Juma 
et al. 2016).  The chromosomal breakpoints are located between the upstream regulatory region and 
the coding region of both translocation partners; thus, preserving the coding sequence and functionality 
of the translated proteins downstream (Juma et al. 2016).  In the case of PLAG1, expression becomes 
driven by strong promoters, leading to overexpression in human cancers.  This is reminiscent of 
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activation by retroviral promoter insertion, which is consistent with the two clonal integrations observed 
in our study in exon 1 of PLAG1.   
 Lastly, Gli-similar 3 (GLIS3) is part of a subfamily of Krüpple-like zinc-finger proteins, also termed 
Krüpple-like factors (KLBFs), which have the capability to bind to GC-rich DNA sequences.  Originally 
named from the study of segmentation defects in Drosophila, KLFs are involved in many aspects of 
biological processes, including differentiation, development, proliferation, and apoptosis (Pearson et al. 
2008).  Not surprisingly, the activation of KLFs like GLIS3 are associated with many human cancers (Chou 
et al. 2017).  Once again, GLIS3 has been shown to also be activated by means of an abnormal 
chromosomal translocation event resulting in the fusion of GLIS3 and another oncogenic factor, cleft lip 
and palate transmembrane protein 1-like (CLPTM1L), in cases of fibrolamellar hepatocellular carcinoma 
(Xu et al. 2015).  This translocation event between chromosome 5 and 9 produces a fusion protein that 
contains the first 7 exons of CLPTM1L and exons 5-11 of GLIS3 that promotes cancer phenotypes in 
hepatocellular carcinoma cell lines (Xu et al. 2015). 
What makes this particularly interesting are the sites of translocation.  In humans, CLPTM1L is 
upstream of TERT and the TERT-CLPTM1L locus is a known target for recurrent somatic chromosomal 
translocations to immunoglobulin sites in human B-cell neoplasms (Nagel et al. 2010).  In these cases, 
TERT is transcriptionally activated by promoter insertion of immunoglobulin promoters (Nagel et al. 
2010).  Interestingly, the human TERT-CLPTM1L locus contains the coding region for a human TERT 
Antisense Promoter Associated (TAPAS) lncRNA (Malhotra, Freeberg, et al. 2017).  The TERT-CLPTM1L 
locus is conserved in chickens and is the site of the clonally expanded TERT promoter integrations we 
previously reported, as well as the coding region of chicken TAPAS  (Yang et al. 2007; Justice, Morgan, 
and Beemon 2015; Nehyba et al. 2016).  Furthermore, our integration data shows that the unique 
integration site in GLIS3 in tumor 792M and 94K are located upstream of exon 3 in the sense direction, 
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which may implicate the upregulation of a truncated GLIS3 product similar to what is observed in 
fibrolamellar hepatocellular carcinoma. 
In conclusion, this study expands the number of genes associated with ALV-induced 
tumorigenesis.  In addition to previously reported genes, new potential genes of interest are observed.  
Tumor 791L1 implicates ARID5B as a potential associated gene for TERT overexpressing tumors while 
791L2 reaffirmed our previous reports of potential cooperation between MYB and TERT in ALV B-cell 
lymphomas (Malhotra, Winans, et al. 2017).  In addition, the analysis of ALV-A-induced hemangiomas 
offers new potential players, FRK, PLAG1, and GLIS3, in hemangioma development. All three genes 
appear to be associated with activating translocation events in various human cancers.  This may 
implicate a relationship between selection for sites of translocation and common sites of proviral 
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Avian leukosis virus (ALV) is a simple retrovirus that can induce B-cell lymphoma in chicken(s) and other 
birds by insertional mutagenesis. The promoter region of telomerase reverse transcriptase (TERT) has 
been identified as an important integration site for tumorigenesis. Tumors with TERT promoter 
integrations are associated with increased TERT expression. The mechanism of this activation is still 
under investigation. We asked whether insertion of proviral DNA perturbs the epigenome of the 
integration site and, subsequently, impacts the regulation of neighboring genes. DNA cytosine 
methylation, which generally acts to suppress transcription, is one major form of epigenetic regulation. 
In this study, we examine allele-specific methylation patterns of genomic DNA from chicken tumors by 
bisulfite sequencing. We observed that alleles with TERT promoter integrations are associated with 
decreased methylation in the host genome near the site of integration. Our observations suggest that 
insertion of ALV in the TERT promoter region may induce expression of TERT through inhibition of 
maintenance methylation in the TERT promoter region. 
Introduction 
Avian leukosis virus (ALV) is a simple retrovirus that can induce B-cell lymphoma in chickens and 
other fowl by means of insertional mutagenesis. Proviral integration can upregulate the expression of 
proximal genes through enhancer and promoter elements in the viral long terminal repeat (LTR) 
sequences (Beemon and Rosenberg 2012; J. Justice and Beemon 2013). Previous studies have shown 
common integration sites in ALV-induced lymphomas near MYC, MYB, BIC and, more recently, the 
telomerase reverse transcriptase (TERT) genes (Justice, Morgan, and Beemon 2015; Hayward, Neel, and 
Astrin 1981; Baba and Humphries 1986; Clurman and Hayward 1989; Yang et al. 2007; Nehyba et al. 
2016; Malhotra, Winans, et al. 2017). Previously, we found that integrations in the TERT promoter 
region were one of the most clonally expanded—or most abundant unique—integrations in tumors 
tested from ALV infected chickens (Justice, Morgan, and Beemon 2015; Malhotra, Winans, et al. 2017). 
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This suggests that TERT promoter integrations occurred early during ALV-infection in tumors with 
abundant copies of a unique TERT integration, implicating them as important early events in 
tumorigenesis (Justice, Morgan, and Beemon 2015; Malhotra, Winans, et al. 2017).  
TERT encodes the catalytic subunit of telomerase, which has been shown to be upregulated in 
90% of different types of human cancers surveyed, including lymphomas (Shay and Bacchetti 1997). 
Elevated TERT expression contributes to telomerase-dependent maintenance of telomeres that is often 
required for long-term proliferation and survival of cancer cells (Blasco 2005). Similar phenotypes can be 
achieved through a telomerase-independent process, known as alternative lengthening of telomeres 
(ALT), which has been observed in both humans (Bryan et al. 1997, 1995) and chickens O’Ha e a d 
Delany 2011). Expression of TERT is tightly regulated through many mechanisms, including epigenetic 
modification of the promoter region to regulate telomerase activity in most somatic cells (Delany and 
Daniels 2004; Zhu, Zhao, and Wang 2010). Systematic analysis of the Cancer Genome Atlas database 
revealed that methylation of the TERT promoter region is one of the most prevalent markers associated 
with TERT expression in human cancers, in addition to the discovery of common somatic point 
mutations in the TERT promoter (Barthel et al. 2017; Horn et al. 2013; Huang et al. 2013).  
DNA methylation is generally associated with repression of gene expression and occurs almost 
exclusively at regions of DNA where a cytosine nucleotide is followed by a guanine nucleotide (CpGs) in 
vertebrates (Li et al. 2011; Bird 2002; Weber and Schübeler 2007). The vast majority of DNA is highly 
methylated at CpGs; however, a small fraction of DNA comprising CpG islands, areas containing a high 
concentration of CpGs (at least 200 bp long with >60% GC), show differential methylation during 
development and disease states (Li et al. 2011; Bird 2002; Weber and Schübeler 2007). These CpG 
islands are frequently associated with gene promoters (Li et al. 2011; Bird 2002; Weber and Schübeler 
2007). In the case of TERT, the relationship between TERT promoter methylation and expression has 
proven to be complex and is still under active investigation. Surprisingly, early studies suggest a direct 
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relationship between TERT promoter methylation and expression, and, subsequently, telomerase 
activity (Devereux et al. 1999; Dessain et al. 2000; Nomoto et al. 2002; Guilleret and Benhattar 2004; 
Guilleret et al. 2002). In multiple studies, normal human somatic cells that do not express TERT are 
associated with unmethylated or hypomethylated promoters, while some cancer lines with completely 
hypermethylated TERT promoter regions express TERT (Devereux et al. 1999; Dessain et al. 2000; 
Nomoto et al. 2002; Guilleret and Benhattar 2004; Guilleret et al. 2002). In contrast, other reports of 
TERT promoter DNA methylation suggest that methylation is associated with gene silencing (Liu et al. 
2004; Lopatina et al. 2003; Shin et al. 2003). Further investigations reveal that the activation of TERT 
expression can be allele-specific in cancer cells, which are under pressure to maintain active alleles 
protected from DNA methylation (Zinn et al. 2007). Most recently, common TERT promoter mutations 
are shown to be associated with allele-specific hypomethylation of the TERT promoter in cancer cells 
with TERT expression (Stern et al. 2017).  
DNA methylation also plays an important role in the regulation of retroviral proviruses. First 
introduced by Katz and co-workers, evidence of proviral DNA methylation was observed in a rat 
restriction cell line (XC) that was established from rat sarcoma tumors induced through 
heterotransplantation by inoculating newborn rats with suspensions of Rous sarcoma tissue (Svoboda 
1960; Guntaka et al. 1980). Using this model, Svoboda and co-workers demonstrated that DNA 
methylation was involved in transcriptional silencing of avian proviruses (Svoboda et al. 2000; Hejnar et 
al. 1999). Daxx, a cytoplasmic Fas death domain-associated protein, was later discovered to be required 
for long-term maintenance of silencing and full viral DNA methylation of avian proviruses in human cells 
(Shalginskikh et al. 2013).  
Further investigation revealed a dynamic relationship between the methylation state of the 
proviruses and the context of the integration site. The integrations of ALV-related retroviruses like Rous 
sarcoma virus (RSV) and Moloney murine leukemia virus (MLV) can perturb the methylation state of 
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flanking host DNA in different ways. RSV integration has been associated with transient 
hypomethylation of flanking genomic DNA in hamster cells (Hejnar et al. 2003). In contrast, MLV 
integration is associated with de novo methylation in mice (Jähner and Jaenisch 1985). Proviruses 
integrated close to transcriptional start sites of active genes may have long-term transcriptional activity 
and be resistant to transcriptional silencing by DNA methylation; in contrast, proviruses in intergenic 
regions tend to become transcriptionally silenced (Senigl, Auxt, and Hejnar 2012). Studies with other 
human viruses suggest that there is a direct correlation between the methylation state at the site of 
integration prior to proviral integration and the methylation status of the provirus (Watanabe et al. 
2015; Hatano et al. 2017). Ultimately, local changes in DNA methylation are dependent on a growing list 
of factors that include the host cell properties, integrating virus, and the site of integration.  
Chicken and human telomerase activity and telomere biology share some key similarities. High 
levels of telomerase activity are observed in early stage chicken embryos and human prenatal organs, 
and telomerase activity is downregulated in a temporal and tissue-specific manner for most somatic 
tissues (Forsyth, Wright, and Shay 2002; Taylor and Delany 2000; Swanberg et al. 2010). With some 
exceptions, constitutive activity is observed in renewable tissue types and diminished telomerase 
activity in most differentiated somatic tissues (Forsyth, Wright, and Shay 2002; Taylor and Delany 2000; 
Swanberg et al. 2010). Division-dependent telomere shortening occurs in chicken somatic tissues, and 
telomerase activity upregulation is present in transformed chicken cells (Swanberg and Delany 2003). 
Furthermore, chicken TERT also has CpG islands spanning from the TERT promoter region and into the 
odi g egio . Mo e spe ifi all , the e is a s alle  CpG isla d f o  −  to −  elati e to the TERT 
transcriptional start site (TSS), and a larger one f o  −  to +  spa i g a oss the fi st TERT e o  
and into the first intron (Figure 3.1 . I  o pa iso , hu a  TERT has CpG isla ds spa i g f o  −  to 




Figure 3.1. Schematic illustration of PCR primers, the cytosine-guanine dinucleotide (CpG) islands, and avian 
leukosis virus (ALV) telomerase reverse transcriptase (TERT) integrations in the chicken TERT promoter region. 
Primers are labeled A–H and depicted as letters and blue arrows. The targeted CpG island of interest is depicted 
within 333–536 bp upstream of the TERT transcriptional start site (TSS). The six ALV integrations tested are labeled 
and indicated with orange arrows at the site of integration. At the bottom, a schematic of ALV provirus in tumor 
D2L is depicted with primers labeled in the long terminal repeats (LTRs). 
 
The influence of ALV integration on the methylation of the chicken TERT promoter has not 
been characterized previously in ALV-induced lymphomas. Our lab has observed that the clonally 
expanded integrations in the TERT promoter remain transcriptionally active in chicken tumors. 
Expression analysis revealed the upregulation of a novel TERT antisense promoter-associated 
(TAPAS) long non-coding RNA (lncRNA), in chicken tumors with TERT promoter integrations. TAPAS 
transcripts corresponded to a region downstream of the common ALV integration site in the TERT 
promoter region. Expression of TAPAS was shown to be partly driven by the ALV proviral promoter, 
which was supported by the detection of spliced proviral transcripts fused with TAPAS (Nehyba et al. 
2016). Furthermore, the same subset of tumors was associated with increased TERT expression (Yang 
et al. 2007; Nehyba et al. 2016). Thus, we studied the epigenetic state of the ALV provirus and the 
TERT promoter in chicken lymphomas with clonally expanded TERT promoter integrations. To better 
understand the interplay between the epigenome of the host DNA and provirus, we compared the 
DNA methylation status of the unoccupied allele (without a TERT promoter integration) with the 
occupied allele (with a TERT promoter integration) in individual tumors with known clonally 
expanded TERT integrations. In this study, we found that ALV integrations in the TERT promoter are 




Materials and Methods 
Tumor Induction and Samples 
Groups of 5- and 10-day-old chicken embryos were infected with ALV by injection with either 
ALV-LR9, ALV-ΔLR , ALV-G919A, or ALV-U916A as described previously (Nomoto et al. 2002; Justice, 
Morgan, and Beemon 2015; Polony et al. 2003). Chickens injected include inbred single comb (SC) White 
Leghorn line embryos from Hy-Line International (Dallas Center, IA, USA) and specific pathogen free 
embryos from Charles River (North Franklin, CT, USA). ALV-LR-9 mutants have a deletion (ALV-ΔLR  o  
silent mutation (ALV-G919A and ALV-U A  i  a ′ egulato  ele e t that esults i  apid o set of B-
cell lymphomas in chickens. Chickens were observed daily after hatching and euthanized when 
moribund or at the end of 10–12 weeks. Once sacrificed, tumor tissue and normal tissue were harvested 
f o  i fe ted i ds a d f oze  at −  °C. No al tissues e e olle ted f o  u i fe ted hi ke s that 
were sham injected with media as controls. In total, five normal tissues (bursa, kidney, liver, spleen and 
non-tumor tissue from an infected bird, C2K), nine tumors without any known TERT promoter 
integrations, nine tumors with known TERT promoter integrations, and two chicken cell cultures were 
used for bisulfite sequencing (Table 3.1) (Justice, Morgan, and Beemon 2015; Malhotra, Winans, et al. 
2017). 
 
Sample group Tissue type 
Normal control tissues 
 
normal bursa (NB), normal kidney (NK), 
normal liver (NL), normal spleen (NS), C2K 
Chicken cell culture primary chicken embryo fibroblast (CEF),  
bursal lymphoma cell line (DT-40) 
Tumors without telomerase reverse 
transcriptase (TERT) promoter integration 
205L1, 209L, 214L4, 215K1, 218K, 
796L, 223K, 791L1, B8L 
Tumors with TERT promoter integration 206L1, 208L2, A1B, C2B, C6L, C7B, C7L, D2L, 4-w-lr-9 




Chicken experiments were performed at the University of Delaware. These experiments were 
approved by the Institutional Animal Care and Use Committee (AUP Number 1271-2016-2), which 
was renewed on 1 August 2016. 
DNA Extraction and Bisulfite Treatment 
50 mg of tissue was homogenized with a Kimble-Chase Kontes pellet pestle and digested with 
proteinase K at 50 °C for 15 h. DNA was extracted with two rounds of phenol-chloroform extraction, 
with a 2 µg RNase A treatment for 1 h at 37 °C in between the rounds, followed by ethanol precipitation. 
DNA concentration was measured with a Thermo Scientific Nanodrop 2000c instrument (Waltham, MA, 
USA). For bisulfite treatment, an optimized protocol was adapted from Pappas et al. (Pappas, Toulouse, 
and Bradley 2013). In brief, 5 µg of genomic DNA was sonicated briefly with a Bioruptor UCD-200 
instrument (Diagenode Inc., Denville, NJ, USA). DNA samples were then denatured using 3 N NaOH at 37 
°C for 15 min. Sulfonation of unmethylated cytosines was performed by the addition of sodium bisulfite-
hydroquinone solution in a thermal cycler at 95 °C for 4 min followed by 55 °C for 2 h. DNA was then 
desalted using a Thermal Scientific GeneJet PCR purification Kit (Waltham, MA, USA) and deaminated 
with the addition of 3 N NaOH at 37 °C for 15 min. Lastly, desulfonation and precipitation were 
performed by adding glycogen, 10 M ammonium acetate, chilled in 95% ethanol and incubated 
o e ight at −  °C. “a ples e e e t ifuged at , × g for 30 min, washed with 70% ethanol, air-
d ied, a d sto ed at −  °C fo  PCR a plifi atio  a d se ue i g. 
PCR Amplification and Sequencing Analysis 
 Target sequences for tumor samples 4-wlr-9, A1B, and D2L were amplified by one round of PCR 
using bisulfite treated DNA. A schematic representation of the positions of corresponding primers, 
targeted region, and ALV integration sites are shown in Figure 3.1. Henceforth, alleles without a TERT 
promoter integration will be referred to as unoccupied alleles and alleles with an integration as 
occupied alleles. For amplification of the unoccupied alleles, a target CpG island within 333–536 bp 
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upstream of the chicken TERT TSS was amplified using primer A (GTTTTTGTTTTGTTTTTGAGGAGAT) and 
primer B (AACTAAAAATTTTCTCTATCAAATTATATT). For the amplification of occupied alleles, primers 
flanking the proviral-host junction at the site of integration were used. For 4-wlr-9 and A1B, primer A 
and primer C (CAACCCAAATACACACCAATATAATAA  e e used to a plif  the ′LTR-host junction. For 
D L, p i e  B a d p i e  D e e used to a plif  the ′LTR-host junction. Amplification of occupied 
alleles in C7L, C2B, and 208L2 required a semi-nested PCR approach. The first round of PCR was 
performed using primer E (TCACAAAAATAAATAAAAAACATTACTT) and primer G (TATATTGGTGTGTATTT-
GGGTTGAT . I  the se o d ou d, ′LTR as a plified usi g p i e  F AAAAAAACCTCTAAAATCACTTAA-
TCC) and primer G, while the target CpG island was amplified using primer H (ATGTAGAAGTAGAAGGTT-
TTATTT) and primer F. PCR amplifications were performed using Thermo Scientific Phusion U Hot Start 
DNA pol e ase Waltha , MA, U“A  ith opti ized o ditio s adapted f o  a ufa tu e ’s 
instructions. 
PCR amplicons were analyzed by conventional sequencing provided by Eurofins Genomics 
services (Louisville, KY, USA). Quantification of methylation was performed manually by digitally 
measuring the peak height of chromatograms. For each CpG site, percent methylation was calculated by 
dividing the cytosine peak height by the total peak height of cytosine and thymidine and multiplying by 
100. Percent methylation means were calculated by averaging percent methylation of all CpG sites 
sequenced region of one representative sample. All unmethylated CpG sites had undetectable cytosine, 
or showed only thymidine peaks. All non-CpG cytosine showed complete conversion to thymidine. At 
least two technical repeats were performed from extracted genomic DNA. 
 PCR amplification and sequencing analysis of the larger CpG that was closer to the TSS proved to 






Chicken TERT Promoters Were Significantly Methylated in Unoccupied Alleles 
Limited data were available about the methylome of chicken tumors. In order to assess the 
effects of ALV integration on the methylation status of the TERT promoter, we required data on the 
methylation status of a CpG rich region in the TERT promoter of unoccupied alleles. We performed 
conventional bisulfite sequencing of genomic DNA samples that include five normal tissues, two chicken 
cell culture samples, nine tumors that do not have clonal TERT promoter integrations, and nine tumors 
that do have clonal TERT promoter integrations (Table 3.1). Sequencing was performed on PCR 
amplicons 333–536 bp upstream of the chicken TERT TSS of the unoccupied allele (Figure 3.1). This 
specific region was selected because multiple chicken tumors have neighboring TERT promoter 
integrations (Figure 3.1). CpG site distribution is depicted in this region in Figure 3.2. All tissues tested 








Figure 3.2. CpG methylation profiles of the targeted TERT promoter region in unoccupied alleles. Schematic 
representation of the CpG dinucleotide distribution is shown at the top. Four CpG sites of interest (CpG386, 
CpG402, CpG430, and CpG435) are indicated. Bisulfite sequencing analysis of the target region is depicted  as a 
linear array of open circles representing non-modified CpG residues and closed circles representing 
methylated CpG residues. At the bottom, a box and whisker plot shows percent methylation distribution 
between each sample tested at four CpG sites that varied in the targeted CpG island of the TERT promoter 
region. Each dot may represent more than one measure of percent methylation in one sample at the indicated 
CpG site when percent methylation is the same. A total 25 samples are tested across the four  CpG sites. 
Median percent methylation for each site is indicated next to each box in the corresponding color.  
 
Variation in methylation between samples was observed at 4 of 10 CpG sites measured: 
CpG386, CpG402, CpG430, and CpG435 (Figure 3.2). Percent methylation at CpG386, CpG402, CpG430, 
and CpG435 ranged from 28–100, 17–100, 78–100, and 22–100% with a median of 62, 64, 90, and 64%, 
respectively (Figure 3.2). The remaining CpG sites were either unmethylated or completely methylated 
as indicated, across all samples tested (Figure 3.2). Variation in methylation between the samples did 
not separate into any obvious groups, like normal and tumor tissues. Taken together, significant 
methylation of unoccupied alleles was observed in both normal and tumor tissues with no obvious 
trends between sample groups. 
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ALV LTRs of Proviruses in the TERT Promoter Were Not Methylated 
To examine the methylation state of ALV LTRs, we performed conventional bisulfite sequencing 
of six different tumors (4-wlr-9, A1B, D2L, C7L, C2B, and 208L2) with known clonally expanded TERT 
promoter integration sites. Sequencing was performed on PCR amplicons generated using primers 
flanking the proviral-host junction (Figure 3.1). With ALV integrations downstream of the target CpG 
island, tumors 4-wlr-  a d A B e e used to a al ze the U  egio  of the ′LTR. I  oth ases, the e 
were no detectable evidence of modified CpG dinucleotides. With integrations upstream of the target 
CpG island, tumors D2L, C7L, C2B, and 208L2 were used to analyze the R a d U  egio  of the ′LTR. No 
evidence of methylation was detected in the 6 samples. Taken together, there was no evidence of 
methylated CpG dinucleotides throughout the LTR (Figure 3.3). Thus, ALV integration into the chicken 
TERT promoter region is not associated with de novo methylation of LTRs in B-cell lymphomas. 
 
Figure 3.3. CpG methylation profiles of TERT promoter proviral LTRs in selected tumor samples. Schematic 
representation of the CpG dinucleotide distribution in the ALV LTR is shown at the top. Bisulfite sequencing 
analysis of the LTR sequences are depicted as a linear array of open circles representing non -modified CpG 
residues and closed circles representing methylated CpG residues. Each line represents a representative 
sequenced result of the LTR region from host-proviral PCR amplicons. No methylation was detected in 
proviruses of tumor tissues tested. 
 
Occupied Alleles in the TERT Promoter Had Decreased Methylation in Flanking Host DNA 
 To examine the effects of ALV integration on the methylation of the flanking host DNA in the 
TERT promoter, bisulfite sequencing was performed on six different tumors (4-wlr-9, A1B, D2L, C7L, 
C2B, and 208L2). They all had known clonally expanded TERT promoter integrations near the target 
CpG island. For each tumor, two parallel sequencing experiments were performed. For the 
72 
 
unoccupied alleles, PCR amplicons were generated from the region that is 333–536 bp upstream of 
the chicken TERT TSS containing the target CpG island, using primers for the host genome. For the 
occupied alleles, PCR amplicons were generated using an LTR specific primer for the LTR closest to 
the target CpG island of the TERT promoter and a shared primer in the host genome (Figure 3.1). 
In all six cases, a decrease in methylation was detected in the occupied allele compared to 
the paired unoccupied allele (Figure 3.4). Mean percent methylation decrease ranged from a 
complete loss of methylation in 4-wlr-9 and A1B to an approximately two-fold decrease in D2L, C7L, 
C2B, and 208L2 (Figure 3.4). Decreases in methylation at individual CpG sites appeared to be more 
dramatic closer to the site of integration (Figure 3.4). For example, occupied alleles of D2L show a 
complete loss of methylation at CpG sites immediately downstream of the integration but show 
retention of methylation at CpG sites farther downstream. Being farther upstream, occupied alleles 
from C2B, 208L2, and C7L show methylation at some sites that are unmethylated in occupied alleles 
of D2L, A1B, and 4-wlr-9. Taken together, ALV integrations near methylated sites in the host genome 







Figure 3.4. CpG methylation profiles of host genomic DNA in selected tumor samples. Schematic 
representation of the CpG dinucleotide distribution in the target CpG island in the TERT promoter region is 
shown at the top. The six TERT promoter integrations tested are labeled and indicated with orange arrows at 
the site of integration. For each tumor sample listed, bisulfite sequencing analyses are depicted as linear arrays 
of open circles representing non-modified CpG residues and closed circles representing methylated CpG 
residues. For each tumor sample, CpG methylation data in the target CpG island is shown for the unoccupied 
allele and the occupied allele. Corresponding mean percent CpG are listed, which were calculated by averaging 
percent methylation of all CpG sites in the displayed array. 
 
Discussion 
 Our lab has previously shown that the TERT promoter region is a common integration site in 
ALV-induced B-cell lymphoma. These integrations are the most clonally expanded in a subset of tumors, 
suggesting that proviral integration into this region is an important early event in lymphoma 
development (Justice, Morgan, and Beemon 2015; Malhotra, Winans, et al. 2017). Tumors with TERT 
promoter integrations are associated with increased TERT expression (Yang et al. 2007; Nehyba et al. 
2016). The mechanism of this activation is presently under investigation. The present study investigates 
the influence of ALV integration on the TERT promoter region methylation status at the site of 
integration in ALV-induced lymphoma. In this study, we observed that the chicken TERT promoter is 
significantly methylated in unoccupied alleles across normal and cancer tissues. Tested tumors with 
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TERT promoter integrations appear to have proviruses that are free of any detectable CpG methylation 
in the LTRs. Adjacent host sequences show a decrease in methylation in occupied alleles compared to 
unoccupied alleles. 
 DNA methylation of promoter regions is often associated with transcriptional silencing (Li et al. 
2011; Bird 2002; Weber and Schübeler 2007). We observed significant methylation in the chicken TERT 
promoter region of unoccupied alleles, suggesting that in normal tissues and tumors, cellular factors 
were actively repressing transcription of TERT by means of DNA methylation. This is consistent with the 
downregulation of telomerase activity observed in chicken somatic tissues after the embryonic stage 
(Forsyth, Wright, and Shay 2002; Swanberg et al. 2010; Taylor and Delany 2000; S.E. Swanberg and 
Delany 2003). In contrast, there was a complete lack of detectable methylation in the ALV LTRs of 
proviruses in the TERT promoter region in lymphomas. As methylation in the LTR generally suppresses 
ALV proviral transcription (Svoboda et al. 2000; Hejnar et al. 2003; Senigl, Auxt, and Hejnar 2012), this 
result suggests that the ALV proviruses were likely transcriptionally active, which is consistent with the 
upregulation of spliced proviral transcripts containing TAPAS (Nehyba et al. 2016). 
 More importantly, we observe an allele-specific decrease in methylation in the host DNA near 
the site of ALV integration in the TERT promoter in the occupied alleles. This decrease in methylation 
may lead to derepression of the TERT gene and contribute to the observed increase in TERT expression 
in an allele-specific manner. Additional studies are required to determine if the methylation status 
directly impacts TERT expression. This is confounded by the presence of the LTR enhancer that has been 
demonstrated to activate transcription from the TERT promoter in cultured cells (Yang et al. 2007). To 
decouple the effects on TERT expression from the LTR enhancer and integration site methylation, future 
studies comparing expression from reporter constructs comprised of methylated and unmethylated 
TERT promoter region and ALV LTR may provide further insight. Taken together, the pattern of 
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methylation observed would suggest that methylation behaves in the conventional sense as a repressive 
marker of expression at the chicken TERT promoter. 
 Presently, the relationship between human TERT promoter methylation and TERT expression is 
still under investigation. On the one hand, increased TERT expression correlates with the 
hypermethylation of the TERT promoter region in many human cancers (Barthel et al. 2017). The 
mechanism of activation of TERT expression by increased TERT promoter methylation is presently 
unclear in humans. On the other hand, TERT promoter hypermethylation is associated with gene 
silencing (Liu et al. 2004; Lopatina et al. 2003; Shin et al. 2003); thus, in the tumor environment, one 
would expect selection for cells that acquired different mechanisms to protect the TERT promoter from 
DNA methylation. Our observations support the latter. Furthermore, the allele-specific hypomethylation 
of TERT promoter region that is associated with ALV integration is in agreement with recent work in 
humans. This idea of allele-specific activation of TERT was recently explored by multiple groups in 
different contexts. Common somatic TERT promoter mutations were recently discovered in many 
human cancers (Horn et al. 2013; Huang et al. 2013). Further investigation revealed that these somatic 
mutations were associated with an allele-specific switch to an active transcriptional state and 
monoallelic TERT expression of the allele containing the TERT promoter mutation across multiple human 
cancers (Huang et al. 2015; Stern et al. 2015). More recently, allele-specific hypomethylation was 
associated with TERT promoter mutations (Stern et al. 2017). 
 In regards to the seemingly contradictory observations about TERT promoter methylation, TERT 
hypermethylation may represent a broadly applicable prognostic marker for TERT expression and cancer 
progression (Castelo-Branco et al. 2013, 2016) that is distinct from what is observed in cancers with 
observed mechanisms of TERT activation like proviral- or mutation-associated hypomethylation. 
Presently, most of the published data looked at the average methylation across a population of alleles in 
tumors. Reanalyzing these samples and data, taking in account allele-specific methylation, may present 
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novel insight into the relationship between TERT promoter methylation and cancer. Perhaps in some 
human cancers, there is a decrease in TERT promoter methylation in the activated allele while on 
average there was an increase in methylation across the population of alleles when compared to 
corresponding normal tissue. 
 Concurrently, investigations into the effects of human integrating viruses on methylation in 
tumors were performed. Human herpesvirus 6B has been shown to integrate into subtelomeric regions 
and induce hypomethylation in these regions (Engdahl et al. 2017). Notably, the human TERT gene is 
located in the subtelomeric region of chromosome 5. Integrated human papillomavirus and hepatitis B 
virus show allele-specific methylation changes at the site of integration (Watanabe et al. 2015; Hatano 
et al. 2017). In these studies, methylation of the integrated viral genomes directly correlated with the 
methylation state of the integrated site prior to viral integration at specific sites tested (Watanabe et al. 
2015; Hatano et al. 2017). Interestingly, the most frequent hepatitis B virus integrations were found in 
the TERT promoter region (Buendia and Neuveut 2015). To our knowledge, the methylation status at 
these integration sites have not been tested. 
Future studies into the impact of human integrating viruses on DNA methylation and TERT 
expression in human cancers offers an exciting direction to test our observations observed in chicken 
tumors. Furthermore, chickens with TERT promoter integrations represent a subset of a larger collection 
of ALV-induced lymphomas. Ongoing work with other common integration sites may present novel 
trends that may provide further insight into the role DNA methylation plays in cancer. From these initial 
findings, a more comprehensive approach, such as high-throughput sequencing of integration sites, may 
be designed to address the specificity of this phenomenon. 
We propose an additional selection factor in the growing model of ALV-induced tumorigenesis 
in chicken B-cell lymphoma. During early embryonic development, chicken embryos can become 
infected with ALV. Cells that acquire proviral integrations into the TERT promoter receive an 
77 
 
advantageous enhancement to proliferation and survival by means of TERT upregulation. This 
upregulation is in part associated with changes in the methylation state of the TERT promoter through 
the insertion of ALV. Additional studies are required to understand the mechanism and impact of the 
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Non-Hodgkin lymphomas (NHL) are a heterogeneous group of immune cell neoplasms that comprise 
molecularly distinct lymphoma subtypes. Recent work has identified high frequency promoter point 
mutations in the telomerase reverse transcriptase (TERT) gene of different cancer types, including 
melanoma, glioma, liver and bladder cancer. TERT promoter mutations appear to correlate with 
increased TERT expression and telomerase activity in these cancers. In contrast, breast, pancreatic, 
and prostate cancer rarely demonstrate mutations in this region of the gene. TERT promoter 
mutation prevalence in NHL has not been thoroughly tested thus far. We screened 105 B-cell 
lymphoid malignancies encompassing nine NHL subtypes and acute lymphoblastic leukemia, 
for TERT promoter mutations. Our results suggest that TERT promoter mutations are rare or absent 
in most NHL. Thus, the classical TERT promoter mutations may not play a major oncogenic role in 
TERT expression and telomerase activation in NHL. 
Introduction 
 Non-Hodgkin lymphomas (NHL) are a heterogeneous group of B, T, and natural killer cell 
neoplasms that arise primarily in lymph nodes. Most NHL in the western hemisphere are B-cell 
derived and comprise a variety of lymphomas, with diffuse large B-cell lymphoma (DLBCL), follicular 
lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) being the 
most common (Campo et al. 2011). Recent advances in molecular genetics have confirmed the 
molecular heterogeneity of NHL. Classically, NHL can be characterized by chromosomal translocation 
events that have been shown to occur frequently with different subtypes of NHL (Barrans et al. 2003; 
Bertoni et al. 2006; Biagi and Seymour 2002). Whole exome sequencing has further expanded 
molecular characterizations of NHL. Parallel sequencing experiments with DLBCL patients (Lohr et al. 
2014) and FL patients (Okosun et al. 2014) have identified recurrent mutations in functionally 
relevant genes as well as novel genes that have not been previously implicated. Despite these 
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advances, NHL remains a heterogeneous group of malignancies, with many less characteri zed 
subtypes that remain difficult to diagnose and treat with current therapeutic strategies (Ansell 2015). 
 Recently, non-coding sequences have become an emerging field of active investigation in 
cancer research (Diederichs et al. 2016). In 2013, specific high frequency promoter mutations in the 
telomerase reverse transcriptase (TERT) gene in melanoma were reported, and were associated with 
a two- to four-fold increase in transcriptional activity (Horn et al. 2013; Huang et al. 
2013). TERT encodes the catalytic subunit of telomerase, an enzyme that preserves chromosomal 
ends through telomere maintenance. The reported so ati  t a sitio s − C>T a d − C>T i  
the TERT promoter region create a novel binding site for the ETS transcription factor GABP, which 
increases transcription of TERT (Bell et al. 2015). Increased TERT expression may confer increased 
proliferative potential and cell survival, which are essential factors in tumorigenesis (Cao et al. 2002). 
Strikingly, TERT promoter mutations are not unique to melanomas, but have been later found to be 
frequent in many other malignancies such as hepatocellular carcinoma, bladder cancer, and 
glioblastoma (Heidenreich, Rachakonda, et al. 2014; Killela et al. 2013; Weinhold et al. 2014; Vinagre 
et al. 2013; Liu et al. 2013; Rachakonda et al. 2013; Bell et al. 2016). However, TERT promoter 
mutations are not universal. Mutations have been shown to be absent, or rarely observed, in other 
cancer types like breast, pancreatic, and prostate cancer (Heidenreich, Rachakonda, et al. 2014; 
Killela et al. 2013; Bell et al. 2016). 
 Our lab has used the avian leukosis virus (ALV) as a tool to screen for common proviral 
integration sites in the host chicken genome to assess events involved in lymphoma development. By 
high-throughput sequencing and inverse PCR, we have previously shown that early chicken TERT 
(chTERT) expression through proviral integrations is associated with a similar two- to four-fold 
increase in transcriptional activity (Buendia and Neuveut 2015; Yang et al. 2007; Justice, Morgan, and 
Beemon 2015) and is likely important in lymphomagenesis. Although lymphocytes are known to be a 
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cell type characterized by high telomerase activity throughout their life cycle, lymphoid malignancies 
are associated with elevated TERT expression like the majority of cancers, suggesting a requirement 
for persistent TERT activity in transformed cells (Davison 2007; Lobetti-Bodoni et al. 2010). 
We sought to investigate whether TERT promoter mutations play a role in TERT activation in 
human lymphomas. Presently, published work on the TERT promoter status of NHL is limited. Since 
the original reports in melanoma, we have found some published work that suggests TERT promoter 
mutations are absent in DLBCL and CLL (Weinhold et al. 2014; Vinagre et al. 2013). In 
contrast, TERT promoter mutations were detected in primary central nervous system lymphoma 
(Bruno et al. 2015). Here, we report a TERT promoter mutation screen of a collection of 105 human 
B-cell malignancies encompassing nine different subtypes of NHL. Our results indicate that  TERT 
promoter mutations are absent across all tested NHL. These findings suggest that  TERT promoter 
mutations are not major drivers for TERT up-regulation in lymphomas in contrast to the 
aforementioned cancers. 
Materials and Methods 
Patients and Samples 
Representative cases of a variety of B-cell neoplasms were obtained from archived formalin-
fixed paraffin-embedded (FFPE) tissues as well as frozen cells and tissues previously banked as de-
identified research samples after obtaining institutional review board approval (Johns Hopkins 
Institution Review Board no. NA_00028682). The FFPE archives were searched from 2000 to 2014 for 
cases of Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-
cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal 
zone lymphoma, myeloma/plasmacytoma, and plasmablastic lymphoma. Cases of glioblastoma and 
reactive lymph nodes were also queried as expected positive and negative control cases for formalin-
fixed paraffin-embedded (FFPE) tissue. Representative cases with unambiguous pathologic diagnoses 
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and sufficient material were selected for histologic re-review by a board-certified Pathologist (Rena R. 
Xian). Both tumor neoplastic cell content and tissue adequacy was assessed, and only cases with at least 
25% neoplastic cells and sufficient tissue were selected for the study. FFPE tissue sections were then 
acquired from the respective archival cases for subsequent analysis. B-cell acute lymphoblastic leukemia 
(B-ALL) bone marrow aspirate samples with at least 15% lymphoblasts, and normal bone marrow 
aspirate samples without phenotypic abnormalities were consecutively collected over a two-month 
period from remnant material from routine clinical flow cytometric testing. Fresh aspirate material 
collected in EDTA blood tubes was obtained and frozen until further analysis. 
DNA Isolation and Mutational Analysis 
DNA extraction from bone marrow was performed using Qiagen DNeasy Blood and Tissue Kit 
Vale ia, CA, U“A  a o di g to a ufa tu e ’s p oto ol. DNA e t a tio  f o  FFPE tissue slides as 
performed using Pinpoint Slide DNA Isolation SystemTM (Irvine, CA, USA) accordi g to a ufa tu e ’s 
p oto ol. P i e s ith the se ue es ′-M13F-CGGGCTCCCAGTGGATTCGC- ′ a d ′-CGGGGCCGCGGAA-
AGGAA- ′ e e used to PCR-a plif  the p o i al TERT p o ote  egio  o tai i g − C>T 
h : , NM_ , GRCh /hg  a d − C>T h :1295250, NM_198253, GRCh37/hg19). 
Amplified products were then sequenced using standard Sanger sequencing techniques (Louisville, KY, 
USA) with the universal sequencing priming site, M13F. 
Results 
Absence of TERT Promoter Mutations in NHLs 
NHLs (Table 4.1) were screened for TERT promoter mutations. The PCR amplified region 
e o passes the t o ost o o l  utated u leotides − C>T h : G>A  a d − C>T 
(chr5:1295250G>A) upstream of the translational start site of TERT (Figure 4.1A). Altogether, 93 tumor 
samples were evaluated with at least 7 samples of each subtype in additional to a subset of gliomas as 
positive controls, and reactive lymph nodes and normal bone marrows as negative controls (Table 4.1). 
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We confirmed TERT promoter mutations in glioblastomas (n = 2), which is lower than expected 
(Bushman and Craigie 1990; Heidenreich, Nagore, et al. 2014; Weinhold et al. 2014; Vinagre et al. 2013) 
but demonstrates that we can detect the mutation. A glioma control trace that is heterozygous for the 
− C>T utatio  is sho n (Figure 4.1B). Glioblastoma samples (n = 7) previously identified with 
promoter mutations were used as additional positive controls. All 7 control samples were confirmed to 
ha e the − C>T utatio . No TERT promoter mutations were detected in any NHL samples in the 
amplified promoter region. A representative NHL trace showing the wildtype TERT promoter sequences 
at both positions are shown from a mantle cell lymphoma tumor sample (Table 4.1 and Figure 4.1B). 
 
 
Figure 4.1. Screening of TERT promoter mutations in Non-Hodgkin lymphomas (NHLs). (A) Schematic of the 
a plified egio  a d the lo atio  of − C>T a d − C>T i  the  TERT promoter. (B) Sequencing 
chromatographs of the TERTp o ote  lo us i  a glio a o t ol that is hete oz gous fo  − C>T top  a d a 
representative NHL tumor sample that is wildtype at both positions (middle and bottom). 1 A representative 










Tumor Type No. of Tumors No. of Tumors Mutated 
B-cell acute lymphoblastic leukemia 12 0 
Burkitt lymphoma 9 0 
Chronic lymphocytic leukemia 11 0 
Diffuse large B-cell lymphoma 9 0 
Follicular lymphoma 13 0 
Lymphoplasmacytic lymphoma 7 0 
Mantle cell lymphoma 12 0 
Marginal zone lymphoma 16 0 
Myeloma/plasmacytoma 9 0 
Plasmablastic lymphoma 7 0 
1 Glioblastoma tissues were used as positive controls (n = 11); reactive lymph nodes (n = 13) 
were used as negative controls for formalin-fixed paraffin-embedded (FFPE) samples; 
normal bone marrow samples (n = 13) were used as negative controls for B-cell acute 
lymphoblastic leukemia (B-ALL) samples 
 
Table 4.1 Samples tested for telomerase reverse transcriptase (TERT) promoter mutations 1 
 
Discussion 
 As a terminally differentiated cell type, normal human lymphocytes have atypical telomere 
and telomerase biology. In contrast to other cell types, lymphocytes have above average telomere 
length and telomerase activity (Davison 2007; Bruno et al. 2015). Despite the presence of longer 
telomeres, and enhanced telomerase activity, lymphocytes still experience division-dependent 
telomere shortening. Malignant transformation is associated with increased TERT expression and 
telomere length (Machiela et al. 2016). Furthermore, longer telomeres and higher telomerase 
activity are associated with more aggressive NHL than indolent ones, and have been suggested to be 
a prognostic risk factor for NHL (Ohyashiki et al. 2002). Our lab has repeatedly observed TERT 
activation in chicken lymphomas via ALV integration into the chTERT promoter region as an early 
event in avian B-cell lymphomagenesis (Yang et al. 2007; Justice, Morgan, and Beemon 2015). 
 Taken together, to overcome the restriction of telomere shortening, and support higher 
proliferative potential and survival, we hypothesized that lymphocytes may acquire TERT promoter 
mutations in the process of malignant transformation, which can directly up-regulate TERT 
expression and drive telomerase function. However, our data suggest that the NHLs tested were free 
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of the two most prevalent TERT promoter mutations (Horn et al. 2013; Huang et al. 2013). This result 
does not exclude the possibility of promoter mutations further upstream of the area we investigated, 
and the small sample size does not exclude the presence of low-frequency TERT promoter mutations, 
which would require much larger screens to resolve. 
 Concurrent to this study, TERT promoter mutations were reported to be present in 33% of 
circulating mantle cell lymphoma (Panero et al. 2016). In this study, a limited subset of other 
lymphoid neoplasms was reported to be free of TERT promoter mutations. While we detected 
no TERT promoter mutations in our set of mantle cell lymphoma, there are a few possible reasons for 
this apparent discordance. First, the small sample size of mantle cell lymphoma (n = 12) eva luated in 
the current study may be too small to detect a change that may be present in a small fraction of 
cases. Second, the source of neoplastic B-cells in our study was different from the concurrent study. 
The peripheral blood source of mantle cell lymphoma in the concurrent study indicates that all 
patients had circulating leukemic-phase disease, which is associated with advanced stage disease, 
and worse prognosis when coupled with nodal involvement (Pittaluga et al. 1996). This is compared 
to the node-based disease selected in our study, irrespective of circulating cells, which may harbor 
different clonal abnormalities commensurate with the stage of the lymphoma. TERT promoter 
mutations may be more prevalent in a particular stage in mantle cell lymphomagenesis. This has 
been previously shown to be true in melanoma, in which TERT mutations are associated with 
different histology types of the disease, and are more commonly found in melanoma without 
regression as compared to melanoma with regression (de Unamuno Bustos et al. 2016). 
Our findings suggest that activation of TERT expression by acquired TERT promoter mutations 
is not a major driver for TERT activation in NHL. As observed previously, the frequency of this 
phenomenon is perhaps associated with the intrinsic proliferative potential of the cell type, in which 
cells with higher proliferative potential like lymphocytes are less likely to have TERT promoter 
86 
 
mutations (Weinhold et al. 2014). In the case of lymphocytes, perhaps activation of TERT expression 
indirectly through the up-regulation of other genes like MYC is far more common and supplants the 
requirement of other mechanisms of TERT activation like TERT promoter mutations. Despite our 
results, the non-coding sequences of NHL tissues remain an uncharted territory, as novel mutated 
regulatory sites are being discovered across many different cancers (Melton et al. 2015), and future 
analysis by whole-genome sequencing may lead to the discovery of novel mechanisms in 
lymphomagenesis. As whole-genome patient sequencing and clinical data becomes available, we can 
begin to explain these observations and apply them to enhance our understanding of cancer biology 













































 In this thesis, I describe our work characterizing the effects of overexpressing chicken TERT in 
chickens coinfected with ALV in chapter 2.  I also analyze ALV integrations in the resulting tumors in 
chapter 2.  Overall, no conclusions could be made about TERT overexpression and tumor progression in 
ALV-induced tumorigenesis.  Nevertheless, we identified one chicken out of the 27 chickens that carried 
two tumors (791L1 and 791L2) that retained the recombinant TERT virus.  Investigation into the ALV 
integration pattern of these two tumors revealed that the tumors had different clonal integrations.  
While tumor 791L1 was associated with genes previously observed like MYB, tumor 791L2 implicated 
ARID5B as a potential cooperating gene in transformation of TERT overexpressing cells.  No DAS provirus 
was detected in tumors from the DAS group. 
 Unexpectedly, we also observed an increased incidence of hemangiomas across every chicken 
group, which accounted for the majority of the lesions observed.  In contrast, ALV-A has been reported 
to commonly be associated with B-cell lymphomas.  ALV integration analysis of these hemangiomas 
implicated a distinct subset of genes that may play a causal role in hemangioma development.  Notable 
genes include FRK, PLAG1, and GLIS3, which were associated with multiple tumors that did not show a 
clear lymphoma phenotype.  No TERT proviruses or TERT promoter integration sites were detected in 
hemangiomas. 
 In chapter 3, we further characterized the effects of ALV integration at the site of integration.  
Specifically looking at clonal integrations in the TERT promoter, we identified a decrease of DNA 
methylation in the flanking genomic DNA of ALV-occupied alleles compared to unoccupied alleles in 
every tumor tested.  This allele specific ALV-associated hypomethylation at the TERT promoter presents 
another potential mechanism of gene activation in ALV-induced tumorigenesis. 
 Lastly, we investigated the frequency of TERT promoter mutations in human hematological 
malignancies.  We did not observe any previously described TERT promoter mutations in any of the ten 
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types of malignancies tested.  This result is consistent with earlier reports investigating smaller subsets 
of hematological malignancies (Killela et al. 2013).  Our results suggest that TERT promoter mutation is 
not a primary driver of TERT activation in hematological malignancies. 
 Taken together, this body of work tackle the role of TERT in tumorigenesis from various angles.  
Previous data and data presented here provide converging evidence that TERT may provide essential 
oncogenic functions in cooperation with a specific network of genes in lymphoma development.  ALV-
induced tumors show that TERT may be activated directly by ALV proviral integrations in the TERT 
promoter in a subset of lymphomas.  This activation may be mediated by proviral LTR enhancers.  In 
addition, hypomethylation of the TERT promoter associated with ALV proviral integration may be 
another mechanism in achieving TERT activation.  Other lymphomas implicate the activation of genes 
that have been shown to activate TERT, like MYC.  Together, these genes and TERT are recurring factors 
in lymphomas.  Tumors 791L1 and 791L2 further support this association between MYC and TERT by 
implicating additional players, ARID5B and PHF2. 
 The activation of TAPAS by TERT promoter integrations presents another layer to the potential 
interaction with TERT function and regulation and its associated genes.  The relationship between TAPAS 
in chickens and humans are currently being explored.  In chickens, TAPAS expression correlates with 
TERT expression in adult tissues and during chick development (Nehyba et al. 2016).  Both show 
increased expression in ALV-induced tumors with TERT promoter integrations (Nehyba et al. 2016).  In 
contrast, TAPAS expression is negatively correlated with TERT expression in human cancer patients 
(Malhotra, Freeberg, et al. 2017). 
 The discovery of ALV-A induced hemangiomas constitutes another dimension of tumorigenesis 
that requires more exploration.  Our initial investigation suggest that hemangiomas may be driven by an 
exclusive set of genes.  Many of the genes, including FRK, PLAG1, and GLIS3, are still under active 
investigation and do not have clearly defined functions in tumorigenesis.  At the moment, no association 
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is known between the genes implicated in the hemangiomas and lymphomas in our study.  How these 
genes in hemangiomas may be related to the oncogenic functions provided by TERT and associated 
genes in lymphomas presents an exciting new direction in understanding the role each set of genes play 
in their corresponding lesion types.  The approach used in this work could be optimized to 
comprehensively expand the pathways associated with TERT, as well as, other genes of interest.  While 
TERT promoter mutations may not be a primary mechanism of TERT activation in human hematological 
malignancies, our preliminary results from our chicken experiments may have identified alternative 
players involved in TERT function, like ARID5B and PHF2.  
This work expands our understanding of retroviral induced tumorigenesis and continues to 
support the valuable application of using chicken as a model for cancer studies.  Several avenues for 
future research are described below in this chapter. 
How is the expression of the genes of interest affected by ALV integration? 
 The resulting impact on the expression of neighboring genes from ALV integration can be 
unpredictable.  While promoter insertion and enhancer activation are common mechanisms of 
activation, epigenetic changes, like DNA methylation, may also play a role in regulation which is 
explored in chapter 3.  Quantifications of endogenous transcripts, as well as any proviral fusion 
transcripts are required to determine the net change in expression of neighboring genes.  A candidate 
approach using qPCR can be used to validate any changes in total expression of genes of interest. 
 The clonal integration near ARID5B is located in the opposite orientation in the promoter region 
of ARID5B, suggesting that ALV may induce expression by means of enhancer activation in a manner 
analogous to TERT.  Induction of ARID5B would be consistent with the reported association of ARID5B 
expression and tumorigenesis in humans (Leong et al. 2017).  Integration sites identified in FRK, PLAG1, 
and GLIS3 are all in the same orientation at the ’ e d of the ge e.  Both i teg atio s fo  FRK a d PLAG  
are located in exon 1, and GLIS3 integrations are located in intron 2.  Consequently, the expression of 
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these three genes is likely to be increased by promoter insertion.  Increased expression of these genes 
would be consistent with their associations with various human cancers (Goel and Lukong 2016; Astrom 
et al. 2000; Chou et al. 2017).  In the case of the FRK, PLAG1, and GLIS3, proviral driven expression may 
lead to fusion transcripts that overexpress truncated proteins from their respective genes similar to 
what happens with MYB.  All three genes have been previously shown to be activated by reciprocal 
translocation events in human cancers where the resulting fusion proteins are comprised of modified 
proteins of the two genes involved (Hosoya et al. 2005; Juma et al. 2016; Xu et al. 2015). 
Does ARID5B cooperate with TERT in tumorigenesis in chickens? 
 From our integration site analysis, we observed a clonal integration near ARID5B in tumor 
791L1, which harbored the TERT recombinant provirus.  Consistent with our tissue culture experiments, 
the recombinant provirus was able to drive TERT overexpression in the tumor.  The clonal integration 
near ARID5B suggest selection for the activation of ARID5B in the TERT overexpressing tumor.  We could 
test the effects of ARID5B expression by establishing an analogous environment using CEFs.  CEFs are 
primary cells that have been observed to stop dividing over time in tissue culture, and this observation 
coincides with a decrease in TERT expression (data not shown). 
 Knowing this, we can establish a stable TERT overexpressing CEF cell line using our TERT 
recombinant virus.  This can be achieved by transfecting our TERT recombinant vector into CEFs and 
propagating primary CEFs for at least a few weeks, which is often when CEFs begin to stop dividing.  
Propagation will naturally select for cells that are immortalized by TERT overexpression.  This method 
has previously been shown to work for chicken adipocytes (Wang et al. 2017).  After establishing 
immortalized CEFs, we can overexpress ARID5B by similar means and look for any phenotypic indicators 
of malignant transformation.  As ARID5B has been shown to be sufficient in driving malignant 
transformation in human cells (Leong et al. 2017), comparing ARID5B and TERT overexpression with 
ARID5B overexpression alone may present some interesting new findings for future investigation.  
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Furthermore, the establishment of immortalized CEFs from the overexpression of TERT may prove to be 
useful for any future experiments involving TERT.  Immortalized cells may present an excellent tool for 
the production of reagents that may benefit the poultry industry, such as vaccine production. 
Is there an association between the distinct subsets of genes that define lymphomas and 
hemangiomas in ALV-induced tumors? 
 Extending from the previous question about potential cooperation between ARID5B and TERT, 
we could also look to similar experiments altering expression of different genes in each subset of genes 
that are attributed to lymphomas and hemangiomas and observe if any of these genes are associated 
with changes in other genes in their corresponding group.  With the data we have collected with ALV-
induced tumors, we know that MYB, MYC, mir-155, TERT, and, possibly ARID5B appears to be associated 
primarily with lymphomas.  On the other hand, our investigation of hemangiomas introduces FRK, 
PLAG1, and GLIS3 as potential factors in hemangioma development in addition to the previously 
described MET. 
 With the exception of TERT, all the noted genes have canonical functions in regulating many 
downstream targets.  MYB, MYC, PLAG1, and GLIS3 are known transcription factors, ARID5B is a 
transcription coactivator, FRK is a Src-like tyrosine kinase, and mir-155 is a miRNA.  The possibility that 
some of these may activate one another in the associated lesion types would not be surprising.  To test 
this idea, we could initially take a candidate approach and look at expression of these genes in the 
corresponding tumor types and investigate if there is a significant association between the genes.  If a 
correlation exists, we would then test if the associated genes are sufficient to drive the expression of 
related genes in tissue culture to account for other spurious effects that may be driven by ALV 
integrations.  Together, this data may reveal novel associations that are important to lymphoma and 





Are abnormal translocation sites common integration sites for retroviral integration? 
 Understanding the determinants of proviral integration site preferences is an active area of 
investigation.  Information regarding site preferences can be applicable to many areas of biology, 
especially, research involving the use of retroviral vectors.  In our lab, we have rigorously profiled 
integration site selection and preferences of ALV-A (J. F. Justice, Morgan, and Beemon 2015; Malhotra, 
Winans, et al. 2017).  Our analysis of the hemangiomas observed in our most recent chicken 
experiments sho ed that i teg atio s i to the ’ egio  of FRK, PLAG , a d GLI“  e e sele ted fo  i  
tumors tested.  Interestingly, all three of these genes have been previously described to be the target of 
abnormal reciprocal translocation events in human cancers (Hosoya et al. 2005; Juma et al. 2016; Xu et 
al. 2015).  The clonal integration sites identified in our study are near the reported breakpoints of the 
translocation events of each gene. 
 There may be an association between sites prone to translocation and common integration sites 
for retroviral integration in tumors.  While translocation information is limited in chickens, there is more 
information regarding translocation events in humans.  However, translocation events are largely 
restricted to disease states, as well as integration site studies of human integrating viruses.  To better 
characterize this association, we can perform analogous integration site studies using primary human 
cells in tissue culture.  Primary human cells can be infected with an integrating virus of interest and 
integration sites can be used to compare with the current reported translocation events.  Furthermore, 
any transformed cells can be isolated by means of a traceable marker and propagated for comparison.  
A similar approach was recently applied to the investigation of genomic features that enable long-term 
proviral expression Miklík, Šenigl, and Hejnar 2018).  The findings could provide insight into another 





Is the chicken TERT promoter an exceptional region for ALV-associated hypomethylation? 
 In chapter 3, we observed an ALV-associated hypomethylation of the flanking genomic DNA.  
The relationship between DNA methylation at the site of integration prior to proviral integration and the 
type of integrating virus is a complex one as explored in the introduction to my thesis.  Our investigation 
into TERT promoter integrations suggest that the significantly methylated state of the chicken TERT 
promoter was not associated with methylation of the ALV provirus after integration.  In contrast, 
analysis of human cancers associated with integrating viruses showed a positive correlation with the 
methylation status of the genomic DNA prior to integration and the methylation state of the provirus 
(Watanabe et al. 2015; Hatano et al. 2017).   
In both studies, various loci were tested, and allele-specific methylation analysis suggested that 
the HBV and HPV16 integrants remained hypomethylated when the flanking host genome was 
hypomethyled (Watanabe et al. 2015; Hatano et al. 2017).  In contrast, after integration into highly 
methylated human genome regions, integrates became methylated (Watanabe et al. 2015; Hatano et al. 
2017).  Interestingly, the most frequent hepatitis B virus integrations were found in the TERT promoter 
region (Buendia and Neuveut 2015).  Coincidentally, the methylation status of the flanking genomic 
region and a HBV integrant in the human TERT promoter was tested (Watanabe et al. 2015; Hatano et 
al. 2017).  Both the flanking TERT promoter region and provirus were shown to be hypomethylated 
(Watanabe et al. 2015; Hatano et al. 2017). 
The relationship of the type of integrating virus and proviral silencing was explored recently.  
HIV, MLV, and ALV showed different extents of silencing upon infection of human cells Miklík, Še igl, 
and Hejnar 2018).  In this study, the group concluded that the proximity to active regulatory chromatin 
segments correlated with stable provirus expression for all three retroviruses even though the extent of 
silencing globally varied Miklík, Še igl, a d Hej a  .  Our observations in the TERT promoter are 
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consistent with this association between active epigenetic markers, in our case DNA hypomethylation of 
the flanking genomic DNA was associated with stable proviral activity, which is inferred by activation of 
TERT expression and proviral fusion transcripts of ALV and TAPAS. 
However, in our specific case, analysis of the unoccupied allele suggests that the TERT promoter 
is repressed in the same tumor cells.  Thus, this would suggest that the resulting DNA methylation status 
at the integration site may be more dependent on the integrating virus, ALV.  A natural follow-up 
question would concern the specificity of this phenomenon.  To test site specificity, other clonal ALV 
integrations can be tested using the same approach.  Preliminary results suggest that clonal integrations 
at the MYB locus do not appear to change between the occupied and unoccupied alleles.  However, the 
difference in the location of the integration sites with respect to the gene may contribute significantly to 
the results.  Common integration sites are located in intragenic region of MYB (Kanter, Smith, and 
Hayward 1988), in contrast to integrations in the TERT promoter.  The relationship between DNA 
methylation and expression in intragenic regions varies more than promoter regions (Bird 2002). 
Specific targeting strategies like CRISPR can be utilized in chickens to attain more direct control 
over site selection (Véron et al. 2015).  To test genomic site specificity, a minimal ALV LTR can be 
targeted to various gene promoters that have varied DNA methylation states, and comparison of allele 
specific methylation can be performed with the same approach used previously.  The reverse 
relationship can be tested using the same CRISPR approach.  In this case, LTRs from different viruses can 
be tested at a single genomic site. 
Integrating high-throughput sequencing may offer a more comprehensive approach to analyzing 
the relationship between proviral integration and methylation status at the site of integration.  Using 
our established method of mapping provirus integration, a parallel experiment with some modifications 
using bisulfite treated tumor DNA can be used to investigate the methylation status of flanking genomic 
DNA.  With enough coverage and depth, comparison of the two datasets will theoretically screen the 
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methylation status of flanking sequences throughout the genome.  Expression can then be correlated by 
RNA-seq experiments.   
Alternatively, one can map proviral integration while tracking transcriptional activity by adapting 
a method originally designed for HIV proviruses called barcoded HIV ensembles (B-HIVE) described in 
detail by Chen et al. 2017.  This method involves the generation of a barcoded library of minimal viral 
vectors of the virus of interest.  The library will utilize barcodes with enough complexity to assure that 
each viral vector in the library contains a unique barcode in between the LTR and essential viral genes.  
Once packaged, virions can infect a host of interest.  Integrations can be mapped from genomic DNA 
using inverse PCR coupled with high-throughput sequencing.  Quantification of proviral expression can 
be achieved by measuring barcode abundance from the ratio of read counts after RT-PCR on the RNA 
pool and the DNA pool.  Data from these experiments may provide valuable insight into the 
determinants of DNA methylation at the site of ALV integration, which can also be applied to other 
integrating viruses. 
 The cellular environment also plays a role in the silencing of proviruses.  While ALV is largely 
permissive in chicken cells, ALV is efficiently silenced in mouse (Guntaka et al. 1980) and human cells 
Miklík, Še igl, a d Hej a  .  However, the artificial insertions of a CpG island core element into the 
LTR of an RSV-derived vector has been shown to be able to provide efficient protection of the integrated 
vector from silencing and gradual CpG methylation in rodent and human cells (F. Senigl, Plachy, and 
Hejnar 2008).  The TERT promoter may act in a similar manner.  One can test this idea by performing an 
analogous experiment by artificially inserting TERT promoter next to an ALV LTR and observing the 
methylation status of the recombinant ALV provirus in non-permissive mammalian cells.  Furthermore, 
any elements identified from the above experiments may also provide potential candidates that alter 
the susceptibility to proviral silencing.  Such experiments may provide further insight into the 
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determinants that restrict permissiveness in heterologous infections, as well as useful information for 
the development of genetic tools. 
What are other mechanisms of TERT activation in hematological malignancies? 
 In chapter 4, we attempted to investigate potential somatic changes in the TERT promoter that 
may be major drivers of TERT expression in human cancers.  To this end, we investigated the prevalence 
of TERT promoter mutations in a large subset of hematological malignancies and concluded that TERT 
promoter mutations are not a prominent mechanism of TERT activation.  Human integrating viruses may 
offer another direct way of activating TERT expression.  Human herpesvirus 6B has been shown to 
integrate into subtelomeric regions and induce hypomethylation in these regions (Engdahl et al. 2017).  
Notably, the human TERT gene is located in the subtelomeric region of chromosome 5.  As mentioned 
previously, the most frequent hepatitis B virus integrations were found in the TERT promoter region 
(Buendia and Neuveut 2015).  These observations may offer potential sources to test if any of our 




























Adki s, H B, J B ojats h, a d J A You g. . Ide tifi atio  a d Cha a te izatio  of a “ha ed TNFR-
Related Receptor for Subgroup B, D, and E Avian Leukosis Viruses Reveal Cysteine Residues 
Re ui ed “pe ifi all  fo  “u g oup E Vi al E t .  Journal of Virology 74 (8):3572–78. 
http://www.ncbi.nlm.nih.gov/pubmed/10729132. 
Andrake, Mark D, Monica M Sauter, Kim Boland, Andrew D Goldstein, Maryem Hussein, and Anna 
“kalka. . Nu lea  I po t of A ia  “a o a Vi us I teg ase Is Fa ilitated  Host Cell Fa to s.  
Retrovirology 5 (1):73. https://doi.org/10.1186/1742-4690-5-73. 
A sell, “tephe  M. . Hodgki  L pho a: Diag osis a d T eat e t.  Mayo Clinic Proceedings 90 
(11):1574–83. https://doi.org/10.1016/j.mayocp.2015.07.005. 
A igo, “, a d K Bee o . . Regulatio  of Rous “a o a Vi us RNA “pli i g a d “ta ilit .  Molecular 
and Cellular Biology 8 (11):4858–67. http://www.ncbi.nlm.nih.gov/pubmed/2850470. 
Ast o , A, E “ D’A o e, L “ai ati, C Pa a ello, C Mo e io, J Ma k, a d G “te a . . E ide e of 
I ol e e t of the PLAG  Ge e i  Lipo lasto as.  International Journal of Oncology 16 (6):1107–
10. http://www.ncbi.nlm.nih.gov/pubmed/10811981. 
Ba a, T W, a d E H Hu ph ies. . “ele tive Integration of Avian Leukosis Virus in Different 
He atopoieti  Tissues.  Virology 155 (2):557–66. http://www.ncbi.nlm.nih.gov/pubmed/3024400. 
Balti o e, D. . RNA-Depe de t DNA Pol e ase i  Vi io s of RNA Tu ou  Vi uses.  Nature 226 
(5252):1209–11. http://www.ncbi.nlm.nih.gov/pubmed/4316300. 
Ba a d, R J O, a d J A T You g. . Alpha et o i us E elope-Re epto  I te a tio s.  Current Topics 
in Microbiology and Immunology 281:107–36. http://www.ncbi.nlm.nih.gov/pubmed/12932076. 
Barr, S. D., J. Leipzig, P. “hi , J. R. E ke , a d F. D. Bush a . . I teg atio  Ta geti g  A ia  
Sarcoma-Leukosis Vi us a d Hu a  I u odefi ie  Vi us i  the Chi ke  Ge o e.  Journal of 
Virology 79 (18):12035–44. https://doi.org/10.1128/JVI.79.18.12035-12044.2005. 
99 
 
Ba a s, “ha o  L, Paul A “ E a s, “heila J M O’Co o , “ Ja e Ke dall, Roge  G O e , A d e  P Ha es, 
Ga eth J Mo ga , a d A d e  “ Ja k. . The t ;  Is Asso iated ith Ge i al Ce te -
Derived Diffuse Large B-Cell Lymphoma and Is a Strong Predicto  of Out o e.  Clinical Cancer 
Resear h : A  Offi ial Jour al of the A eri a  Asso iatio  for Ca er Resear h 9 (6):2133–39. 
http://www.ncbi.nlm.nih.gov/pubmed/12796378. 
Barré-Sinoussi, F, J C Chermann, F Rey, M T Nugeyre, S Chamaret, J Gruest, C Dauguet, et al. 1983. 
Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency 
“ d o e AID“ .  Science (New York, N.Y.) 220 (4599):868–71. 
http://www.ncbi.nlm.nih.gov/pubmed/6189183. 
Barthel, Floris P, Wei Wei, Ming Tang, Emmanuel Martinez-Ledesma, Xin Hu, Samirkumar B Amin, Kadir 
C Akde i , et al. . “ ste ati  A al sis of Telo e e Le gth a d “o ati  Alte atio s i   
Ca e  T pes.  Nature Genetics 49 (3):349–57. https://doi.org/10.1038/ng.3781. 
Bates, P, J A Young, and H E Varmus. 199 . A Re epto  fo  “u g oup A Rous “a o a Vi us Is Related to 
the Lo  De sit  Lipop otei  Re epto .  Cell 74 (6):1043–51. 
http://www.ncbi.nlm.nih.gov/pubmed/8402880. 
Bed a ik, D P, J A Cook, a d P M Pitha. . I a ti atio  of the HIV LTR  DNA CpG Methylation: 
E ide e fo  a Role i  Late .  The EMBO Journal 9 (4):1157–64. 
http://www.ncbi.nlm.nih.gov/pubmed/2323336. 
Bee o , K, a d T Hu te . . Cha a te izatio  of Rous “a o a Vi us “  Ge e P odu ts “ thesized 
i  Vit o.  Journal of Virology 28 (2):551–66. http://www.ncbi.nlm.nih.gov/pubmed/214578. 
Bee o , Ka e , a d Nao i Rose e g. . Me ha is s of O oge esis  A ia  a d Mu i e 
Ret o i uses.  I  Cancer Associated Viruses, 677–704. Boston, MA: Springer US. 
https://doi.org/10.1007/978-1-4614-0016-5_27. 
Bell, R. J. A., H. T. Rube, A. Xavier-Magalhaes, B. M. Costa, A. Mancini, J. S. Song, and J. F. Costello. 2016. 
100 
 
U de sta di g TERT P o ote  Mutatio s: A Co o  Path to I o talit .  Molecular Cancer 
Research 14 (4):315–23. https://doi.org/10.1158/1541-7786.MCR-16-0003. 
Bell, Robert J A, H Tomas Rube, Alex Kreig, Andrew Mancini, Shaun D Fouse, Raman P Nagarajan, Serah 
Choi, et al. . Ca e . The T a s iptio  Fa to  GABP “ele ti el  Bi ds a d A ti ates the 
Muta t TERT P o ote  i  Ca e .  Science (New York, N.Y.) 348 (6238):1036–39. 
https://doi.org/10.1126/science.aab0015. 
Berry, Charles C., Nicolas A. Gillet, Anat Melamed, Niall Gormley, Charles R. M. Bangham, and Frederic 
D. Bush a . . Esti ati g A u da es of Ret o i al I se tio  “ites from DNA Fragment 
Le gth Data.  Bioinformatics 28 (6):755–62. https://doi.org/10.1093/bioinformatics/bts004. 
Be to i, F a es o, A d ea Ri aldi, E a uele )u a, a d F a o Ca alli. . Update o  the Mole ula  
Biolog  of Ma tle Cell L pho a.  Hematological Oncology 24 (1):22–27. 
https://doi.org/10.1002/hon.767. 
Biagi, Ja es J, a d Joh  F “e ou . . I sights i to the Mole ula  Pathoge esis of Folli ula  
L pho a A isi g f o  A al sis of Geog aphi  Va iatio .  Blood 99 (12):4265–75. 
http://www.ncbi.nlm.nih.gov/pubmed/12036852. 
Bi d, A. . DNA Meth latio  Patte s a d Epige eti  Me o .  Genes & Development 16 (1):6–21. 
https://doi.org/10.1101/gad.947102. 
Bla k u , Eliza eth H. . Telo e e “tates a d Cell Fates.  Nature 408 (6808):53–56. 
https://doi.org/10.1038/35040500. 
Blankenberg, D., A. Gordon, G. Von Kuster, N. Coraor, J. Taylor, A. Nekrutenko, and Galaxy Team. 2010. 
Ma ipulatio  of FA“TQ Data ith Gala .  Bioinformatics 26 (14):1783–85. 
https://doi.org/10.1093/bioinformatics/btq281. 
Blasco, M A, H W Lee, M P Hande, E Samper, P M Lansdorp, R A DePinho, and C W Greider. 1997. 




Blasco, Maria A. 2005. Telo e es a d Hu a  Disease: Agei g, Ca e  a d e o d.  Nature Reviews 
Genetics 6 (8):611–22. https://doi.org/10.1038/nrg1656. 
Bolisett , M., J. Blo e g, F. Be a he hou, G. “pe e , a d K. Bee o . . U e pe ted Di e sit  
and Expression of Avian Endoge ous Ret o i uses.  mBio 3 (5):e00344-12-e00344-12. 
https://doi.org/10.1128/mBio.00344-12. 
B ojats h, J, J Naughto , M M Rolls, K )i gle , a d J A You g. . CAR , a TNFR-Related Protein, Is a 
Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Vi uses a d Mediates Apoptosis.  Cell 87 
(5):845–55. http://www.ncbi.nlm.nih.gov/pubmed/8945512. 
B uediga , Claudia, a d “te e  W La e. . Telo e ase i  He atologi  Malig a ies.  Current 
Opinion in Hematology 23 (4):346–53. https://doi.org/10.1097/MOH.0000000000000252. 
Bruno, Aurélie, Agusti Alentorn, Mailys Daniau, Marianne Labussière, Amithys Rahimian, Emeline 
Ta ou et, Ma  Poli ka, et al. . TERT P o ote  Mutatio s i  P i a  Ce t al Ne ous “ ste  
Lymphoma Are Associated with Spatial Distributio  i  the “ple iu .  Acta Neuropathologica 130 
(3):439–40. https://doi.org/10.1007/s00401-015-1461-9. 
Bryan, T M, A Englezou, L Dalla-Pozza, M A Du ha , a d R R Reddel. . E ide e fo  a  Alte ati e 
Mechanism for Maintaining Telomere Length in Human Tumors and Tumor-De i ed Cell Li es.  
Nature Medicine 3 (11):1271–74. http://www.ncbi.nlm.nih.gov/pubmed/9359704. 
B a , T M, A E glezou, J Gupta, “ Ba hetti, a d R R Reddel. . Telo e e Elo gatio  i  I o tal 
Human Cells without Detectable Telomerase A ti it .  The EMBO Journal 14 (17):4240–48. 
http://www.ncbi.nlm.nih.gov/pubmed/7556065. 
Buendia, Marie-A i k, a d Ch isti e Neu eut. . Hepato ellula  Ca i o a.  Cold Spring Harbor 
Perspectives in Medicine 5 (2):a021444. https://doi.org/10.1101/cshperspect.a021444. 
Bu ge, C B, T Tus hl, a d P “ “ha p. . “pli i g P e u so s to RNAs  the “pli eoso es.  I  The 
102 
 
RNA World, edited by R F Gesteland, 525–60. Cold Spring Harbor, New York: Cold Spring Harbor 
Laboratory Press. 
Bushman, F D, and R Craigie. . “e ue e Re ui e e ts fo  I teg atio  of Molo e  Mu i e 
Leuke ia Vi us DNA i  Vit o.  Journal of Virology 64 (11):5645–48. 
http://www.ncbi.nlm.nih.gov/pubmed/2214030. 
Bush a , F D, T Fuji a a, a d R C aigie. . Ret o i al DNA I teg atio  Di ected by HIV Integration 
P otei  i  Vit o.  Science (New York, N.Y.) 249 (4976):1555–58. 
http://www.ncbi.nlm.nih.gov/pubmed/2171144. 
Campanella, Nathália C, Ricardo Celestino, Ana Pestana, Cristovam Scapulatempo-Neto, Antonio Talvane 
de Oliveira, Maria José B ito, A tó io Gou eia, et al. . Lo  F e ue  of TERT P o ote  
Mutatio s i  Gast oi testi al “t o al Tu o s GI“Ts .  European Journal of Human Genetics 23 
(6):877–79. https://doi.org/10.1038/ejhg.2014.195. 
Campo, E., S. H. Swerdlow, N. L. Harris, S. Pile i, H. “tei , a d E. “. Jaffe. . The  WHO 
Classifi atio  of L phoid Neoplas s a d e o d: E ol i g Co epts a d P a ti al Appli atio s.  
Blood 117 (19):5019–32. https://doi.org/10.1182/blood-2011-01-293050. 
Canela, Andrés, Juan Martín-Caballe o, Jua a M Flo es, a d Ma ía A Blas o. . Co stituti e 
Expression of Tert in Thymocytes Leads to Increased Incidence and Dissemination of T-Cell 
Lymphoma in Lck-Te t Mi e.  Molecular and Cellular Biology 24 (10):4275–93. 
http://www.ncbi.nlm.nih.gov/pubmed/15121848. 
Cao, Ying, He Li, Siddhartha Deb, and Jun-Pi g Liu. . TERT Regulates Cell “u i al I depe de t of 
Telo e ase E z ati  A ti it .  Oncogene 21 (20):3130–38. 
https://doi.org/10.1038/sj.onc.1205419. 
Carter, J K, S J Proctor, and R E Smith. . I du tio  of A giosa o as  Ri g-Necked Pheasant 
Vi us.  Infection and Immunity 40 (1):310–19. http://www.ncbi.nlm.nih.gov/pubmed/6299960. 
103 
 
Castelo-Branco, Pedro, Sanaa Choufani, Stephen Mack, Denis Gallagher, Cindy Zhang, Tatiana Lipman, 
Natali a )huko a, et al. . Meth latio  of the TERT P o ote  a d Risk “t atifi atio  of 
Childhood B ai  Tu ou s: A  I teg ati e Ge o i  a d Mole ula  “tud .  The Lancet Oncology 14 
(6):534–42. https://doi.org/10.1016/S1470-2045(13)70110-4. 
Castelo-Branco, Pedro, Ricardo Leão, Tatiana Lipman, Brittany Campbell, Donghyun Lee, Aryeh Price, 
Ci d  )ha g, et al. . A Ca e  “pe ifi  H pe eth latio  “ig atu e of the TERT P o ote  
P edi ts Bio he i al Relapse i  P ostate Ca e : A Ret ospe ti e Coho t “tud .  Oncotarget 7 
(36):57726–36. https://doi.org/10.18632/oncotarget.10639. 
Ca uela, Ma ía Luisa, Jua a M Flo es, a d Ma ía A Blas o. . The Telo e ase RNA Co po e t Te  
Is Required for the Tumour-P o oti g Effe ts of Te t O e e p essio .  EMBO Reports 6 (3):268–
74. https://doi.org/10.1038/sj.embor.7400359. 
Chai, Ni g, a d Paul Bates. . Na+/H+ E ha ge  T pe  Is a Re epto  fo  Pathoge i  “u g oup J 
A ia  Leukosis Vi us.  Proceedings of the National Academy of Sciences of the United States of 
America 103 (14):5531–36. https://doi.org/10.1073/pnas.0509785103. 
Chen, Heng-Chang, Javier P Martinez, Eduard Zorita, Andreas Meyerhans, and Guillaume J Filion. 2017. 
Positio  Effe ts I flue e HIV Late  Re e sal.  Nature Structural & Molecular Biology 24 (1):47–
54. https://doi.org/10.1038/nsmb.3328. 
Choi, Jinkuk, Lucinda K. Southworth, Kavita Y. Sarin, Andrew S. Venteicher, Wenxiu Ma, Woody Chang, 
Peggie Cheu g, et al. . TERT P o otes Epithelial P olife atio  th ough T a s iptio al Co t ol 
of a Myc- and Wnt-Related De elop e tal P og a .  PLoS Genetics 4 (1):e10. 
https://doi.org/10.1371/journal.pgen.0040010. 
Chou, Chon-Kit, Chin-Ju Tang, Han-Lin Chou, Chun-Yen Liu, Ming-Chong Ng, Yu-Ting Chang, Shyng-Shiou 
F Yuan, Eing-Mei Tsai, and Chien-Chih Chiu. . The Potential Role of Krüppel-Like Zinc-Finger 
P otei  Glis  i  Ge eti  Diseases a d Ca e s.  Archivum Immunologiae et Therapiae 
104 
 
Experimentalis 65 (5):381–89. https://doi.org/10.1007/s00005-017-0470-x. 
Clu a , B E, a d W “ Ha a d. . Multiple P oto-Oncogene Activations in Avian Leukosis Virus-
Induced Lymphomas: Evidence for Stage-“pe ifi  E e ts.  Molecular and Cellular Biology 9 
(6):2657–64. http://www.ncbi.nlm.nih.gov/pubmed/2548084. 
Coffi , J M. . “t u tu e a d Classifi atio  of Ret o i uses.  In The Retroviridae, edited by J.A. Levy, 
19–49. New York: Plenum Press. 
Coffin, John M, Stephen H Hughes, and Harold E Varmus. 1997. Retroviruses. Retroviruses. Cold Spring 
Harbor Laboratory Press. http://www.ncbi.nlm.nih.gov/pubmed/21433340. 
Cook, C R, a d M T M Nall . . I te a tio  et ee  the Negati e Regulato  of “pli i g Ele e t a d 
a ’ “pli e “ite: Re ui e e t fo  U  “ all Nu lea  Ri o u leop otei  a d the ’ “pli e “ite B a h 
Poi t/p i idi e T a t.  Journal of Virology 73 (3):2394–2400. 
http://www.ncbi.nlm.nih.gov/pubmed/9971823. 
Counter, C M, A A Avilion, C E LeFeuvre, N G Stewart, C W Greider, C B Harley, and S Bacchetti. 1992. 
Telo e e “ho te i g Asso iated ith Ch o oso e I sta ilit  Is A ested i  I o tal Cells Whi h 
Express Telomerase A ti it .  The EMBO Journal 11 (5):1921–29. 
http://www.ncbi.nlm.nih.gov/pubmed/1582420. 
C itte de , L B, a d J V Motta. . The Role of the T  Lo us i  Ge eti  Resista e to R“V RAV-O .  
Virology 67 (2):327–34. http://www.ncbi.nlm.nih.gov/pubmed/171832. 
C itte de , L B, H A “to e, R H Rea e , a d W Okazaki. . T o Lo i Co t olli g Ge eti  Cellula  
Resistance to Avian Leukosis-“a o a Vi uses.  Journal of Virology 1 (5):898–904. 
http://www.ncbi.nlm.nih.gov/pubmed/4316238. 
Crittenden, L B, E J Wendel, a d J V Motta. . I te a tio  of Ge es Co t olli g Resista e to 
RSV(RAV-O .  Virology 52 (2):373–84. http://www.ncbi.nlm.nih.gov/pubmed/4350221. 
Da iso , Gle da Ma . . Telo e es a d Telo e ase i  Leukae ia a d L pho a.  Transfusion 
105 
 
and Apheresis Science 37 (1):43–47. https://doi.org/10.1016/j.transci.2007.04.006. 
Dela , M., L. Da iels, “. “ a e g, a d H. Ta lo . . Telo e es i  the Chi ke : Ge o e “ta ilit  
a d Ch o oso e E ds.  Poultry Science 82 (6):917–26. https://doi.org/10.1093/ps/82.6.917. 
Dela , Ma  E., a d Lau a M. Da iels. . The Chi ke  Telo e ase Re e se T a s iptase hTERT : 
Mole ula  a d C toge eti  Cha a te izatio  ith a Co pa ati e A al sis.  Gene 339 
(September):61–69. https://doi.org/10.1016/j.gene.2004.05.024. 
Dessai , “ K, H Yu, R R Reddel, R L Beije s e ge , a d R A Wei e g. . Meth latio  of the Hu a  
Telo e ase Ge e CpG Isla d.  Cancer Research 60 (3):537–41. 
http://www.ncbi.nlm.nih.gov/pubmed/10676632. 
Devereux, T R, I Horikawa, C H Anna, L A Annab, C A Afsha i, a d J C Ba ett. . DNA Meth latio  
A al sis of the P o ote  Regio  of the Hu a  Telo e ase Re e se T a s iptase hTERT  Ge e.  
Cancer Research 59 (24):6087–90. http://www.ncbi.nlm.nih.gov/pubmed/10626795. 
Deville, Laure, Josette Hillion, and Evelyne Ségal-Be di djia . . Telo e ase Regulatio  i  
He atologi al Ca e s: A Matte  of “te ess?  Biochimica et Biophysica Acta 1792 (4):229–39. 
https://doi.org/10.1016/j.bbadis.2009.01.016. 
Diederichs, Sven, Lorenz Bartsch, Julia C Berkmann, Karin Fröse, Jana Heitmann, Caroline Hoppe, Deetje 
Igge a, et al. . The Da k Matte  of the Ca e  Ge o e: A e atio s i  Regulato  Ele e ts, 
U t a slated Regio s, “pli e “ites, No ‐ odi g RNA a d “ o ous Mutatio s.  EMBO Molecular 
Medicine 8 (5):442–57. https://doi.org/10.15252/emmm.201506055. 
Dol etti, Ri a do, a d A ita De Rossi. . Telo e e/telo e ase I te pla  i  Vi us-Driven and Virus-
I depe de t L pho age esis: Pathoge i  a d Cli i al I pli atio s.  Medicinal Research Reviews 
32 (2):233–53. https://doi.org/10.1002/med.20211. 
Doughe t , R M, a d H “ Di “tefa o. . “ites of A ia  Leukosis Vi us Multipli atio  i  Co ge itall  




Duff, R G, and P K Vogt. . Cha a te isti s of T o Ne  A ia  Tu o  Vi us “u g oups.  Virology 39 
(1):18–30. http://www.ncbi.nlm.nih.gov/pubmed/4309068. 
Eckhardt, Florian, Joern Lewin, Rene Cortese, Vardhman K Rakyan, John Attwood, Matthias Burger, John 
Burton, et al. 2006. DNA Meth latio  P ofili g of Hu a  Ch o oso es ,  a d .  Nature 
Genetics 38 (12):1378–85. https://doi.org/10.1038/ng1909. 
Ei feld, D, a d E Hu te . . Oligo e i  “t u tu e of a P otot pe Ret o i us Gl op otei .  
Proceedings of the National Academy of Sciences of the United States of America 85 (22):8688–92. 
http://www.ncbi.nlm.nih.gov/pubmed/2847170. 
Elleder, Daniel, Volodymir Stepanets, Deborah C Melder, Filip Senigl, Josef Geryk, Petr Pajer, Jirí Plachý, 
Jirí Hejnar, Jan Svoboda, and Mark J Fede spiel. . The Re epto  fo  the “u g oup C A ia  
Sarcoma and Leukosis Viruses, Tvc, Is Related to Mammalian Butyrophilins, Members of the 
I u oglo uli  “upe fa il .  Journal of Virology 79 (16):10408–19. 
https://doi.org/10.1128/JVI.79.16.10408-10419.2005. 
Engdahl, Elin, Nicky Dunn, Pitt Niehusmann, Sarah Wideman, Peter Wipfler, Albert J. Becker, Tomas J. 
Ekström, Malin Almgren, and Anna Fogdell-Hah . . Hu a  He pes i us B I du es 
Hypomethylation on Chromosome 17p13.3, Correlating with Increased Gene Expression and Virus 
I teg atio .  Edited  Ri ha d M. Lo g e ke . Journal of Virology 91 (11):e02105-16. 
https://doi.org/10.1128/JVI.02105-16. 
E gel a , A, K Mizuu hi, a d R C aigie. . HIV-1 DNA Integration: Mechanism of Viral DNA 
Cleavage and DNA “t a d T a sfe .  Cell 67 (6):1211–21. 
http://www.ncbi.nlm.nih.gov/pubmed/1760846. 
Fadl , A M, a d V Nai . . Leukosis/sa o a G oup.  I  Diseases of Poultry, edited by Y M Saif, A M 
Fadly, J R Glisson, L R McDougald, L K Nolan, and D E Swayne, 12th ed., 514–68. Ames, IA: Iowa 
107 
 
State University Press. 
Fa , Hu g, a d Chassid  Joh so . . I se tio al O oge esis  No -Acute Retroviruses: 
I pli atio s fo  Ge e The ap .  Viruses 3 (4):398–422. https://doi.org/10.3390/v3040398. 
Ficht, T A, L J Chang, a d C M “toltzfus. . A ia  “a o a Vi us Gag a d E  Ge e “t u tu al P otei  
Precursors Contain a Common Amino-Te i al “e ue e.  Proceedings of the National Academy 
of Sciences of the United States of America 81 (2):362–66. 
http://www.ncbi.nlm.nih.gov/pubmed/6320182. 
Flo es, I., Ma ía L Ca uela, a d Ma ía A Blas o. . Effe ts of Telo e ase a d Telo e e Le gth o  
Epide al “te  Cell Beha io .  Science 309 (5738):1253–56. 
https://doi.org/10.1126/science.1115025. 
Forsyth, Nicholas R., Woodring E. W ight, a d Je  W. “ha . . Telo e ase a d Diffe e tiatio  i  
Multi ellula  O ga is s: Tu  It Off, Tu  It O , a d Tu  It off Agai .  Differentiation 69 (4–
5):188–97. https://doi.org/10.1046/j.1432-0436.2002.690412.x. 
Ge, Zhiyun, Bao Lin Quek, Kare  L Bee o , a d J Ro e t Hogg. . Pol p i idi e T a t Bi di g 
Protein 1 Protects mRNAs from Recognition by the Nonsense-Mediated RNA De a  Path a .  
eLife 5 (January). https://doi.org/10.7554/eLife.11155. 
Ghosh, Arkasubhra, Gaye Saginc, Shi Chi Leow, Ekta Khattar, Eun Myong Shin, Ting Dong Yan, Marc 
Wo g, et al. . Telo e ase Di e tl  Regulates NF-κB-Depe de t T a s iptio .  Nature Cell 
Biology 14 (12):1270–81. https://doi.org/10.1038/ncb2621. 
Giardine, B., Cathy Riemer, Ross C Hardison, Richard Burhans, Laura Elnitski, Prachi Shah, Yi Zhang, et al. 
. Gala : A Platfo  fo  I te a ti e La ge-“ ale Ge o e A al sis.  Genome Research 15 
(10):1451–55. https://doi.org/10.1101/gr.4086505. 
Giles, Keith E, a d Ka e  L Bee o . . Ret o i al “pli i g “upp esso  “e ueste s a ’ “pli e “ite i  a 




Gillet, N. A., N. Malani, A. Melamed, N. Gormley, R. Carter, D. Bentley, C. Berry, F. D. Bushman, G. P. 
Ta lo , a d C. R. M. Ba gha . . The Host Ge o i  E i o e t of the P o i us Dete i es 
the Abundance of HTLV-1-Infected T-Cell Clo es.  Blood 117 (11):3113–22. 
https://doi.org/10.1182/blood-2010-10-312926. 
Goecks, Jeremy, A to  Nek ute ko, Ja es Ta lo , a d The Gala  Tea . . Gala : A 
Comprehensive Approach for Supporting Accessible, Reproducible, and Transparent Computational 
Resea h i  the Life “ ie es.  Genome Biology 11 (8):R86. https://doi.org/10.1186/gb-2010-11-8-
r86. 
Goel, Raghu ee a Ku a , a d Ki e  E i ue Luko g. . U de sta di g the Cellula  Roles of F -
Related Ki ase FRK : I pli atio s i  Ca e  Biolog .  Cancer Metastasis Reviews 35 (2):179–99. 
https://doi.org/10.1007/s10555-016-9623-3. 
Gonzalez-Suarez, E., E Samper, A Ramírez, J M Flores, J Martín-Caballero, J L Jorcano, and M A Blasco. 
. I eased Epide al Tu o s a d I eased “ki  Wou d Heali g i  T a sge i  Mi e 
Overexpressing the Catalytic Subunit of Telomerase, mTERT, in Basal Keratinocytes.  The EMBO 
Journal 20 (11):2619–30. https://doi.org/10.1093/emboj/20.11.2619. 
Greger, James G, Richard A Katz, Konstantin Taganov, Glenn F Rall, and Anna Marie Skalka. 2004. 
T a sdu tio  of Te i all  Diffe e tiated Neu o s  A ia  “a o a Vi us.  Journal of Virology 
78 (9):4902–6. http://www.ncbi.nlm.nih.gov/pubmed/15078971. 
GRO““, L. . “tudies o  the Natu e a d Biologi al P ope ties of a T a s issi le Age t Causi g 
Leuke ia Follo i g I o ulatio  i to Ne o  Mi e.  Annals of the New York Academy of Sciences 
68 (2):501–21. http://www.ncbi.nlm.nih.gov/pubmed/13488302. 
Gudleski, Nicole, John M Flanagan, Eileen P Ryan, Maria C Bewley, and Leslie J Parent. 2010. 
Di e tio alit  of Nu leo toplas i  T a spo t of the Ret o i al Gag P otei  Depe ds o  
109 
 
Se ue tial Bi di g of Ka ophe i s a d Vi al RNA.  Proceedings of the National Academy of 
Sciences of the United States of America 107 (20):9358–63. 
https://doi.org/10.1073/pnas.1000304107. 
Guille et, Isa elle, a d Jea  Be hatta . . U usual Dist i utio  of DNA Methylation within the 
hTERT CpG Isla d i  Tissues a d Cell Li es.  Biochemical and Biophysical Research Communications 
325 (3):1037–43. https://doi.org/10.1016/j.bbrc.2004.10.137. 
Guilleret, Isabelle, Pu Yan, Fabienne Grange, Richard Braunschweig, Fred T. Bosman, and Jean Benhattar. 
. H pe eth latio  of the Hu a  Telo e ase Catal ti  “u u it hTERT  Ge e Co elates 
ith Telo e ase A ti it .  International Journal of Cancer 101 (4):335–41. 
https://doi.org/10.1002/ijc.10593. 
Guntaka, R V, P Y Rao, “ A Mitsialis, a d R Katz. . Modifi atio  of A ia  “a o a P o i al DNA 
“e ue es i  No pe issi e XC Cells ut Not i  Pe issi e Chi ke  Cells.  Journal of Virology 34 
(2):569–72. http://www.ncbi.nlm.nih.gov/pubmed/6246282. 
HANAFU“A, H. . ANALYSIS OF THE DEFECTIVENESS OF ROUS SARCOMA VIRUS. 3. DETERMINING 
INFLUENCE OF A NEW HELPER VIRUS ON THE HOST RANGE AND SUSCEPTIBILITY TO INTERFERENCE 
OF R“V.  Virology 25 (February):248–55. http://www.ncbi.nlm.nih.gov/pubmed/14297212. 
Hanahan, Douglas, and Robert A. Wei e g. . Hall a ks of Ca e : The Ne t Ge e atio .  Cell 144 
(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013. 
Ha le , Cal i  B., A. B u e Fut he , a d Ca ol W. G eide . . Telo e es “ho te  du i g Agei g of 
Human Fibroblasts.  Nature 345 (6274):458–60. https://doi.org/10.1038/345458a0. 
Hata, Kenji, Rikako Takashima, Katsuhiko Amano, Koichiro Ono, Masako Nakanishi, Michiko Yoshida, 
Makoto Waka a ashi, et al. . A id  Fa ilitates Cho d oge esis  Re uiti g the Histo e 




Hatano, Takashi, Daisuke Sano, Hideaki Takahashi, Hiroshi Hyakusoku, Yasuhiro Isono, Shoko Shimada, 
Kae “a aku a, et al. . Ide tifi ation of Human Papillomavirus (HPV) 16 DNA Integration and 
the Ensuing Patterns of Methylation in HPV-Associated Head and Neck Squamous Cell Carcinoma 
Cell Li es.  International Journal of Cancer 140 (7):1571–80. https://doi.org/10.1002/ijc.30589. 
Hatziioannou, T, a d “ P Goff. . I fe tio  of No di idi g Cells  Rous “a o a Vi us.  Journal of 
Virology 75 (19):9526–31. https://doi.org/10.1128/JVI.75.19.9526-9531.2001. 
Ha a d, W “, B G Neel, a d “ M Ast i . . A ti atio  of a Cellula  O  Ge e  P omoter Insertion 
in ALV-I du ed L phoid Leukosis.  Nature 290 (5806):475–80. 
http://www.ncbi.nlm.nih.gov/pubmed/6261142. 
Heidenreich, Barbara, Eduardo Nagore, P. Sivaramakrishna Rachakonda, Zaida Garcia-Casado, Celia 
Requena, Victor Traves, Jürgen Becker, Nadem Soufir, Kari Hemminki, and Rajiv Kumar. 2014. 
Telo e ase Re e se T a s iptase P o ote  Mutatio s i  P i a  Cuta eous Mela o a.  Nature 
Communications 5 (February):3401. https://doi.org/10.1038/ncomms4401. 
Heidenreich, Barbara, P Sivaramakrishna Ra hako da, Ka i He i ki, a d Raji  Ku a . . TERT 
P o ote  Mutatio s i  Ca e  De elop e t.  Current Opinion in Genetics & Development 24 
(February):30–37. https://doi.org/10.1016/j.gde.2013.11.005. 
Heidenreich, Barbara, Sivaramakrishna P. Rachakonda, Ismail Hosen, Florian Volz, Kari Hemminki, Astrid 
We e o k, a d Raji  Ku a . . &lt;i&gt;TERT&lt;/i&gt; P o ote  Mutatio s a d Telo e e 
Le gth i  Adult Malig a t Glio as a d Re u e es.  Oncotarget 6 (12):10617–33. 
https://doi.org/10.18632/oncotarget.3329. 
Hej a , J, J Pla hý, J Ge k, O Ma ho , K T ej alo á, R V Gu taka, a d J “ o oda. . I hi itio  of the 
Rous Sarcoma Virus Long Terminal Repeat-Driven Transcription by in Vitro Methylation: Different 




Hejnar, Jirí, Daniel Elleder, Petra Hájková, Jörn Walter, Jana Blazková, and Jan Svoboda. 2003. 
De eth latio  of Host-Cell DNA at the Site of Avian Retrovirus Integratio .  Biochemical and 
Biophysical Research Communications 311 (3):641–48. 
http://www.ncbi.nlm.nih.gov/pubmed/14623319. 
He a , Ja es G., a d “tephe  B. Ba li . . Ge e “ile i g i  Ca e  i  Asso iatio  ith P o ote  
H pe eth latio .  New England Journal of Medicine 349 (21):2042–54. 
https://doi.org/10.1056/NEJMra023075. 
Ho , “., A. Figl, P. “. Ra hako da, C. Fis he , A. “u ke , A. Gast, “. Kadel, et al. . TERT P o ote  
Mutatio s i  Fa ilial a d “po adi  Mela o a.  Science 339 (6122):959–61. 
https://doi.org/10.1126/science.1230062. 
Hosoya, Noriko, Ying Qiao, Akira Hangaishi, Lili Wang, Yasuhito Nannya, Masashi Sanada, Mineo 
Ku oka a, “hige u Chi a, Hisa a u Hi ai, a d “eishi Oga a. . Ide tifi atio  of a “RC-like 
Tyrosine Kinase gene,FRK, Fused withETV6 in a Patient with Acute Myelogenous Leukemia Carrying 
a t ; ;p  T a slo atio .  Genes, Chromosomes and Cancer 42 (3):269–79. 
https://doi.org/10.1002/gcc.20147. 
Huang, F. W., E. Hodis, M. J. Xu, G. V. Kryukov, L. Chin, and L. A. Garraway. . Highl  Re u e t TERT 
P o ote  Mutatio s i  Hu a  Mela o a.  Science 339 (6122):957–59. 
https://doi.org/10.1126/science.1229259. 
Huang, F W, C M Bielski, M L Rinne, W C Hahn, W R Sellers, F Stegmeier, L A Garraway, and G V Kryukov. 
. TERT P o ote  Mutatio s a d Mo oalleli  A ti atio  of TERT i  Ca e .  Oncogenesis 4 
(12):e176–e176. https://doi.org/10.1038/oncsis.2015.39. 
Hughes, “ H, A Muts hle , J M Bishop, a d H E Va us. . A Rous “a o a Vi us P o i us Is Fla ked 
by Short Direct Repeats of a Cellula  DNA “e ue e P ese t i  O l  O e Cop  p io  to I teg atio .  




International Committee on Taxonomy of Viruses., and Andrew. King. 2011. Virus Ta o o  : Ni th 
Report of the International Committee on Taxonomy of Viruses. Elsevier. 
https://www.sciencedirect.com/science/book/9780123846846. 
Ja ks, T, H D Madha i, F R Masia z, a d H E Va us. . “ig als for Ribosomal Frameshifting in the 
Rous Sarcoma Virus Gag-Pol Regio .  Cell 55 (3):447–58. 
http://www.ncbi.nlm.nih.gov/pubmed/2846182. 
Jäh e , D, a d R Jae is h. . Ret o i us-Induced de Novo Methylation of Flanking Host Sequences 
Correlates with Gene I a ti it .  Nature 315 (6020):594–97. 
http://www.ncbi.nlm.nih.gov/pubmed/2989695. 
Jia g, W, M R Ka te , I Du kel, R G Ra sa , K L Bee o , a d W “ Ha a d. . Mi i al T u atio  
of the c-Myb Gene Product in Rapid-Onset B-Cell L pho a.  Journal of Virology 71 (9):6526–33. 
http://www.ncbi.nlm.nih.gov/pubmed/9261372. 
Jo es, Pete  A, a d “tephe  B Ba li . . The Fu da e tal Role of Epige eti  E e ts i  Ca e .  
Nature Reviews. Genetics 3 (6):415–28. https://doi.org/10.1038/nrg816. 
Juma, Almas R, Pauliina E Damdimopoulou, Sylvia V H Grommen, Wim J M Van de Ven, and Bert De 
G oef. . E e gi g Role of PLAG  as a Regulato  of G o th a d Rep odu tio .  Journal of 
Endocrinology 228 (2):R45–56. https://doi.org/10.1530/JOE-15-0449. 
Justice, James, and Karen L Bee o . . A ia  Ret o i al Repli atio .  Current Opinion in Virology 3 
(6):664–69. https://doi.org/10.1016/j.coviro.2013.08.008. 
Justi e, Ja es F., Ro i  W. Mo ga , a d Ka e  L. Bee o . . Co o  Vi al I teg atio  “ites 
Identified in Avian Leukosis Virus-Induced B-Cell L pho as.  mBio 6 (6):e01863-15. 
https://doi.org/10.1128/mBio.01863-15. 
Justice, James, Sanandan Malhotra, Miguel Ruano, Yingying Li, Guillermo Zavala, Nathan Lee, Robin 
113 
 
Mo ga , a d Ka e  Bee o . . The MET Gene Is a Common Integration Target in Avian 
Leukosis Virus Subgroup J-I du ed Chi ke  He a gio as.  Edited  “. R. Ross. Journal of Virology 
89 (9):4712–19. https://doi.org/10.1128/JVI.03225-14. 
Ka g, M K, W Guo, a d N H Pa k. . Repli ati e “e es e e of No al Hu a  Oral Keratinocytes Is 
Asso iated ith the Loss of Telo e ase A ti it  ithout “ho te i g of Telo e es.  Cell Growth & 
Differentiation : The Molecular Biology Journal of the American Association for Cancer Research 9 
(1):85–95. http://www.ncbi.nlm.nih.gov/pubmed/9438392. 
Ka te , M R, R E “ ith, a d W “ Ha a d. . Rapid I du tio  of B-Cell Lymphomas: Insertional 
Activation of c-Myb b  A ia  Leukosis Vi us.  Journal of Virology 62 (4):1423–32. 
http://www.ncbi.nlm.nih.gov/pubmed/2831403. 
Kas, Koen, Marianne L. Voz, Eva Röijer, Anna-Karin Åström, Eva Meyen, Göran Stenman, and Wim J.M. 
Va  de Ve . . P o ote  “ appi g et ee  the Ge es for a Novel Zinc Finger Protein and β-
Cate i  i  Pleio o phi  Ade o as ith t ; p ;  T a slo atio s.  Nature Genetics 15 
(2):170–74. https://doi.org/10.1038/ng0297-170. 
Katz, R A, a d A M “kalka. . Co t ol of Ret o i al RNA “pli i g th ough Mai te a e of “u opti al 
Processing Sig als.  Molecular and Cellular Biology 10 (2):696–704. 
http://www.ncbi.nlm.nih.gov/pubmed/2153921. 
Katz, Ri ha d A., Ja es G. G ege , a d A a Ma ie “kalka. . Effe ts of Cell C le “tatus o  Ea l  
E e ts i  Ret o i al Repli atio .  Journal of Cellular Biochemistry 94 (5):880–89. 
https://doi.org/10.1002/jcb.20358. 
Katz, Richard A, James G Greger, Kristen Darby, Pamela Boimel, Glenn F Rall, and Anna Marie Skalka. 
. T a sdu tio  of I te phase Cells  A ia  “a o a Vi us.  Journal of Virology 76 (11):5422–
34. http://www.ncbi.nlm.nih.gov/pubmed/11991971. 
Killela, Patrick J, Zachary J Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A Diaz, Allan 
114 
 
H F ied a , et al. . TERT P o ote  Mutatio s O u  F e ue tl  i  Glio as a d a “u set of 
Tumors Derived from Cells with Low Rates of Self-Re e al.  Proceedings of the National Academy 
of Sciences of the United States of America 110 (15):6021–26. 
https://doi.org/10.1073/pnas.1303607110. 
Koiwa, Tsukasa, Akiko Hamano-Usami, Takaomi Ishida, Akihiko Okayama, Kazunari Yamaguchi, Shimeru 
Ka ihi a, a d Toshiki Wata a e. . ’-long Terminal Repeat-Selective CpG Methylation of 
Latent Human T-Cell Leuke ia Vi us T pe  P o i us i  Vit o a d i  Vi o.  Journal of Virology 76 
(18):9389–97. http://www.ncbi.nlm.nih.gov/pubmed/12186921. 
Kubuki, Yoko, Muneou Suzuki, Hidenori Sasaki, Takanori Toyama, Kiyoshi Yamashita, Koichi Maeda, Akio 
Ido, et al. . Telo e ase A ti it  a d Telo e e Le gth as P og osti  Fa to s of Adult T-Cell 
Leuke ia.  Leukemia & Lymphoma 46 (3):393–99. https://doi.org/10.1080/10428190400018349. 
Landrette, Sean F, Ya-Huei Kuo, Karen Hensen, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, 
Paola N Pe at, Wi  J M Va  de Ve , Ruud Del el, a d Lu io H Castilla. . Plag  a d Plagl  A e 
Oncogenes That Induce Acute Myeloid Leukemia in Cooperation with Cbfb-MYH .  Blood 105 
(7):2900–2907. https://doi.org/10.1182/blood-2004-09-3630. 
La ie, Lau e e, Mile a Kito a, Esthe  Malde e , E ka t Meese, a d Je s Ma e . . CpG 
Methylation Directly Regulates Transcriptional Activity of the Human Endogenous Retrovirus 
Family HERV-K(HML- .  Journal of Virology 79 (2):876–83. https://doi.org/10.1128/JVI.79.2.876-
883.2005. 
LeBlanc, Jason J, Sabena Uddowla, Benjamin Abraham, Sarah Clatterbuck, and Karen L Beemon. 2007. 
Tap a d D p , ut Not Gag, A e I ol ed i  DR-Mediated Nuclear Export of Unspliced Rous 
“a o a Vi us RNA.  Virology 363 (2):376–86. https://doi.org/10.1016/j.virol.2007.01.026. 
Lee, J, Y H Sung, C Cheong, Y S Choi, H K Jeon, W Sun, W C Hahn, F Ishikawa, and H-W Lee. . TERT 




Leong, Wei Zhong, Shi Hao Tan, Phuong Cao Thi Ngoc, Stella Amanda, Alice Wei Yee Yam, Wei-Siang 
Liau, )hi ua  Go g, Lee N. La to , Da iel G. Te e , a d Takao i “a da. . ARID B as a 
Critical Downstream Target of the TAL1 Complex That Activates the Oncogenic Transcriptional 
Program and Promotes T-Cell Leukemogenesis.  Genes & Development 31 (23–24):2343–60. 
https://doi.org/10.1101/gad.302646.117. 
Le is, P F, a d M E e a . . Passage th ough Mitosis Is Re ui ed fo  O o et o i uses ut Not 
fo  the Hu a  I u odefi ie  Vi us.  Journal of Virology 68 (1):510–16. 
http://www.ncbi.nlm.nih.gov/pubmed/8254763. 
Li, Qi ghe, Ni g Li, Xiao ia g Hu, Ji iu Li, )huo Du, Li Che , Gua glia g Yi , et al. . Ge o e-Wide 
Mappi g of DNA Meth latio  i  Chi ke .  Edited  Pie e-Antoine Defossez. PLoS ONE 6 
(5):e19428. https://doi.org/10.1371/journal.pone.0019428. 
Li, Y., X. Liu, ). Ya g, C. Xu, D. Liu, J. Qi , M. Dai, et al. . The MYC, TERT, a d )IC  Ge es A e 
Common Targets of Viral Integration and Transcriptional Deregulation in Avian Leukosis Virus 
Subgroup J-Induced Myeloid Leukosis.  Journal of Virology 88 (6):3182–91. 
https://doi.org/10.1128/JVI.02995-13. 
Liau, Jau-Yu, Jia-Huei Tsai, Yung-Ming Jeng, Chia-Yu Chu, Kuan-Ting Kuo, and Cher-Wei Liang. 2014. 
TERT P o ote  Mutatio  Is U o o  i  A al Le tigi ous Mela o a.  Journal of Cutaneous 
Pathology 41 (6):504–8. https://doi.org/10.1111/cup.12323. 
Liu, Liang, Sabita N. Saldanha, Mitchell S. Pate, Lucy G. Andrews, and Trygve O. Tollefsbol. 2004. 
Epige eti  Regulatio  of Hu a  Telo e ase Re e se T a s iptase P o ote  Activity during 
Cellula  Diffe e tiatio .  Genes, Chromosomes and Cancer 41 (1):26–37. 
https://doi.org/10.1002/gcc.20058. 
Liu, Xiaoli, Guojun Wu, Yuan Shan, Christian Hartmann, Andreas von Deimling, and Mingzhao Xing. 2013. 
116 
 
Highl  P e ale t TERT Promoter Mutatio s i  Bladde  Ca e  a d Glio lasto a.  Cell Cycle 12 
(10):1637–38. https://doi.org/10.4161/cc.24662. 
Lobetti-Bodoni, Chiara, Elisa Bernocco, Elisa Genuardi, Mario Boccadoro, and Marco Ladetto. 2010. 
Telo e es a d Telo e ase i  No al a d Malig a t B-Cells.  Hematological Oncology 28 
(4):157–67. https://doi.org/10.1002/hon.937. 
Lohr, Jens G., Petar Stojanov, Scott L. Carter, Peter Cruz-Gordillo, Michael S. Lawrence, Daniel Auclair, 
Ca ie “oug ez, et al. . Widesp ead Ge eti  Hete oge eit  i  Multiple Myeloma: Implications 
fo  Ta geted The ap .  Cancer Cell 25 (1):91–101. https://doi.org/10.1016/j.ccr.2013.12.015. 
Lopatina, Nadejda G, Joseph C Poole, Sabita N Saldanha, Nathaniel J Hansen, Jason S Key, Mark A Pita, 
Lucy G Andrews, and Trygve O Tollefs ol. . Co t ol Me ha is s i  the Regulatio  of 
Telo e ase Re e se T a s iptase E p essio  i  Diffe e tiati g Hu a  Te ato a i o a Cells.  
Biochemical and Biophysical Research Communications 306 (3):650–59. 
http://www.ncbi.nlm.nih.gov/pubmed/12810068. 
Lo , Kee Chu g, a d Vi a  Te gao ka . . Telo e ase: Ce t al Regulato  of All of the Hall a ks of 
Ca e .  Trends in Biochemical Sciences 38 (9):426–34. https://doi.org/10.1016/j.tibs.2013.07.001. 
Luo, Juan, Ying Yu, Apratim Mitra, Shuang Chang, Huanmin Zhang, George Liu, Ning Yang, and Jiuzhou 
“o g. . Ge o e-Wide Copy Number Variant Analysis in Inbred Chickens Lines With Different 
“us epti ilit  to Ma ek’s Disease.  G3&amp;#58; Genes|Genomes|Genetics 3 (2):217–23. 
https://doi.org/10.1534/g3.112.005132. 
Machiela, Mitchell J., Qing Lan, Susan L. Slager, Roel C.H. Vermeulen, Lauren R. Teras, Nicola J. Camp, 
Ja es R. Ce ha , et al. . Ge eti all  P edi ted Lo ge  Telo e e Le gth Is Asso iated ith 
Increased Risk of B-Cell L pho a “u t pes.  Human Molecular Genetics 25 (8):1663–76. 
https://doi.org/10.1093/hmg/ddw027. 
Maertens, Goedele, Peter Cherepanov, Wim Pluymers, Katrien Busschots, Erik De Clercq, Zeger Debyser, 
117 
 
a d Y es E gel o ghs. . LEDGF/p  Is Esse tial fo  Nu lea  a d Ch o oso al Targeting of 
HIV-  I teg ase i  Hu a  Cells.  Journal of Biological Chemistry 278 (35):33528–39. 
https://doi.org/10.1074/jbc.M303594200. 
Malhot a, “a a da , Mallo  F ee e g, “hel  Wi a s, Ja es Ta lo , a d Ka e  Bee o . . A 
Novel Long Non-Coding RNA i  the hTERT P o ote  Regio  Regulates hTERT E p essio .  Non-
Coding RNA 4 (1). Multidisciplinary Digital Publishing Institute:1. 
https://doi.org/10.3390/ncrna4010001. 
Malhotra, Sanandan, Shelby Winans, Gary Lam, James Justice, Robin Morgan, and Karen Beemon. 2017. 
“ele tio  fo  A ia  Leukosis Vi us I teg atio  “ites Dete i es the Clo al P og essio  of B-Cell 
L pho as.  Edited  Cha les R. M. Ba gha . PLOS Pathogens 13 (11):e1006708. 
https://doi.org/10.1371/journal.ppat.1006708. 
McNally, M T, and K Bee o . . I t o i  “e ue es a d ’ “pli e “ites Co t ol Rous “a o a Vi us 
RNA “pli i g.  Journal of Virology 66 (1):6–11. http://www.ncbi.nlm.nih.gov/pubmed/1309264. 
M Nall , M T, R R Go ta ek, a d K Bee o . . Cha a te izatio  of Rous “a o a Vi us Intronic 
“e ue es That Negati el  Regulate “pli i g.  Virology 185 (1):99–108. 
http://www.ncbi.nlm.nih.gov/pubmed/1656608. 
Melto , Colli , Jaso  A Reute , Da ek V “pa ek, a d Mi hael “ de . . Re u e t “o ati  
Mutations in Regulatory Regions of Hu a  Ca e  Ge o es.  Nature Genetics 47 (7):710–16. 
https://doi.org/10.1038/ng.3332. 
Miklík, Dali o , Filip Še igl, a d Jiří Hej a . . P o i uses ith Lo g-Term Stable Expression 
Accumulate in Transcriptionally Active Chromatin Close to the Gene Regulatory Elements: 
Comparison of ASLV-, HIV- and MLV-De i ed Ve to s.  Viruses 10 (3):116. 
https://doi.org/10.3390/v10030116. 
Mitchell, Rick S, Brett F Beitzel, Astrid R W Schroder, Paul Shinn, Huaming Chen, Charles C Berry, Joseph 
118 
 
R E ke , a d F ede i  D Bush a . . Ret o i al DNA I teg atio : A“LV, HIV, a d MLV “ho  
Disti t Ta get “ite P efe e es.  Edited  Mi hael E e man. PLoS Biology 2 (8):E234. 
https://doi.org/10.1371/journal.pbio.0020234. 
Mizuta i, “, D Boettige , a d H M Te i . . A DNA-Depenent DNA Polymerase and a DNA 
E do u lease i  Vi io s of Rous “a o a Vi us.  Nature 228 (5270):424–27. 
http://www.ncbi.nlm.nih.gov/pubmed/4320562. 
Mosrati, Mohamed Ali, Kerstin Willander, Ingrid Jakobsen Falk, Monica Hermanson, Martin Höglund, 
Di k “to kel e g, Yua  Wei, Kou osh Lotfi, a d Pete  “öde k ist. . Asso iatio  et ee  TERT 
Promoter Polymorphisms and Acute Myeloid Leuke ia Risk a d P og osis.  Oncotarget 6 
(28):25109–20. https://doi.org/10.18632/oncotarget.4668. 
Mothes, W, A L Boe ge , “ Na a a , J M Cu i gha , a d J A You g. . Ret o i al E t  Mediated 
by Receptor Priming and Low pH Triggering of an Envelope Gl op otei .  Cell 103 (4):679–89. 
http://www.ncbi.nlm.nih.gov/pubmed/11106737. 
Nadaraia-Hoke, Shorena, Darrin V Bann, Timothy L Lochmann, Nicole Gudleski-O’Rega , a d Leslie J 
Pa e t. . Alte atio s i  the MA a d NC Do ai s Modulate Phosphoi ositide-Dependent 
Plas a Me a e Lo alizatio  of the Rous “a o a Vi us Gag P otei .  Journal of Virology 87 
(6):3609–15. https://doi.org/10.1128/JVI.03059-12. 
Nagel, Inga, Monika Szczepanowski, José I Martín-Subero, Lana Harder, Takashi Akasaka, Ole 
Ammerpohl, Evelyne Callet-Bau hu, et al. . De egulatio  of the Telo e ase Re e se 
Transcriptase (TERT) Gene by Chromosomal Translocations in B-Cell Malig a ies.  Blood 116 
(8):1317–20. https://doi.org/10.1182/blood-2009-09-240440. 
Narezkina, Anna, Konstantin D Taganov, Samuel Litwin, Radka Stoyanova, Junpei Hayashi, Christoph 
“eege , A a Ma ie “kalka, a d Ri ha d A Katz. . Ge o e-Wide Analyses of Avian Sarcoma 




Neel, B G, W “ Ha a d, H L Ro i so , J Fa g, a d “ M Ast i . . A ia  Leukosis Vi us-Induced 
Tumors Have Common Proviral Integration Sites and Synthesize Discrete New RNAs: Oncogenesis 
 P o ote  I se tio .  Cell 23 (2):323–34. http://www.ncbi.nlm.nih.gov/pubmed/6258798. 
Neh a, Ji i, “a a da  Malhot a, “hel  Wi a s, Tho as H O’Ha e, Ja es Justi e, a d Ka e  Bee o . 
. A ia  Leukosis Vi us A ti atio  of a  A tise se RNA Upst ea  of TERT i  B-Cell 
L pho as.  Edited  “. R. Ross. Journal of Virology 90 (20):9509–17. 
https://doi.org/10.1128/JVI.01127-16. 
Neiman, Paul E, Jovana J Grbiç, Tatjana S Polony, Robert Kimmel, Sandra J Bowers, Jeffrey Delrow, and 
Ka e  L Bee o . . Fu tio al Ge o i  A al sis Re eals Disti t Neoplastic Phenotypes 
Associated with c-M  Mutatio  i  the Bu sa of Fa i ius.  Oncogene 22 (7):1073–86. 
https://doi.org/10.1038/sj.onc.1206070. 
Nomoto, Kiyoaki, Masato Maekawa, Kokichi Sugano, Mineko Ushiama, Noriko Fukayama, Shin Fujita, 
and Tadao Kakizoe. . Meth latio  “tatus a d E p essio  of Hu a  Telo e ase Re e se 
Transcriptase mRNA in Relation to Hypermethylation of the p16 Gene in Colorectal Cancers as 
Analyzed by Bisulfite PCR-““CP.  Japanese Journal of Clinical Oncology 32 (1):3–8. 
http://www.ncbi.nlm.nih.gov/pubmed/11932355. 
O’Ha e, T H, a d M E Dela . . Mole ula  a d Cellula  E ide e fo  the Alte ati e Le gthe i g of 
Telo e es ALT  Me ha is  i  Chi ke .  Cytogenetic and Genome Research 135 (1):65–78. 
https://doi.org/10.1159/000330125. 
O’“ulli a , Ch istophe  T, Tatja a “ Polo , Ro e t E Pa a, a d Ka e  L Bee o . . Rous “a o a 
Virus Negative Regulator of Splicing Selectively Suppresses SRC mRNA Splicing and Promotes 
Pol ade latio .  Virology 302 (2):405–12. http://www.ncbi.nlm.nih.gov/pubmed/12441084. 
Oh ashiki, Ju ko H, Go o “ashida, Tetsuzo Tau hi, a d Kazu a Oh ashiki. . Telo e es a d 
120 
 
Telo e ase i  He atologi  Neoplasia.  Oncogene 21 (4):680–87. 
https://doi.org/10.1038/sj.onc.1205075. 
Okosun, Jessica, Csaba Bödör, Jun Wang, Shamzah Araf, Cheng-Yuan Yang, Chenyi Pan, Sören Boller, et 
al. . I teg ated Ge o i  A al sis Ide tifies Re u e t Mutatio s a d E olutio  Patte s 
D i i g the I itiatio  a d P og essio  of Folli ula  L pho a.  Nature Genetics 46 (2):176–81. 
https://doi.org/10.1038/ng.2856. 
Pa a, R E, R A Oge t, C “ Hi e t, E Izau alde, a d K L Bee o . . Rous “a o a Vi us DR 
Postt a s iptio al Ele e ts Use a No el RNA E po t Path a .  Journal of Virology 74 (20):9507–
14. http://www.ncbi.nlm.nih.gov/pubmed/11000220. 
Pal ite , R D, J Gag o , V M Vogt, “ Riple , a d R N Eise a . . The NH -Terminal Sequence of 
the A ia  O o i us Gag P e u so  Pol p otei  P gag .  Virology 91 (2):423–33. 
http://www.ncbi.nlm.nih.gov/pubmed/217156. 
Panero, Julieta, Raquel M Alves-Paiva, Alejandro Roisman, Barbara A Santana-Lemos, Roberto P Falcão, 
Gustavo Oliveira, Diego Martins, Carmen Stanganelli, Irma Slavutsky, and Rodrigo T Calado. 2016. 
A ui ed TERT P o ote  Mutatio s “ti ulate TERT T a s iptio  i  Ma tle Cell L pho a.  
American Journal of Hematology 91 (5):481–85. https://doi.org/10.1002/ajh.24324. 
Papaemmanuil, Elli, Fay J Hosking, Jayaram Vijayakrishnan, Amy Price, Bianca Olver, Eammon Sheridan, 
“all  E Ki se , et al. . Lo i o  p . , .  a d .  Are Associated with Risk of 
Childhood A ute L pho lasti  Leuke ia.  Nature Genetics 41 (9):1006–10. 
https://doi.org/10.1038/ng.430. 
Pappas, Ja e J, A d é Toulouse, a d Walte  Ed a d Cla ke B adle . . The Bisulfite Ge o i  
“e ue i g P oto ol   :21–25. https://doi.org/10.4236/alc.2013.21004. 
Park, Jae-Il, Andrew S. Venteicher, Ji Yeon Hong, Jinkuk Choi, Sohee Jun, Marina Shkreli, Woody Chang, 
et al. . Telo e ase Modulates W t “ig alli g  Asso iatio  ith Ta get Ge e Ch o ati .  
121 
 
Nature 460 (7251):66–72. https://doi.org/10.1038/nature08137. 
Parrinello, Simona, Enrique Samper, Ana Krtolica, Joshua Goldstein, Simon Melov, and Judith Campisi. 
. O ge  “e siti it  “e e el  Li its the Repli ati e Lifespa  of Mu i e Fi o lasts.  Nature 
Cell Biology 5 (8):741–47. https://doi.org/10.1038/ncb1024. 
Pa e, L. N., a d P. K. Pa i. . E ide e fo  Li kage Bet ee  Ge eti  Lo i Co t olli g Respo se of 
Fo l to “u g oup A a d “u g oup C “a o a Vi uses.  Journal of General Virology 13 (2):253–59. 
https://doi.org/10.1099/0022-1317-13-2-253. 
Pa e, L N, a d P M Biggs. . Ge eti  Basis of Cellula  “us epti ilit  to the “ h idt-Ruppin and 
Ha is “t ai s of Rous “a o a Vi us.  Virology 29 (2):190–98. 
http://www.ncbi.nlm.nih.gov/pubmed/4287328. 
PAYNE, L N, a d P M BIGG“. . ADIFFERENCE IN “U“CEPTIBILITY TO LYMPHOID LEUKO“I“ VIRU“ 
AND ROU“ “ARCOMA VIRU“ BETWEEN CELL“ FROM TWO INBRED LINE“ OF DOME“TIC FOWL.  
Nature 203 (September):1306–7. http://www.ncbi.nlm.nih.gov/pubmed/14230229. 
Payne, L N, K Howes, A M Gillespie, a d L M “ ith. . Host Ra ge of Rous “a o a Vi us 
Pseudotype RSV(HPRS-103) in 12 Avian Species: Support for a New Avian Retrovirus Envelope 
“u g oup, Desig ated J.  The Journal of General Virology 73 ( Pt 11) (11):2995–97. 
https://doi.org/10.1099/0022-1317-73-11-2995. 
Pea so , Ri ha d, Ja ueli e Fleet ood, “all  Eato , Me li  C ossle , a d “hisa  Bao. . K üppel-
like T a s iptio  Fa to s: A Fu tio al Fa il .  The International Journal of Biochemistry & Cell 
Biology 40 (10):1996–2001. https://doi.org/10.1016/j.biocel.2007.07.018. 
Pille , “ C, L Cal , a d D A Ja s. . Nu lea  I po t of the P e-Integration Complex (PIC): The Achilles 
Heel of HIV?  Current Drug Targets 4 (5):409–29. 
http://www.ncbi.nlm.nih.gov/pubmed/12816349. 
Pin eti , A d e , a d Jo atha  Leis. . The Me ha is  of Buddi g of Ret o i uses F o  Cell 
122 
 
Me a es.  Advances in Virology 2009 (January):6239691–99. 
https://doi.org/10.1155/2009/623969. 
Pittaluga, Stefania, Gregor Verhoef, Arnold Criel, Alex Maes, Johan Nuyts, Marc Boogaerts, and Chris De 
Wolf Peete s C. . P og osti  “ig ifi a e of Bo e Ma o  T ephi e a d Pe iphe al Blood 
“ ea s i   Patie ts ith Ma tle Cell L pho a.  Leukemia & Lymphoma 21 (1–2):115–25. 
https://doi.org/10.3109/10428199609067588. 
Pize , E “, T W Ba a, a d E H Hu ph ies. . A ti atio  of the -Myb Locus Is Insufficient for the 
Rapid Induction of Disseminated Avian B-Cell L pho a.  Journal of Virology 66 (1):512–23. 
http://www.ncbi.nlm.nih.gov/pubmed/1309260. 
Poiesz, B J, F W Rus etti, A F Gazda , P A Bu , J D Mi a, a d R C Gallo. . Dete tio  a d Isolatio  
of Type C Retrovirus Particles from Fresh and Cultured Lymphocytes of a Patient with Cutaneous T-
Cell L pho a.  Proceedings of the National Academy of Sciences of the United States of America 
77 (12):7415–19. http://www.ncbi.nlm.nih.gov/pubmed/6261256. 
Polo , Tatja a “, “a d a J Bo e s, Paul E Nei a , a d Ka e  L Bee o . . “ile t Poi t Mutatio  i  
an Avian Retrovirus RNA Processing Element Promotes c-Myb-Associated Short-Latency 
L pho as.  Journal of Virology 77 (17):9378–87. 
http://www.ncbi.nlm.nih.gov/pubmed/12915553. 
Rachakonda, P. S., I. Hosen, P. J. de Verdier, M. Fallah, B. Heidenreich, C. Ryk, N. P. Wiklund, et al. 2013. 
TERT P o ote  Mutatio s i  Bladder Cancer Affect Patient Survival and Disease Recurrence 
th ough Modifi atio   a Co o  Pol o phis .  Proceedings of the National Academy of 
Sciences 110 (43):17426–31. https://doi.org/10.1073/pnas.1310522110. 
Röth, A, S Vercauteren, H J Sutherland, and P M La sdo p. . Telo e ase Is Li iti g the G o th of 




Rous, P. . A “ARCOMA OF THE FOWL TRAN“MI““IBLE BY AN AGENT “EPARABLE FROM THE TUMOR 
CELL“.  The Journal of Experimental Medicine 13 (4):397–411. 
http://www.ncbi.nlm.nih.gov/pubmed/19867421. 
RUBIN, H. . GENETIC CONTROL OF CELLULAR “U“CEPTIBILITY TO P“EUDOTYPE“ OF ROU“ 
“ARCOMA VIRU“.  Virology 26 (June):270–76. http://www.ncbi.nlm.nih.gov/pubmed/14323995. 
“a pe , E i ue, Jua a M Flo es, a d Ma ía A Blas o. . Resto atio  of Telo e ase A ti it  Res ues 
Chromosomal Instability and Premature Aging in  Terc −/−  Mi e ith “ho t Telo e es.  EMBO 
Reports 2 (9):800–807. https://doi.org/10.1093/embo-reports/kve174. 
“ heifele, L. )., E. P. R a , a d L. J. Pa e t. . Detailed Mappi g of the Nu lea  E po t “ig al i  the 
Rous “a o a Vi us Gag P otei .  Journal of Virology 79 (14):8732–41. 
https://doi.org/10.1128/JVI.79.14.8732-8741.2005. 
Schröder, Astrid R W, Paul Shinn, Huaming Chen, Charles Berry, Joseph R Ecker, and Frederic Bushman. 
. HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots.  Cell 110 
(4):521–29. http://www.ncbi.nlm.nih.gov/pubmed/12202041. 
“e igl, F., J. Pla h , a d J. Hej a . . The Co e Ele e t of a CpG Isla d P ote ts A ia  “a o a a d 
Leukosis Virus-De i ed Ve to s f o  T a s iptio al “ile i g.  Journal of Virology 82 (16):7818–
27. https://doi.org/10.1128/JVI.00419-08. 
“e igl, Filip, Mi osla  Au t, a d Ji í Hej a . . T a s iptio al P o i us “ile i g as a C osstalk of de 
No o DNA Meth latio  a d Epige o i  Featu es at the I teg atio  “ite.  Nucleic Acids Research 40 
(12):5298–5312. https://doi.org/10.1093/nar/gks197. 
Shain, A Hunter, Iwei Yeh, Ivanka Kovalyshyn, Aravindhan Sriharan, Eric Talevich, Alexander Gagnon, 
Rei ha d Du e , et al. . The Ge eti  E olutio  of Mela o a f o  P e u so  Lesio s.  The 
New England Journal of Medicine 373 (20):1926–36. https://doi.org/10.1056/NEJMoa1502583. 
“halgi skikh, Natalia, A d e  Poleshko, A a Ma ie “kalka, a d Ri ha d A Katz. . Ret o i al DNA 
124 
 
Methylation and Epigenetic Repression Are Mediated by the Anti i al Host P otei  Da .  Journal 
of Virology 87 (4):2137–50. https://doi.org/10.1128/JVI.02026-12. 
“ha a, A., R. C. La ue, M. R. Plu , N. Mala i, F. Male, A. “laughte , J. J. Kessl, et al. . BET 
Proteins Promote Efficient Murine Leukemia Virus Integ atio  at T a s iptio  “ta t “ites.  
Proceedings of the National Academy of Sciences 110 (29):12036–41. 
https://doi.org/10.1073/pnas.1307157110. 
“ha , J W, a d “ Ba hetti. . A “u e  of Telo e ase A ti it  i  Hu a  Ca e .  European Journal 
of Cancer (Oxford, England : 1990) 33 (5):787–91. https://doi.org/10.1016/S0959-8049(97)00062-
2. 
“he , C J, a d R A DePi ho. . Cellula  “e es e e: Mitoti  Clo k o  Cultu e “ho k?  Cell 102 
(4):407–10. http://www.ncbi.nlm.nih.gov/pubmed/10966103. 
Shin, K-H, M K Kang, E Dicterow, and N-H Pa k. . H pe eth latio  of the hTERT P o ote  I hi its 
the Expression of Telomerase Activity in Normal Oral Fibroblasts and Senescent Normal Oral 
Ke ati o tes.  British Journal of Cancer 89 (8):1473–78. https://doi.org/10.1038/sj.bjc.6601291. 
“i o , M C, W “ Ne ka e e , W “ Ha a d, a d R E “ ith. . Ge eti  Dete i a ts of Neoplasti  
Diseases I du ed  a “u g oup F A ia  Leukosis Vi us.  Journal of Virology 61 (4):1203–12. 
http://www.ncbi.nlm.nih.gov/pubmed/3029416. 
Singh, Parmit Kumar, Matthew R. Plumb, Andrea L. Ferris, James R. Iben, Xiaolin Wu, Hind J. Fadel, Brian 
T. Luke, et al. . LEDGF/p  I te a ts ith RNA “pli i g Fa to s a d Ta gets HIV-1 
I teg atio  to Highl  “pli ed Ge es.  Genes & Development 29 (21):2287–97. 
https://doi.org/10.1101/gad.267609.115. 
“ ith, M R, R E “ ith, I Du kel, V Hou, K L Bee o , a d W “ Ha a d. . Ge eti  Dete i a t of 




“ope , D.“. . “ig ifi a e of the Diffe e e et ee  T o “lopes Cal ulato .  . 
http://www.danielsoper.com/statcalc. 
Stern, Josh Lewis, Richard D. Paucek, Franklin W. Huang, Mahmoud Ghandi, Ronald Nwumeh, James C. 
Costello, and Thomas R. Ce h. . Allele-Specific DNA Methylation and Its Interplay with 
Repressive Histone Marks at Promoter-Muta t TERT Ge es.  Cell Reports 21 (13):3700–3707. 
https://doi.org/10.1016/j.celrep.2017.12.001. 
Stern, Josh Lewis, Dan Theodorescu, Bert Vogelstein, Nickolas Papadopoulos, and Thomas R Cech. 2015. 
Mutatio  of the TERT P o ote , “ it h to A ti e Ch o ati , a d Mo oalleli  TERT E p essio  i  
Multiple Ca e s.  Genes & Development 29 (21):2219–24. 
https://doi.org/10.1101/gad.269498.115. 
Stewart, C L, H “tuhl a , D Jäh e , a d R Jae is h. . De No o Meth latio , E p essio , a d 
I fe ti it  of Ret o i al Ge o es I t odu ed i to E o al Ca i o a Cells.  Proceedings of the 
National Academy of Sciences of the United States of America 79 (13):4098–4102. 
http://www.ncbi.nlm.nih.gov/pubmed/6955793. 
Stoehr, Robert, Helge Taubert, Ulrike Zinnall, Johannes Giedl, Nadine T Gaisa, Maximilian Burger, Petra 
Rue ele, et al. . F e ue  of TERT P o ote  Mutatio s i  P ostate Ca e .  
Patho iolog  : Jour al of Immunopathology, Molecular and Cellular Biology 82 (2):53–57. 
https://doi.org/10.1159/000381903. 
“VOBODA, J. . P ese e of Chi ke  Tu ou  Vi us i  the “a o a of the Adult Rat I o ulated afte  
Bi th ith Rous “a o a Tissue.  Nature 186 (June):980–81. 
http://www.ncbi.nlm.nih.gov/pubmed/13835975. 
“ o oda, J, J Hej a , J Ge k, D Ellede , a d ) Ve e o á. . Ret o i uses i  Fo eig  “pe ies a d the 




Swa e g, “.E., a d M.E. Dela . . D a i s of Telo e e E osio  i  T a sfo ed a d No -
T a sfo ed A ia  Cells &lt;i&gt;i  Vit o&lt;/i&gt;  Cytogenetic and Genome Research 102 (1–
4):318–25. https://doi.org/10.1159/000075769. 
Swanberg, Susan E, Thomas H O’Ha e, Eliza eth A Ro , Cha ai e M Ro i so , Ho g Cha g, a d Ma  
E Dela . . Telo e e Biolog  of the Chi ke : A Model fo  Agi g Resea h.  Experimental 
Gerontology 45 (9):647–54. https://doi.org/10.1016/j.exger.2010.04.002. 
Swanberg, Susan E, William S Payne, Henry D Hunt, Jerry B Dodgson, and Mary E Delany. 2004. 
Telo e ase A ti it  a d Diffe e tial E p essio  of Telo e ase Ge es a d -Myc in Chicken Cells in 
Vit o.  Develop e tal D a i s : A  Offi ial Pu li atio  of the A eri a  Asso iatio  of Anatomists 
231 (1):14–21. https://doi.org/10.1002/dvdy.20149. 
Swanstrom, R, and JW Wills. 1997. Synthesis, Assembly, and Processing of Viral Proteins. Retroviruses. 
http://www.ncbi.nlm.nih.gov/pubmed/21433349. 
Tam, W, D Ben-Yehuda, a d W “ Ha a d. . Bic, a Novel Gene Activated by Proviral Insertions in 
Avian Leukosis Virus-I du ed L pho as, Is Likel  to Fu tio  th ough Its No odi g RNA.  
Molecular and Cellular Biology 17 (3):1490–1502. http://www.ncbi.nlm.nih.gov/pubmed/9032277. 
Taylor, H A, and M E Dela . . O toge  of Telo e ase i  Chi ke : I pa t of Do egulatio  o  
Pre- a d Post atal Telo e e Le gth i  Vi o.  Development, Growth & Differentiation 42 (6):613–
21. http://www.ncbi.nlm.nih.gov/pubmed/11142683. 
Te i , Ho a d M. . “tudies on Carcinogenesis by Avian Sarcoma Viruses. VI. Differential 
Multipli atio  of U i fe ted a d of Co e ted Cells i  Respo se to I suli .  Journal of Cellular 
Physiology 69 (3):377–84. https://doi.org/10.1002/jcp.1040690314. 
Trapp, Sascha, Mark S. Parcells, Jeremy P. Kamil, Daniel Schumacher, B. Karsten Tischer, Pankaj M. 
Ku a , Ve ugopal K. Nai , a d Nikolaus Oste iede . . A Vi us-Encoded Telomerase RNA 




Treviño, Lisa R, Wenjian Yang, Deborah French, Stephen P Hunger, William L Carroll, Meenakshi Devidas, 
Che l Will a , et al. . Ge li e Ge o i  Va ia ts Asso iated ith Childhood A ute 
L pho lasti  Leuke ia.  Nature Genetics 41 (9):1001–5. https://doi.org/10.1038/ng.432. 
Unamuno Bustos, Blanca de, Rosa Murria Estal, Gema Pérez Simó, Vicente Oliver Martínez, Margarita 
Lla ado  Ros, “a ai Pala a “uela, a d Rafael Botella Est ada. . La k of TERT P o ote  
Mutatio s i  Mela o as ith E te si e Reg essio .  Journal of the American Academy of 
Dermatology 74 (3):570–72. https://doi.org/10.1016/j.jaad.2015.10.003. 
U e , A G, J Kool, A Be s, a d M a  Lohuize . . Ret o i al I se tio al Mutage esis: Past, P ese t 
a d Futu e.  Oncogene 24 (52):7656–72. https://doi.org/10.1038/sj.onc.1209043. 
Ve de a e, M F, T D Nelle, a d J W Wills. . The Me a e-Binding Domain of the Rous Sarcoma 
Vi us Gag P otei .  Journal of Virology 70 (4):2664–68. 
http://www.ncbi.nlm.nih.gov/pubmed/8642704. 
Véron, Nadège, Zhengdong Qu, Phoebe A.S. Kipen, Claire E. Hirst, and Christophe Marcelle. 2015. 
CRI“PR Mediated “o ati  Cell Ge o e E gi ee i g i  the Chi ke .  Developmental Biology 407 
(1):68–74. https://doi.org/10.1016/j.ydbio.2015.08.007. 
Vicente-Dueñas, Carolina, Marcos Barajas-Diego, Isabel Romero-Camarero, Ines Gonzalez-Herrero, 
Teresa Flores, and Isidro Sanchez-Ga ia. . Esse tial Role fo  Telo e ase i  Ch o i  M eloid 
Leukemia Induced by BCR-ABL i  Mi e.  Oncotarget 3 (3):261–66. 
https://doi.org/10.18632/oncotarget.461. 
Vilhel , Elle a , a d Oluf Ba g. . E pe i e telle Leukä ie Bei Hüh e . )e t al l. Bakte iol. 
Pa asite kd. I fe tio sk .  Hyg. Abt. Orig 46:595–609. 
Vinagre, João, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, et al. 




Vogt, P K, a d R Ishizaki. . Re ip o al Patte s of Ge eti  Resistance to Avian Tumor Viruses in Two 
Li es of Chi ke s.  Virology 26 (4):664–72. http://www.ncbi.nlm.nih.gov/pubmed/4284168. 
Wang, Wei, Tianmu Zhang, Chunyan Wu, Shanshan Wang, Yuxiang Wang, Hui Li, and Ning Wang. 2017. 
I o talizatio  of Chi ke  P eadipo tes  Ret o i al T a sdu tio  of Chi ke  TERT a d TR.  
Edited by Michel M. Ouellette. PloS One 12 (5):e0177348. 
https://doi.org/10.1371/journal.pone.0177348. 
Was lishe , A. R., a d L. ). Pe . . M : The Beaut  a d the Beast.  Genes & Cancer 1 (6):532–41. 
https://doi.org/10.1177/1947601910378024. 
Watanabe, Yoshiyuki, Hiroyuki Yamamoto, Ritsuko Oikawa, Minoru Toyota, Masakazu Yamamoto, 
No ihi o Kokudo, “hi ji Ta aka, et al. . DNA Meth latio  at Hepatitis B Vi al I teg a ts Is 
Associated with Meth latio  at Fla ki g Hu a  Ge o i  “e ue es.  Genome Research 25 
(3):328–37. https://doi.org/10.1101/gr.175240.114. 
We e , Mi hael, a d Di k “ hü ele . . Ge o i  Patte s of DNA Meth latio : Ta gets a d 
Fu tio  of a  Epige eti  Ma k.  Current Opinion in Cell Biology 19 (3):273–80. 
https://doi.org/10.1016/j.ceb.2007.04.011. 
Weil, Jaso  E, Mi halis Hadjitho as, a d Ka e  L Bee o . . “t u tu al Cha a te izatio  of the Rous 
“a o a Vi us RNA “ta ilit  Ele e t.  Journal of Virology 83 (5):2119–29. 
https://doi.org/10.1128/JVI.02113-08. 
Wei hold, Nils, A de s Ja o se , Nikolaus “ hultz, Ch is “a de , a d Willia  Lee. . Ge o e-Wide 
A al sis of No odi g Regulato  Mutatio s i  Ca e .  Nature Genetics 46 (11):1160–65. 
https://doi.org/10.1038/ng.3101. 
Weiss, Ro i  A., a d Pete  K. Vogt. .  Yea s of Rous “a o a Vi us.  The Journal of 
Experimental Medicine 208 (12):2351–55. https://doi.org/10.1084/jem.20112160. 
129 
 
Williams, Ruth M., Upeka Senanayake, Mara Artibani, Gunes Taylor, Daniel Wells, Ahmed Ashour 
Ahmed, and Tatjana Sauka-“pe gle . . Ge o e a d Epige o e E gi ee i g CRI“PR Toolkit 
for in Vivo Modulation of Cis -Regulato  I te a tio s a d Ge e E p essio  i  the Chi ke  E o.  
Development 145 (4):dev160333. https://doi.org/10.1242/dev.160333. 
Willia s, “usa  M., “ ott D. Fitzge ald, Willie M. Reed, Lu  F. Lee, a d Al  M. Fadl . . Tissue 
Tropism and Bursal Transformation Ability of Subgroup J Avian Leukosis Virus in White Leghorn 
Chi ke s.  Avian Diseases 48 (4):921–27. https://doi.org/10.1637/7196-041904R. 
Wilusz, Je e  E, a d Ka e  L Bee o . . The Negati e Regulato  of “pli i g Ele e t of Rous 
“a o a Vi us P o otes Pol ade latio .  Journal of Virology 80 (19):9634–40. 
https://doi.org/10.1128/JVI.00845-06. 
Winans, Shelby, Ross C. Larue, Carly M. Abraham, Nikolozi Shkriabai, Amelie Skopp, Duane Winkler, 
Ma uka K a atskhelia, a d Ka e  L. Bee o . . The FACT Co ple  P o otes A ia  Leukosis 
Vi us DNA I teg atio .  Edited  “usa  R. Ross. Journal of Virology 91 (7):e00082-17. 
https://doi.org/10.1128/JVI.00082-17. 
Withers-Wa d, E “, Y Kita u a, J P Ba es, a d J M Coffi . . Dist i utio  of Ta gets fo  A ia  
Ret o i us DNA I teg atio  i  Vi o.  Genes & Development 8 (12):1473–87. 
http://www.ncbi.nlm.nih.gov/pubmed/7926746. 
Wright, Woodring E., Mieczyslaw A. Piatyszek, William E. Rainey, William Byrd, and Jerry W. Shay. 1996. 
Telo e ase A ti it  i  Hu a  Ge li e a d E o i  Tissues a d Cells.  Developmental 
Genetics 18 (2):173–79. https://doi.org/10.1002/(SICI)1520-6408(1996)18:2<173::AID-
DVG10>3.0.CO;2-3. 
W ight, Wood i g E., a d Je  W. “ha . . Telo e e D a i s i  Ca e  P og essio  a d 




Wu, Kou-Juey, Carla Grandori, Mario Amacker, Nathalie Simon-Vermot, Axel Polack, Joachim Lingner, 
and Riccardo Dalla-Fa e a. . Di e t A ti atio  of TERT T a s iptio   -MYC.  Nature 
Genetics 21 (2):220–24. https://doi.org/10.1038/6010. 
Wu, Ren-Chin, Ayse Ayhan, Daichi Maeda, Kyu-Rae Kim, Blaise A Clarke, Patricia Shaw, Michael Herman 
Chui, Barry Rosen, Ie-Ming Shih, and Tian-Li Wa g. . F e ue t “o ati  Mutatio s of the 
Telomerase Reverse Transcriptase Promoter in Ovarian Clear Cell Carcinoma but Not in Other 
Majo  T pes of G ae ologi al Malig a .  The Journal of Pathology 232 (4):473–81. 
https://doi.org/10.1002/path.4315. 
Wu, X., Yua  Li, B u e C ise, a d “ha  M Bu gess. . T a s iptio  “ta t Regio s i  the Hu a  
Genome Are Fa o ed Ta gets fo  MLV I teg atio .  Science 300 (5626):1749–51. 
https://doi.org/10.1126/science.1083413. 
Xu, Lei, Florette K. Hazard, Anne-Flore Zmoos, Nadine Jahchan, Hassan Chaib, Phillip M. Garfin, Arun 
Rangaswami, Michael P. Snyder, and Julien Sage. 20 . Ge o i  A al sis of Fi ola ella  
Hepato ellula  Ca i o a.  Human Molecular Genetics 24 (1):50–63. 
https://doi.org/10.1093/hmg/ddu418. 
Ya , “i i, Bi g Ha , Yo gji Wu, Dao i  )hou, a d Yo g ia g )hao. . Telo e ase Ge e Mutatio  
Screening and Telo e e O e ha g Dete tio  i  Chi ese Patie ts ith A ute M eloid Leuke ia.  
Leukemia & Lymphoma 54 (7):1437–41. https://doi.org/10.3109/10428194.2012.729834. 
Ya g, Fe g, Re a R Xia , Yi g i g Li, Tatja a “ Polo , a d Ka e  L Bee o . . Telo e ase Re e se 
T a s iptase E p essio  Ele ated  A ia  Leukosis Vi us I teg atio  i  B Cell L pho as.  
Proceedings of the National Academy of Sciences of the United States of America 104 (48):18952–
57. https://doi.org/10.1073/pnas.0709173104. 
Young, J A, P Bates, a d H E Va us. . Isolatio  of a Chi ke  Ge e That Co fe s “us epti ilit  to 




Yuan, X, S Ishibashi, S Hatakeyama, M “aito, J Naka a a, R Nikaido, T Ha u a a, et al. . P ese e 
of Telomeric G-“t a d Tails i  the Telo e ase Catal ti  “u u it TERT K o kout Mi e.  Genes to 
Cells : Devoted to Molecular & Cellular Mechanisms 4 (10):563–72. 
http://www.ncbi.nlm.nih.gov/pubmed/10583505. 
Zatkova, Andrea, Jean-Marie Rouillard, Wolfgang Hartmann, Barbara J Lamb, Rork Kuick, Markus Eckart, 
Diet i h o  “ h ei itz, et al. . A plifi ation and Overexpression of the IGF2 Regulator 
PLAG  i  Hepato lasto a.  Genes, Chromosomes & Cancer 39 (2):126–37. 
https://doi.org/10.1002/gcc.10307. 
)hu, Ji ue, Yua ju  )hao, a d “hu e  Wa g. . Ch o ati  a d Epige eti  Regulatio  of the 
Telomerase Reve se T a s iptase Ge e.  Protein & Cell 1 (1):22–32. 
https://doi.org/10.1007/s13238-010-0014-1. 
)i , Re ekah L, Ke i  P uitt, “a aka Egu hi, “tephe  B Ba li , a d Ja es G He a . . hTERT Is 
Expressed in Cancer Cell Lines despite Promoter DNA Methylation by Preservation of 








































Johns Hopkins University     Telephone (lab): 410-516-6571 
Department of Biology Telephone (mobile): 717-991-7117 
3400 N. Charles St., Mudd Hall E-mail: glam5@jhu.edu 




2011-2018             Ph.D. Cellular, Molecular, Developmental Biology and Biophysics 
                                            Johns Hopkins University, Baltimore, MD 
                                            Supervisor: Dr. Karen Beemon 
 
2005-2009             Bachelor of Science, Biochemistry and Molecular Biology summa cum laude 
 Lebanon Valley College, Annville, PA 




2011-present Ph.D. Thesis, Johns Hopkins University 
  Exploring TERT Expression and Regulation in Tumorigenesis: Lessons from ALV 
 
2009-2011 Post-baccalaureate Research, Cancer Research Training Fellowship, NCI 
  Anti-EGFR therapy in skin carcinogenesis 
 
2006-2009 Undergraduate Research, Lebanon Valley College 




May 2015 Cold Spring Harbor Laboratory Meeting: Telomeres & Telomerase 
 Cold Spring Harbor, New York 
Presented a poster entitled: TERT promoter/enhancer mutations in chickens and   




1. Lam G, Beemon K.  (2018) ALV Integration-Associated Hypomethylation at the TERT Promoter 
Locus.  Viruses. 10(2) 
 
2. Malhotra S, Winans S, Lam G, Justice J, Morgan R, Beemon K.  (2017) Selection for avian leukosis 





3. Lam G, Xian RR, Li Y, Burns KH, Beemon KL.  (2016) Lack of TERT Promoter Mutations in Human B-
cell Non-Hodgkin Lymphoma.  Genes. 7(11) 
 
4. Mascia F, Lam G, Keith C, Garber C, Steinberg SM, Kohn E, Yuspa SH.  (2013) Genetic ablation of 
epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl 
Med. 5(199) 
 
5. Abbott JL, Newell JM, Lightcap CM, Olanich ME, Loughlin DT, Weller MA, Lam G, Pollack S, Patton 













2018 Spring Immunology Teaching Assistant  Johns Hopkins University 
2017 Fall  Genetics Teaching Assistant  Johns Hopkins University 
2017 Spring Cell Biology Teaching Assistant  Johns Hopkins University 
2016 Fall  Genetics Teaching Assistant  Johns Hopkins University 
2015 Fall  Molecular Biology Teaching Assistant Johns Hopkins University 
2014 Fall  Biochemistry Laboratory Assistant Johns Hopkins University 
2013 Spring Cell Biology Laboratory Assistant Johns Hopkins University 




Dr. Karen Beemon  klb@jhu.edu  410-516-6571 PhD. Supervisor 
Dr. David Zapulla  zappulla@jhu.edu 410-955-3022 Thesis Committee 
Dr. Kyle Cunningham kwc@jhu.edu  410-516-7844 Thesis Committee 
Dr. Robin Morgan  morgan@udel.edu 302-831-4296 Thesis Committee 
 
